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A methodology was studied to set up the benzo[a]fluorene skeleton, which provides a 
potential route to the total synthesis of isoprekinamycin (IPK) (1-112) and analogues of this 
natural product that contains an unusual diazo group so as to study the relationship of the 




































Basically the strategy involved a Suzuki coupling between the bromoindenone 2-64 as an 
AB ring building block and the pinacol boronate 2-89 as a D ring building block to generate 
a diaryl intermediate 2-90 that incorporates the A, B and D ring of isoprekinamycin. The 
diaryl intermediate was cyclized via a Dieckmann-like reaction to provide the full ABCD 
benzo[a]fluorene ring system that incorporates a cyano group at the carbon atom intended to 
become the carbon of the diazo group in the final structure. This intermediate was subjected 
to a sequence of reactions involving hydrolysis of the cyano group to the amide followed by 
a modified Hofmann rearrangement that provided the C-N bond at the correct position for 
creation of the diazo group in a three step sequence. This methodology provided a model of 
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IPK 2-58 with the longest linear path of the synthesis being thirteen steps and in a 7% yield 
overall. 
A total synthesis of IPK which followed the method developed in the model synthesis was 
then attempted. In this IPK synthesis, the key Dieckmann-like cyclization that proceeded 
very selectively in the model synthesis proved to be problematic as a result of a competing 
aldol reaction involving the B-ring ketone group. This problem was eventually solved by 
reducing the ketone with LiAlH(n-Bu)(i-Bu)2 to produce a reduced aluminate intermediate 
which served as a protecting group through several steps to the full benzo[a]fluorene system 
that provided a sample of IPK, after appropriate functional group modification. The synthetic 
compound was shown to be identical with a sample of the natural product. The synthesis 
represents the first total synthesis of IPK and was achieved with an overall yield of 6% and 
the longest linear path being fourteen steps. 
An examination of the crystallographic data for the model compound 2-58 and IPK 
provided structure confirmation of the proposal that the diazonium ion character of the diazo 
group in IPK is enhanced by the presence of intramolecular H-bonding. 
An analogue of IPK was designed, incorporating a side chain at C3 of the D ring in order 
to improve solubility and potentially the affinity of the molecule for DNA. An intermediate 
4-74 that contains a carbamate group intended to serve as the precursor of the diazo group of 
the IPK analogue, was synthesized using the same strategy as the model of IPK through 
eleven steps in 14% yield overall. 
Another benzo[a]fluorene 5-28 was synthesized in 6% overall yield, via an eleven steps 
sequence initiated from commercial available 3-methylsalicylic acid. This benzo[a]fluorene 
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is intended to be a key intermediate for the total synthesis of fluorostatin A and for the 
synthesis of analogues of IPK with a side chain at the C4 of the D ring. 
 A discussion of potential significance of the proposed analogues and how they might be 
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Chapter 1 General Introduction 
1.1 Background 
Benzo[b]fluorene quinones are really rare structures in natural products. The first four 
compounds with this structural motif, kinamycin A-D, were originally isolated by Omura and 
co-workers in 1970 from Streptomyces murayamaensis sp. Mov. Heta and Ohtani.1 These 
bright golden-yellow compounds were shown to be strongly active against Gram-positive 
bacteria but less so against Gram-negative organisms.1 Meanwhile, kinamycin C exhibited 
antitumor activity against Ehrlich ascites carcinoma and Sarcoma-180.1 
Until 1989, S. murayamaensis was the only organism known to produce kinamycins. Since 
then, however, other kinamycin-producing microorganisms were reported. For example, in 
1989, Saccharothrix species was found to produce 1-1h and 1-1i, and so was an unidentified 
actinomycete (produces 1-1j, antibiotic A83016A) in 1992; In 1994, S. chattanoogensis was 
reported to produce kinamycin D and six new kinamycins, 1-1k to 1-1n (FL-120A, FL-120C, 
FL-120C’, and FL-120D’ respectively) and 1-2a and 1-2b (FL-120B and FL-120B’). 
Structural variations are confined to ring D, and typically are acetate, propionate and 
isobutyrate substitutions at the C-1 to C-4 positions (1-1). Furthermore, derivatives with 
























































Table 1-1 Natural Kinamycins Derivatives 































































































































Isolated from Streptomyces Source: a murayamaensis; b chattanoogensis; c unidentified; d saccharothrix 
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  Until 1994 it had been believed that kinamycins were N-cyanobenzo[b]carbazoles such as 
structure 1-5 for kinamycin C. In 1994 the structures of kinamycins were altered to 5-
diazobenzo[b]fluorenes 1-1.The number system shown in 1-1, consistent with the numbering 
of benzo[a]anthraquinone biosynthesis precursor9 and with Chemical Abstracts, has been 
adopted for all benzo[b]fluorenes and benzo[a]fluorenes as suggested by Gould.10 
1.2 Structure Elucidation of the Kinamycins 
The kinamycins structures were originally determined in part by chemical, spectroscopic 
methods2 as well as by X-ray study on the p-bromobenzoate of kinamycin C,11 by which the 
absolute configuration and the tetracyclic skeleton were assigned except for the exact nature 
of the linear triatomic moiety, consisting of two nitrogen and one carbon atoms (X-Y-Z in 1-
6). The identification of this key functionality was based solely on chemical degradation 
experiments, which led to the conclusion that kinamycins must incorporate the N-cyano 
instead of N-isocyano group. The possibility of a diazo functionality was not considered 









1-6a  X=N,  Y=C,  Z=N
1-6b  X=C,  Y=N,  Z=N







  In 1985, the proton and carbon NMR of kinamycin D were fully assigned by Gould’s 
group12 except that the 13C NMR signal of an N-cyano group was not observed. In 1988, an 
unexpected doublet of doublet at δ 78.5 ppm (J = 21.2 and 5.4 Hz) was observed in the 13C 
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NMR of [15N2]kinamycin D which was prepared using (15NH4)2SO4 in the fermentation 
medium. Re-examination of previous spectra of natural kinamycin D led to assignment of 
this signal to the N-cyano group,13 even though this signal was ca. 30 ppm upfield compared 
to known N-cyano compounds (e.g. 1-7)13 The large shift upfield was attributed to possible 
















111.9 ppm 104.7 ppm 103.6 ppm  
  However, the 13C NMR characteristics (δ 103–108 ppm) of model N-cyanoindoles (e.g. 1-8 
and 1-9) synthesized later in this laboratory agreed poorly with the data of kinamycins 
indicating that the unusual chemical shift observed from kinamycins could not be simply 
ascribed the N-cyano-indole-dione ring system.14 
  In 1993, Echavarren and co-workers reported the first synthesis of the N-cyano indole 
structure of prekinamycin15 in which the spectroscopic properties of the synthetic compound 
did not match that of natural product.4 Although the possibility of a questionable structure 
assignment of the synthetic product in this study was realized later,16 this work raised 
concerns about the correctness of the assignment to prekinamycin and the kinamycins. 
Meanwhile, S. Mithani in this laboratory synthesized the N-cyanocarbenzo system, 
compound 1-19, using Pd (II)-mediated cyclization of 1-12 and regioselective Diels-Alder 






















































1-10 1-11 1-12   86% 1-13   64%
1-14   74% 1-16   89% 1-17   93%





  Careful spectroscopic analysis of compound 1-19 indicated that this synthetic compound 
was not a derivative of prekinamycin. In the case of prekinamycin diacetate, a 13C NMR 
signal at 83.7 ppm and an IR band at 2119 cm–1 were assigned to cyanamide group.4 The 
apparent cyano group of compound 1-19, on the other hand, gave rise to a 13C NMR signal at 
105.0 ppm and an IR band at 2253 cm–1. In addition, comparison of the characteristics of all 
the N-cyanoindole derivatives prepared in this laboratory clearly revealed that the assignment 
of a cyanamide group to any of the kinamycins was incorrect and kinamycins should be 





Table 1-2 Comparison of Kinamycins and N-cyanoindole Derivatives 
 13C NMR IR 
N-cyanoindole derivative 104–109 ppm 2237–2259 cm–1 
Kinamycins 78.5 ppm for kinamycin D 2119–2170 cm–1 
Prekinamycin diacetate 83.7 ppm 2119 cm–1 
 
Gould and co-workers made the same conclusion independently by careful comparison of 
the statistical R factor for fitting of the three possible linear fragments (N-C-N, N-N-C and 
C-N-N) to the electron density map, based on the X-ray crystallographic data for the α-












1-20a  X=N,  Y=C,  Z=N     5.69%     6.35%
1-20b  X=N,  Y=N,  Z=C     5.73%     6.41%
1-20c   X=C,  Y=N,  Z=N    5.18%     5.63%
R Rw
 
The reassignment of the structures of kinamycins had profound implications to various 
aspects of studies in chemistry and biochemistry in these natural products. In particular, 
Gould and co-workers carried out systematic studies on the biosynthesis of kinamycins since 
the 1980s as pioneers in this area. Their work defined the overall biosynthetic pathway to the 
kinamycins primarily at the structural level. However, the structural revision indicated above 
required a reinterpretation of their earlier observations. 
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1.3 Biosynthesis of Kinamycins 
1.3.1 Determination of the Origin of the Ring System and Diazo Moiety 
Incorporation of sodium [1, 2- 13C2] acetate 1-21 and sodium [1-13C, 2, 2, 2-D3] acetate 1-
22 to kinamycin D and C produced by feeding labelled sodium acetate to S. murayaensis 
revealed that the entire skeleton of kinamycins was derived from acetate, apparently through 
























































A green metabolite, dehydrorabelomycin 1-24, isolated from S. murayamaensis, was 
confirmed to be a key intermediate in the biosynthetic pathway of the kinamycins.9 Then the 
Gould groups assigned the 13C NMR signal at δ 78.5 ppm to the putative cyanamide carbon, 
and they found this carbon was derived from C-2 of the acetate by separately feeding sodium 
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[1-13C] acetate and [2-13C] acetate to S. murayamanensis. The relatively uniform levels of 
isotope enrichment of the carbon of cyanamide moiety and the others of the skeleton led 






























Kinamycin D  
The 1994 landmark reassignment of structure to the kinamycins led to an extensive 
revision of the understanding of their biosynthesis in terms of the intermediate metabolites 
involved. Nevertheless, the new diazobenzo[b]fluorene structure was entirely consistent with 






1-25 Stealthin C  
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This structure correction greatly expanded the number of naturally occurring diazo 
compounds as well as the number of the benzo[b]fluorenes such as stealthin C (1-25), which 
was detected in 1997 in extracts of S. murayamaensis mutant strain MC2 and gained a new 
meaning for the biosynthetic studies.19 Feeding deuterium-enriched stealthin C to S. 
murayamensis produced deuterated kinamycin D. However, the labeled oxime 1-27a, which 
exists in equilibrium with its nitroso tautomer 1-27b, was found to not be a precursor of the 
kinamycins. This result suggested that the diazo group of the kinamycins was formed by 
stepwise addition of the two individual nitrogens, which did not involve a nitroso 
benzo[b]fluorene intermediate. However, the details of the conversion of the amino group in 



















































The labeling studies along with identification of other minor metabolites from S. 
murayamaensis or its mutants (prekinamycin 1-3,4,8,20 kinobscurinone 1-32,21 
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ketoanhydrokinamycin 1-4)4,22 allowed for a formulation of a hypothetical biosynthetic 
pathway for kinamycins as presented in Scheme 1-5. Dehydrorabelomycin 1-24, which can 
be derived from a single decaketide precursor 1-29, might undergo an oxidative ring opening 
at C-5 and C-6. An electrophilic cyclization of hydroquinone 1-30 followed by a 
decarboxylation would afford kinobscurinone 1-32. A transformation equivalent to a 
reductive amination might lead to stealthin C 1-25 and then an oxidative incorporation of 
second nitrogen would provide prekinamycin 1-3. Subsequent steps would alter the level of 










































































1.3.2 Biosynthetic Elaboration of the Kinamycin D-ring 
Incorporation of sodium [1-13C, 1,1-18O2] acetate 1-33 into kinamycin C or D indicated 
that the oxygens of C1, C6, C7 and the ester carbonyl were derived from sodium acetate 
through a polyketide intermediate. A fermentation experiment in the presence of 18O2 was 
carried out and revealed that oxygens attached to C3, C4, and C11 of kinamycin D came from 


























Kinamycin C, R= CH3C
18O



















The biosynthetic study of antibiotic LL-C10037α revealed a procedure involving 
oxidation of a phenol to a hydroquinone, followed by oxidation epoxidation directly to an 
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epoxyquinone, and then reduction to the epoxyquinol.23, 24, 25 On the basis of this example, an 
analogous set of reactions was suggested for the conversion of prekinamycin to 


































The early biosynthetic study had identified kinamycin F, as a metabolite of S. 
murayamaensis, and it is apparently the branch point to the various O-acetylated kinamycins. 
The Gould group isolated kinamycin acetyltransferase I (KAT I) whose enzymatic activity 
was responsible for the two consecutive acetylations of kinamycin F via kinamycin E to 
kinamycin D.26 Furthermore, in order to account for the rest of the ring-D acetylation at least 





























Kinamycin F Kinamycin E Kinamycin D
Kinamycin C or A  
1.4 Synthetic Studies towards the Prekinamycin and Kinamycins 
Since the reassignment of the structure of kinamycins to diazobenzo[b]fluorenes many 
groups have been working on the synthesis of these unusual natural products or the 
biosynthetic precursor prekinamycin 1-3. A number of synthetic strategies have been 
disclosed, and are discussed below. 
Hauser and Zhou reported the first total synthesis of the structure assigned to 
prekinamycin in 1996 as indicated in Scheme 1-9.27 Starting from the dihydrocoumarin 1-36, 
an intramolecular Friedel-Crafts reaction was carried out, followed by methylation to afford 
1-37, which was converted to a silyl enol ether, followed by treatment of Pd(OAc)2 to give 
indenone 1-38. Condensation of the anion of the phthalide sulfone 1-39 with the indenone 1-
38 regiospecifically afforded the benzo[b]fluorene 1-40. Treatment of 1-40 with BBr3 gave 












































1-38   75%
1-39
1-40    73% 1-41
1-42 1-3   38% from 1-40
1-37   60%1-36
 
In 2007, Birman and co-workers reported a rapid construction of benzo[b]fluorenes via 
reaction of 1-indanone dianion with phthalate diesters, which was used in a concise synthesis 
of prekinamycin as presented in scheme 1-10.28 Reaction of the phthalate diester 1-43 with a 
enolate of indanone 1-37, using LTMP as a base, led to the desired product 1-44 
regioslectively. Refluxing this benzo[b]fluorene 1-44 with MsNHNH2 in ethanol gave crude 
mesylhydrazone 1-45, which was demethylated with BBr3 and then converted to 





































1-43 1-37 1-44   81%
1-45 1-46 1-3   85% from 1-44  
In 2006 Porco and Lei achieved the first enantioselective total synthesis of kinamycin C, 
and the retrosynthetic analysis is as presented in Scheme 1-11.29 They reasoned that 
kinamycin C might be derived from oxidation and diazo group formation from MOM-
protected benzofluorene ketone precursor 1-47. Compound 1-47 might be obtained from 
intramolecular Friedel-Crafts cyclization of carboxylic acid 1-48. Acid 1-48 should be 
available through Stille cross coupling of vinyl bromide 1-49 (fragment A) and MOM-
protected arylstannane 1-50 (fragment B). Fragment A 1-49 may be derived from 
epoxyketone precursor 1-51, which could be obtained from tartrate-mediated asymmetric 
nucleophilic epoxidation of quinone monoketal 1-52. Fragment B 1-50 could be achieved 















































(fragment A) (fragment B)  
The synthesis of fragment A 1-49 started from the readily available 2-bromo-3,6-
dihydroxy-benzaldehyde 1-53 as presented in Scheme 1-12. Selective methylation, followed 
by reduction, provided 1-54. Hypervalent iodine oxidation of 1-54, followed by 
transketalization and silyl protection, afforded quinone monoketal 1-55, which was converted 
to the corresponding quinone monoketal 1-52 using Et3P as a nucleophilic activator. These 
were conditions modified relative to those reported by Aggarwal.30 Tartrate-mediated 
asymmetric nucleophilic epoxidation of compound 1-52 generated epoxide 1-51 with higher 
yield and enantioselectivity compared with Sharpless asymmetric epoxidation. This was 
followed by hydroxyl-directed reduction and selective mesylation of the primary alcohol 
which afforded 1-56. Reductive demesylation cleanly produced 1-57, and then selective 






















































    AcOH
2. MsCl
    collidine
Super-Hydride
K-10 clay
1-53 1-54   84% 1-55   72%
1-52   70% 1-51    94%, 90% ee 1-56   77%




The synthesis of fragment B 1-50 began with the readily available 1,5-naphthoquinone 1-
58. Protection of 1-58 with MOMCl/DIPEA generated naphthalenedione 1-59, which was 
subsequently reduced with Na2S2O4 and further protected to provide 1-60. Stannylation of 




















    DIEA
Bu3SnSnBu3
Pd(PPh3)4
1-58 1-59   85% 1-60   70%
1-50   70%  
Cross coupling of fragment A 1-49 and fragment B 1-50 under suitable conditions 
(Pd2(dba)3,  AsPh3, CuCl, DIEA) generated desired product 1-61. Further reduction of 1-61 
with Super-Hydride® provided the syn-epoxyalcohol, which was subjected to the epoxide-
opening using Ti(Oi-Pr)4 and n-Bu4NOAc to afford triol 1-62. Acylation of 1-62 followed by 
deprotection of silyl ether produced alcohol 1-63. Sequential oxidation of 1-63 using TPAP 
and NaClO2 afforded carboxylic acid 1-48, which was cyclized with intramolecular Friedel-
Crafts cyclization to form C ring using TFAA. Meanwhile, two MOM protecting groups 
were also removed regioselectively. MOM deprotection, followed by oxidation using Pd/C 
and air, generated ketoquinone 1-65. Condensation of 1-65 with 1,2-bis(tert-
butyldimethylsilyl)hydrazine afforded 1-66, which was treated with PhIF2 to install the diazo 
















































1-61   70% 1-62   48%











































1-66 Kinamycin C   35%
N
TBS H 1-1c  
In 2007 Ishikawa and co-workers reported the total synthesis of racemic methyl-kinamycin 
C.31 The strategy is as presented in Scheme 1-15: The tetracyclic ring structure 1-68 was 
constructed by Diels-Alder reaction of the benzo[f]indenone 1-70 and Danishefsky-type 
diene 1-71 followed by hydrolysis and oxygenation of the adduct 1-69. Then the oxygen 
functionality was introduced on the D ring stereoselectively.  The benzo[f]indenone 1-70 
may be obtained from the corresponding indanone 1-72, which was achieved from 
naphthalenepropanoic acid 1-73 via intramolecular Friedel-Crafts reaction. The acid 1-73 












































The synthesis of benzo[f]indenone 1-70 was initiated from naphthalene-1,5-diol 1-74. 
Acetylation, followed by the oxidative bromination using NBS in AcOH provided bromo-5-
O-acetyljuglone 1-75, whose acetyl function was replaced by a methyl group to afford 1-76. 
Reduction of 1-76 with SnCl2 and HCl, followed by the methylation, produced 2-bromo-
1,4,5-trimethoxylnaphthalene 1-77. Then subsequent treatment of 1-77 with BuLi and DMF 
provided naphthaldehyde 1-78. The Knoevenagel reaction of 1-78 with malonic acid under 
sonication followed by catalytic hydrogenation generated naphthalenepropanoic acid 1-73. 
Then intramolecular Friedel-Crafts reaction of 1-73 using P2O5 and MeSO3H provided an 










































1-74 1-75   75% 1-76   73% 1-77  77%
1-78   84% 1-73   87% 1-70   61%  
A Diels-Alder reaction in CH2Cl2 using a catalytic amount of ZnCl2 gave smoothly the 
tetracyclic adduct 1-69, which was treated with CSA and then oxidized to enone 1-68 using 
KF in the presence of air. Syn-selective dihydroxylation of enone 1-68 provided the desired 
cis, cis-triol 1-79, which was converted to the corresponding silyl enol ether 1-80 using 
TMSOTf. Oxidation of 1-80 with m-CPBA afforded the undesired 1β-silyloxyketone, which 
was completely isomerized to the desired 1α-silyloxyketone 1-81. Then cleavage of the TMS 


























































ZnCl2, CH2Cl2 1. CSA
2. KF, DMSO
    air
1. OsO4, TMEDA
2. NaHSO3, H2O






1-69 1-68   48%
1-79   66% 1-80   78%
1-81   71% 1-82   91%  
Acetylation of the secondary alcohols in tetraol 1-82 generated diacetate 1-83 selectively, 
which was subjected to diastereoselective reduction with (CH3)4NBH(OAc)3 controlled via 
five-member ring chelation from the o-hydroxy group to afford triol 1-84. Partial over- 
reduction was recovered with MnO2. Then ketalization of triol 1-84, followed by dehydration 
with methyl(carboxysulfamoyl)triethylammonium hydroxide inner salt, produced 
benzofluorene 1-86. Then deketalization and partial acetylation provided triacetyl enone 1-87. 
Condensation of 1-87 with TsNHNH2 using BF3-Et2O followed by treatment with CAN, 
which led to oxidation to naphthoquinone as well as spontaneous desulfination of the tosyl 


































































1-83   70% 1-84   69%
1-85   67% 1-86   52%
1-87   85% 1-67   32%  
Most recently Nicolaou and co-workers reported the enantioselective synthesis of 
kinamycin C, F and J.32 The fluorenone skeleton of kinamycin was built up via an Ullmann-
type coupling between the two key building blocks 1-88 and 1-89 followed by an 
intramolecular benzoin-like condensation and further elaboration. The diazo group was 














The synthesis of building block 1-88 was initiated from 1-90, which was oxidatively 
allylated using Jacobsen-Torssell reaction with vinyl acetic acid in the presence of 
(NH4)2S2O8 and catalytic amount of AgNO3 to generate naphthoquinone 1-91.33 This 
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intermediate was converted to corresponding dimethoxy benzyl form 1-92. Then conjugation 
of the olefinic bond of the latter compound, followed by cleavage using OsO4 and NaIO4, 


























1-90 1-91   75% 1-92   69%
1-88   82%  
The construction of the other building block, iodo-enone 1-89, in its enantiomerically pure 
form was carried out as summarized in Scheme 1-20. Thus, the readily available enone 1-93 
was converted to its methylated derivative 1-94 via conjugate addition of MeMgBr and 
trapping with TMSCl, followed by Saegusa oxidation of the resulting silyl enol ether using 
catalytic Pd(OAc)2  in the presence of O2.34 Then stereoselective dihydroxylation of the latter 
compound 1-94 with catalytic OsO4 and NMO afforded a vicinal diol 1-95, which was 
protected with 2-methoxypropene to generate an acetonide 1-96. Treatment of ketone 1-96 
with LiHMDS-TMSCl, followed by the Saegusa oxidation, led to an enone 1-97. Iodination 
































    TMSCl
2. Pd(OAc)2 cat.





    O2
I2, py
1-93 1-94   90% 1-95   76%, > 98% ee
1-96   95% 1-97   84% 1-89   92%  
The fragments 1-88 and 1-89 were coupled under modified Ullmann condition using Cu, 
catalytic amount of CuI and Pd2(dba)3 to generate coupling product 1-98, which was 
subjected to benzoin-type reaction in the presence of the Rovis catalyst 1-99 to provide 
alcohol 1-100. Acetylation of the latter, followed by the reductive cleavage of the acetate and 
conjugation of the double bond, generated a fluorenone, which was oxidized to an allylic 
alcohol 1-101 stereoselectively. The TBS and acetonide were removed from 1-101 using 
aqueous HF in MeCN, and the resulting tetrol was selectively tri-acetylated and debenzylated 
to afford an advanced fluorenone 1-102. The fluorenone 1-102 was temporarily protected 
with TBSCl and then sequentially treated with TsNHNH2 and CAN to generate TBS-
protected kinamycin C, which could be converted to kinamycin J by acylation and 
deprotection of TBS silyl ether, on one hand, as well as converted to kinamycin C using 
aqueous HCl in MeCN and kinamycin F by treatment of kinamycin C with aqueous LiOH in 































































































1-98   83% 1-99 1-100   78%
1-101   55% 1-102   88%
1-103   38%
Kinamycin C   95% Kinamycin F   92% Kinamycin J   80%  
1.5 Identification of Isoprekinamycin 
As indicated above, Hauser and Zhou reported the first total synthesis of prekinamycin in 
1996.27 However, the synthetic compound was found not to match the spectral properties of 
the prekinamycin (also known in Gould’s group as Cpd A). The synthetic product was found 
to be indistinguishable from a previous structurally uncharacterized metabolite, Cpd B, 
discovered by the Gould group by screening the library of components isolated from S. 
murayamaensis.8 Thus, the Gould group assigned the prekinamycin structure to Cpd B, 
which left Cpd A without an assigned structure. 
Cpd A, originally also referred to as prekinamycin, was first isolated in 1989 by Gould and 
co-workers from a fermentation medium of S. murayamaensisi sp. Nov. Heta et Ohtani.4, 22 
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This purple solid was found to be moderately active against Gram-positive organisms such as 
Staphylococcus aureus ATCC 25923 and Streptococcus faecalis ATCC 29212, which is 
important since these organisms have developed substantial resistance to the more common 
β-lactam antibiotics.22, 35 
   This group at the University of Waterloo cooperated with Proteau’s group at Oregon State 
University to reassign the diazobenzo[a]fluorene structure to Cpd A based on detailed re-
examination of the available chemical and spectroscopic data of Cpd A as well as results of 
synthetic and spectroscopic studies done by R. S. Laufer in this laboratory.36 
  The elemental and mass spectrometric analysis of the Cpd A led to the assignment of 
C18H10N2O4 as the molecular formula so that it is isomeric with prekinamycin (Cpd B). The 
IR spectrum included a band at 2162 cm–1, which was attributed to the diazo group. The 
proton NMR spectrum revealed a pattern of three adjacent hydrogens, just as in the A-ring of 
the kinamycins: δ 7.04 (1H, dd, J = 0.9, 7.2 Hz), 7.17 (1H, dd, J = 7.0, 7.2 Hz), 7.24 (1H, dd, 
J = 0.9, 7.0 Hz). The two other resonances at 6.60 and 6.69 ppm indicated the presence of 
two meta-related protons in a tetra-substituted aromatic ring, which were related to the 
methyl resonance at 2.39 ppm as indicated by HMBC NMR experiments. The two remaining 
resonances at 11.60 and 12.32 ppm could belong to two hydrogen-bonded, exchangeable 
hydrogens, likely phenols in this case. Although this compound was not suitable for 13C 
NMR analysis because of its very poor solubility in any desired solvent, the diacetate of it 
did show resonances at δ 174.14, 192.48, 170.28, 170.64 and a signal at 83.71 ppm, the latter 
of which belonged to the carbon bearing a diazo group.  
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  One particular chemical evidence reported by Gould and co-workers involving the 
deazotization of Cpd A as presented in Scheme 1-22, led them to assign 1-104 to the 
structure of the deazotization product of Cpd A. The monomethylated products 1-105 and 1-
106, which were founded from the deazotization of Cpd A using Rh2(OAc)4 in MeOH 
followed by methylation with MeI/K2CO3, showed nOe enhancements which were 























nOe nOe1-104 1-105 1-106  
However, in the independent work at Waterloo, a comparison of 1-104 and its two 
tautomers 1-107 and 1-108 using ab initio MO calculation led to the conclusion that 1-104 
was expected to be much less stable than the tautomers 1-107 and 1-108. This led to a 
rejection of structure 1-104 for product of the hydrodediazotization of Cpd A. The structures 
1-107 and 1-108 were rejected as possible structures because they were incompatible with 
nOe and HMBC NMR results. These revealed that the deazotization product of Cpd A could 













1-104 1-107 1-108  
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  The HMBC spectrum of Cpd A diacetate showed a weak three bond correlation between H-
10 and carbonyl carbon at 192.48 ppm in addition to the known correlation of H-4 and the 
diazo carbon (82.64 ppm). This indicated that Cpd A incorporated partial structure 1-109 and 
1-110, but how these fragments combined in the structure of Cpd A was unclear. Any 
combination of these partial structure had to fit the criteria that both phenolic hydroxyls are 
capable of intramolecular hydrogen bonding and a carbonyl must be in the ring adjacent to 
the ring A (based on a weak HMBC correlation between H-10 and the carbonyl at 192.48 
ppm). Because the 13C NMR shift of 192.48 ppm suggested that this carbonyl is in a five-
membered ring, the possible structures might have a 6, 5, 6, 6 ring system, rather than the 6, 
6, 5, 6 rings system observed in the kinamycins. Distinguishing between the various 
possibilities by direct NMR experiments, however, was hampered by the lack of protons in 













Fortunately, Proteau and co-workers treated Cpd A with sodium borohydride, which 
reduced the carbonyl and deazotized Cpd A to generate an alcohol in which the necessary 
connectivities suitable for both 1D and 2D NMR analysis (HMQC, HMBC) could be 
established. The two new introduced protons appeared at 7.16 and 7.50 ppm, and turned out 
to be critical for assembling the structure of Cpd A. The proton at 7.16 ppm was attached to a 
carbon at 76.08 ppm, which was the site of ketone reduction. This hydrogen showed HMBC 
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correlation to ring A carbons 6b, 10, 10a, indicating the placement of the secondary alcohol 
center in ring B. Meanwhile, the HMBC correlation from H-10 to the carbon at 76.08 ppm 
confirmed the placement of the alcohol at C-11. The 7.50 ppm proton had HMBC correlation 
with C-4, C-4a, and C-11b, indicating that this hydrogen, H-5, had replaced the diazo group. 
Further HMBC correlations from H-5 to a carbon resonance at 144.2 ppm and an acetate 
carbonyl carbon at 169.92 ppm established C-6 as a phenolic carbon Additional correlations 
in the HMBC spectrum allowed for complete assignment of the tetraacetate which was 



























1-111 1-112 1-113 1-114  
  The structure of this reduction product is compatible only with the structure 1-112 from 
among several possibilities considered for Cpd A. This structure assignment was further 
confirmed by the comparison of the spectroscopic properties of 1-111 and Cpd A with the 
model benzo[a]fluorene systems 1-113 and 1-114 synthesized in this laboratory. 
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Table 1-3 Comparison of 1-111 and Cpd A Diacetate with Model 1-113 and 1-114 
 1-111 1-113 
13C NMR of C-11 76.08 ppm 74.37 ppm 
1H NMR of H-11 7.16 ppm 7.23 ppm 
 
 Cpd A diacetate 1-114 
13C NMR of C-diazo 83.71 ppm 82.64 ppm 
13C NMR of C-11 192.48 ppm 196.77 ppm 
IR band of diazo group 2119 cm-1 2105 cm-1 
 
Thus, Cpd A was shown to have the structure 1-112, and was renamed isoprekinamycin. 
1.6 Studies Related to the Mechanism of Action of Kinamycins and 
Isoprekinamycin  
The kinamycins, shown to exhibit good activity against Gram-positive but not Gram-
negative bacteria, are of additional current interest because of recently reported in vitro 
cytotoxicity profiles against cancer cells which are suggestive of a mode of action different 
than that of anticancer agents in current clinical use.37 The discovery of lomaiviticin 1-115, 
which is a dimeric analogue of the kinamycins possessing potent cytotoxicity against a range 
of cancer cell lines, that is higher than that observed for monomeric kinamycins, has 





















1-115 Lomaiviticin A  
1.6.1 Proposed Mechanism of Action for Cyanobenzo[b]carbazole Structure 
Although much is known about the biosynthesis of the kinamycin39, surprisingly little 
information exists concerning the chemical basis for their biological activity. 
In 1977, Moore speculated that kinamycin C might be a potential reductive alkylation 
agent same as mitomycin C 1-116 based on the fact that both of them had structures 
containing indoloquinones incorporating suitably positioned leaving groups.40 Mitomycin C 
had been known to be a DNA cross-linking agent under reductive conditions as presented in 
Scheme 1-23.41 Thus, a reduction to the hydroquinone, followed sequentially by an expulsion 
of the angular methoxy group then tautomerization, provided a vinylogous quinone methide 
1-119, which was activated to nucleophilic attack (e.g. by deoxyguanosine of DNA42,43). A 
subsequent expulsion of the carbamate group in 1-120 generates a Michael acceptor 1-121. 
The DNA bis-alkylation might be reversible for both strands of DNA,44 but reversal might be 































































1-122 1-123  
For kinamycin C (with the unrevised structure 1-124), an in vivo reduction to the 
hydroquinone 1-125 followed by elimination of two acetate groups might generate a Michael 
acceptor 1-127 as presented in Scheme 1-24. This bioreductive alkylation proposal by Moore 
can not be disregarded even after the reassignment of the structure of kinamycins from N-
cyanocarbazoles to diazobenzo[b]fluorenes since the diazo group is isomeric and 
































































1-127 1-128 1-129  
1.6.2 Suggested Mechanism for Diazobenzofluorenes 
Moore’s proposal did not involve the N-cyano or the isoelectronic diazo group, which 
might be relevant to the biological activity of the kinamycins. In addition, kinafluorenone 1-
130, which lacks a diazo moiety, shows no detectable antibiotic activity against B. stubtilis 
ATCC 663, which is very sensitive to the kinamycins.21 When the project began neither 
prekinamycin and isoprekinamycin (IPK) 1-112 had been known to present anticancer 






















  Since the structural revision of the kinamycins, there have been considerable speculations 
concerning the mode of action based on the assumption that the kinamycins are DNA 
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cleaving agents in vivo. Jebaratnam and Arya suggested that the diazo group in the 
kinamycins may serve as a precursor for carbene or radical intermediate in vivo, which are 
involved in the mode of action for these antitumor antibiotics.45 As presented in Scheme 1-25, 
9H-fluorene-9-diazoniun ion or 9-diazofluorene alone in the presence of the reductive 
regents such as Cu2Cl2 did not induce any cleavage of DNA, but oxidation of 9-diazofluorene 
with cupric acetate led to a cleavage of DNA, which was speculated to involve either copper-



















aq Tris-HCl buffer (pH= 7.6)
DNA
MeOH





  Meanwhile, Zaleski and co-workers used photoreactions of bis(9-diazo-4,5-
diazofluorene)copper(II) nitrate Cu1-1322(NO3)2 as a model for a possible mode of action of 
the kinamycin antibiotics (scheme 1-22), in which CuII again was found important for the 
DNA cleavage.45 The metal-ligand photoredox was suggested to play a critical role in the 
oxidative formation of damaging cation radicals from Cu1-1322(NO3)2.47, 48 
The significance of Zaleski’s work is not clear since there is no experimental evidence for 































1-135  R1 = OH, R2 = H
1-136  R1 = H, R2 = OH
1-1b 1-137










  Model compound 1-114 was synthesized in this laboratory. Comparison of its susceptibility 
to nucleophilic attack with that of isoprekinamycin indicated that this natural product is 
rendered more diazonium ion-like because of the intramolecular H-bonding network present. 
Furthermore ab intio MO calculations supported this and revealed that even greater 
diazonium ion-like character should be expected from kinamycins and lomaiviticin A. All 
these led to the proposal that the enhanced reactivity of the diazo group in these natural 
products may play a role in their antitumor and antibiotic activity.47 
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Table 1-4 Calculated C-N2 Frequencies and N-N Bond Lengths 





























 The IR stretching frequency assigned to the diazo group in the model compound (1-114, 
2105 cm–1) was 57 cm–1 lower than that of isoprekinamycin 1-112 (2162 cm–1), which 
matched quite well with the calculation (∆v = 52 cm–1). Meanwhile the calculation revealed 
that the N-N bond of model 1-114 was shorter relative to that of isoprekinamycin 1-112. 
Furthermore, the N-N bond lengths and stretching frequencies calculated for the related 
systems indicated a trend of increasing the diazonium ion character in the order of 9-
diazofluorene < 2,1-naphthoquinodiazide < 1-114 < 1-335 <1-336 < isoprekinamycin 1-112 
(table 1-4), which indicated that the diazonium ion character of the diazo group in 
isoprekinamycin was enhanced by both the carbonyl group in B ring and the H-bonding 
network. Similar calculations showed that an even higher degree of diazonium ion character 
in the N-N bond in the kinamycins and the simplified model of lomaiviticin A 1-137 
paralleling the trend in antitumor and antibiotic activities (1-112 < 1-1 < 1-115). The 
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enhancement of the reactivity of isoprekinamycin compared to the key model 1-114 was 
confirmed in the experiment as presented in Scheme 1-26. The model 1-114 and 
isoprekinamycin 1-112 were reacted with β-naphthol in the presence of Cs2CO3. At room 
temperature, the model compound gave azo adduct 1-138 whereas isoprekinamycin provided 
a 1:2 mixture of adduct 1-139 and hydrodeazonization product 1-140. However, at 0 °C in 
the same condition, isoprekinamycin 1-112 was completely converted to a mixture of 1-139 









































 Thus, isoprekinamycin, the kinamycins and the lomaiviticins might be activated toward 
attack by nucleophiles at the diazo group. In the case of aryl diazonium ions, nucleophilic 
attack at the terminal nitrogen of the diazonium ion group is an obligatory step prior to 




Ar-N2++ :Nu- N N NuAr Ar + N2 + Nu  
Feldman and Eastman have explored reactions of prekinamycin and its O,O-diacetyl and 
O,O-dimethyl derivatives with tributyltin hydride and AIBN at 80 °C in various aromatic 
solvents. In benzene, the major product is the apparent result of addition of the radical 1-143 















































Bu3Sn H - N2 Bu3Sn H
AIBNSiO2
1-141 1-142 1-143 1-144
1-145
1-1461-147  
It was suggested that this chemistry serves as a model for a single electron transfer 
mechanism for activation of kinamycins as DNA cleaving agents in vivo.  In particular it was 
suggested that the single electron reduction would lead to formation of sp2 radical 1-150 at 




























1-149c 1-150  
It was further hypothesized by Feldman and Eastman that the radical 1-150 might abstract 
a hydrogen atom from a deoxyribose unit of DNA to initiate DNA strand cleavage and to 
produce an o-quinodiazide intermediate 1-153 which itself might contribute to DNA 




































Although they provided a convincing argument in support of the formation of a sp2 radical 
at C-11 as an intermediate in their chemistry it is not clear how relevant these observations 
are to the true mode of action of the kinamycins given the highly non-physiological 
conditions of the model reactions that Feldman and Eastman have reported. 
1.6.3 Studies of Mechanism of the Cytotoxicity of the Kinamycins 
Recently, this group established the collaboration with a cell biology group headed by 
Professor Brian Hasinoff in the Faculty of Pharmacy at the University of Manitoba in order 
to probe the mode of action of the kinamycins and IPK in whole cells. 
Hasinoff, Dmitrienko, and coworkers investigated the cell growth and cell cycle inhibitory 
effects of the kinamycin A and kinamycin C in attempt to determine their mechanism of 
action.37 Both these kinamycins were shown to have very potent cell growth inhibitory 
effects on both Chinese hamster ovary and K562 human leukemia cells. Kinamycin C was 
found to induce a rapid apoptotic response in K562 human leukemia cells. In cell cycle 
analysis results of synchronized Chinese hamster ovary cells, kinamycin A was found to 
induce a G1/S phase block upon entry to the second cycle. Both kinamycins inhibited the 
catalytic decatenation activity of DNA topoismerase IIα, but neither kinamycin acted as a 
topoisomerase II poison. IPK and IPK diacetate were also found to inhibit topoisomerase 
IIα.53 Their inhibition of catalytic activity did not, however, correlate with cell growth 
inhibitory effects. Pretreatment of kinamycins with dithiothreitol protected the topoisomerase 
IIα activity in vitro, which indicated that inhibition of topoisomerase IIα was perhaps as a 
result of reaction with the activated electrophilic diazo group. Although the cellular target(s) 
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of the kinamycins has (have) yet to be identified, the cluster map analysis of the anticancer 
activity of kinamycin C against the 60-cell line panel at the National Cancer Institute, and the 
cell cycle and pro-apoptotic effects suggested that kinamycin C has a target different than 
other established anticancer compounds.37 
More recently, kinamycin F was investigated as a potent antitumor agent by Hasinoff, 
Dmitrienko and coworkers.54 Kinamycin F was shown to react with glutathione (GSH) in a 
complex series of reactions which suggested that kinamycin F may have its cytotoxicity 
modulated by GSH. Kinamycin F was found to bind weakly to DNA and induced DNA 
damage in K562 cells which was independent of GSH level. In vitro studies showed that 
kinamycin F was capable of causing DNA nicking and that this effect was enhanced in the 
presence of GSH at approximately intracellular concentration.  
Still more recent unpublished studies by Hasinoff and Dmitrienko groups55 indicate that 
kinamycin F causes down-regulation of Cyclin D3 in human myelogenous leukemia K562 





Chapter 2 Model Studies for the Synthesis of 
Diazobenzo[a]fluorenes 
2.1 Introduction 
As indicated in Chapter 1, isoprekinamycin (IPK), first assigned structure 2-1,1 is now 
recognized as the diazobenzo[a]fluorene 2-2.2 The previously rare benzo[a]fluorene class of 
natural products now boasts several other members (fluostatins A–E) with various degree of 
oxygenation in D ring but lacking a diazo group.3,4,5,6 In this group, studies suggesting a 
substantial diazonium ion character in the diazo group of IPK, which might play a role in its 
bioactivity, have inspired us to design a practical synthesis of IPK. This work was initiated 
















































Fluostatin B Fluostatin C Fluostatin D Fluostatin E  
 
Besides the formal work in this laboratory there are a number of reports related to the 
synthesis of the benzo[a]fluorenes. Echavarren and coworkers reported that the thermal 
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cyclization of diaryldiynones 2-3 generated not only the benzo[b]fluorenes (2-8 and 2-9), but 
also the unanticipated benzo[a]fluorenes (2-10). The formation of the latter products possibly 
























2-10   8%-63%
2-8  R = SiMe3   9%-41%
2-9  R = H   7%-45%
2-3a: X = OMe, Y = Z= H
2-3b: X = Y = Z = H
2-3c: X = Me, Y = Z = H
2-3d: X = Z = H, Y = Me





















2.2 Previous Works in This laboratory 
Radoslaw S. Laufer in this laboratory developed a methodology for building up the 
diazobenzo[a]fluorene, and a model compound 2-11 of isoprekinamycin was synthesized 
successfully.8 A retrosynthetic analysis is presented in Scheme 2-2. It was reasoned that the 
diazo group was introduced at final stage via the phenol 2-12. The entire ring system might 
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be completed in a Friedel-Crafts cyclization of a biaryl compound such as 2-13, derived from 
























2-2   R1 = OH, R4 = Me




Y= B(OR)2, Z = Br, OTf
R3 = Me
 
The boronic acid fragment 2-18 was synthesized by sequential treatment of benzamide 2-
17 with s-BuLi and B(OMe)3. The benzamide was derived from benzoyl chloride 2-16. 
Orthometalation of 2-methoxynaphthalene 2-19 with n-BuLi, followed by treatment with 
BrCH2CH2Br provided fragment 2-20, which was coupled with 2-18 via Pd catalyzed Suzuki 





















2-16 2-17   quant 2-18   quant






The anionic cyclization of 2-21 produced benzo[a]fluorenone 2-22, which was inert 
towards electrophilic bromination presumably because of deactivation by the carbonyl group 
of the B ring. Thus, 2-22 was reduced with NaBH4 then protected with TBSOTf to form the 
silyl ether 2-23, which could be brominated smoothly with NBS in DMF. The palladium- 
catalyzed amination reaction of aryl bromide 2-24 with benzylamine, via the Buchwald 
procedure with Pd2(dba)3, (S)-BINAP and t-BuOK, resulted in  the desired amination as well 
as in situ desilylation and oxidation to form ketone 2-25. Palladium-catalyzed hydrogenolysis 
of 2-25 provided the aniline 2-26, which was transformed to diazo compound 2-11 by 





























    HCl/ EtOH
2. NaHCO3
2-22   85% 2-23   95%
2-24   73% 2-25   72% and 23% of 2-26 2-26   74%
2-11   64%  
Given the difficulties encountered in the introduction of functionalities ortho to the oxygen 
substituent in the benzo[a]fluorenone system described above, an alternative strategy was 
carried out to improve the efficiency of the synthesis (Scheme 2-5). Thus, ortho-metalation 
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of 2-methoxynaphthalene 2-19 with n-BuLi, followed by treatment with B(OMe)3 afforded 
the desired aryl boronic acid 2-27, which was cross-coupled with 2-28 by Suzuki coupling 
reaction to form diaryl adduct 2-29. The 2-29 was brominated then cyclized via 
intramolecular Friedel-Crafts reaction with methanesulfonic acid to provide aryl bromide 2-
31. Buchwald benzylamination of 2-31 produced the secondary amine 2-25 which could be 
converted into o-quinodiazide 2-21, as done previously, by debenzylation followed by 

































    HCl
3. NaHCO3
2-28
2-30   91%
2-31   91% 2-25   63%
2-11   64%  
After the synthesis of 2-11, an attempt was made to extend the methodology to the total 
synthesis of isoprekinamycin as presented as the retrosynthetic analysis in Scheme 2-6. The 
o-quinodiazide motif in the isoprekinamycin would be established by demethylative 
diazotization as in the synthesis of the model 2-11. The required aniline 2-32 might be 
derived by subjecting biaryl 2-34 to a sequence of bromination, Friedel-Crafts cyclization 
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and palladium-catalyzed amination. The biaryl 2-34 might be synthesized by a cross-
coupling between fragments 2-35 and 2-36, and 2-36 might possibly be derived from the 










































In practice, the A ring precursor boronate 2-40 was synthesized by ortho metalation of 3-
methoxybenzyl alcohol 2-39 followed by an electrophilic boronation with B(OMe)3 and 
acidic aqueous workup. The synthesis of the suitable naphthalene 2-44 was initiated from an 
anionic condensation between dimethyl succcinate with the commercially available 
benzaldehyde 2-41, which was heated with sodium acetate in acetic anhydride to provide an 
aromatic ester 2-42. The 2-42 was reduced with lithium aluminium hydride and subsequently 
diacetylated with acetic anhydride to afford intermediate 2-43, which was transformed to 
triflate 2-44 as the CD ring component of isoprekinamycin by sequential treatment with 

































2-39 2-40   51%
2-41 2-42   61% 2-43   55%
2-44   79%  
The Suzuki coupling between fragment 2-40 and 2-44 with Pd(PPh3)4 in the presence of 
Ba(OH)2 afforded benzylic alcohol 2-45, which was doubly oxidized subsequently by MnO2, 
then NaClO2 to produce carboxylic acid 2-47. However, the cyclization of the 2-47 via 
Friedel-Crafts reaction in the presence of methanesulfonic acid which was quite efficient in 
the synthesis of model compound was unattainable. Attempts to use the mild Lewis acidic 
SnCl4 to effect cyclization of the acyl chloride, prepared by a treatment of 2-47 with oxalyl 





































    cat. DMF
2. SnCl4
2-45   96%
2-46   79% 2-47   quant 2-48   quant  
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In order to investigate the possibility of the anionic approach to the synthesis of the target 
benzo[a]fluorenone ring system, the O-1 acetate functionality was exchanged to a robust 
protected group, isopropyl group. Replacement of the acetate in 2-45 was achieved by a 
sequence involving acidolysis of the protecting group in aqueous methanol and 
isopropylation with i-PrI and K2CO3. Two consecutive oxidations afforded a methyl ester 2-
50, which was transformed to the corresponding secondary amide 2-51. Unfortunately, 


































2-50   89%
2-51   65%  
Then the possibility of cyclization using the less labile O-methyl protecting group was 
explored. The carboxylic acid 2-57 was synthesized by only minor modification of the route 
used before, in which the intermediate 2-42 was saponified and doubly methylated to provide 
methyl ether 2-52 which was subjected to the following steps as shown in Scheme 2-10. 
Heating of the carboxylic acid 2-57 in methanesulfonic acid led to lactonization to 2-58. 
Matthew Buck in this laboratory synthesized the carboxylic acid 2-57' without a methoxyl 
group in A ring, and found that 2-57' was still converted to the lactone 2-58' even without the 
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interaction between the methoxyl groups in the A and C rings, presumably because of the bad 



















































    MeOH/ AcOH
KOH
MeSO3H
2-53   61%
2-54   80% 2-56   45%















2.3  A New Route to Diazobenzo[a]fluorenes 
Facing the fact that the formal methodology, although it was successful for the synthesis of 
the model 2-11, but finally failed to achieve the total synthesis of isoprekinamycin, a new 
route had to be found, which is general and practical for the synthesis of isoprekinamycin and 
its analogues. An alternative strategy was explored as shown in the Scheme 2-11. The diazo 
functionality would be installed late in the sequence by diazo transformation from aniline 2-
59, which might be derived from a suitable benzo[a]fluorene intermediate 2-60. This 2-60 
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could be obtained by an anionic cyclization forming C ring of the system from a diaryl 
precursor 2-61, which might be formed by the cross coupling between fragment 2-62 and 2-





































anionic cyclization C ring formation
+
2-2    R1= R3= OH, R2= Me





Z= B(OH)2, B(OR)2  
2.3.1 Synthesis of the AB Ring of Diazobenzo[a]fluorenes 
In practice, as the retrosynthetic analysis in Scheme 2-12 shows, the AB ring building 
block bromoindenone 2-64 would be obtained from the indanone 2-65, which might be 












2-64 2-65 2-66 2-67  
The indanone 2-67 was synthesized via ring opening/Friedel-Crafts cyclization of 
dihydrocoumarin (2-68) followed by methylation with Me2SO4. Although the condition of 
the cyclization is harsh (180-200 oC, AlCl3),9 the reaction proceeded smoothly with 65% 
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yield after methylation. An alternative procedure was reported by Cannon and coworkers.10 
Ring opening of 2-68 with NaOH followed by protection with benzoyl chloride afforded 
phenyl propanoic acid 2-70, which was converted to an acid chloride then cyclized to provide 
indanone 2-71. Then replacement of the protecting group led to the desired indanone 2-67. 
The latter procedure avoided the former harsh condition, the yield was decreased 



























    NaOH
(ref. 10)
 
The indanone 2-67 was converted to a carboxylic acid 2-66 by the β-carboxylation 
procedure reported by Kozikowski and coworkers.11 The indanone 2-67 was treated with 2.5 
equivalents LDA at -78oC in THF as presented in Scheme 2-14. It was believed that only one 
equivalent LDA was consumed at this stage to generate the enolate anion. The other 
equivalent of LDA remained unreacted. After adding TMSCl, the enolate anion was 
converted to an enol silyl ether, and at this stage the benzylic proton is acidic enough to be 
deprotonated by the remaining one equivalent LDA to afford a homoenolate intermediate 2-
72, which was converted to the carboxylic acid 2-66 by sequential treatment with CO2 and 
HCl. Matthew Buck in this laboratory found that treatment of 2-67 with 2.5 equivalents of 
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LDA, followed by trapping with TMSCl at –78 °C in THF, generated a mixture of 2-72 and 
2-73. Then the anion mixture of 2-72 and 2-73 was carboxylated with solid carbon dioxide 


























2-66 2-74  
Because of the selectivity of the procedure above was not as good as expected, this 
procedure was modified as shown in Scheme 2-15. Thus, enolization of indanone 2-67 with 
1.1 equivalents LDA followed by treatment with 1.05 equivalents TMSCl provided TMS-
protected silyl enolate 2-75. Deprotonation of 2-75 generated anion 2-72, which was 
transformed into the carboxylic acid just as in the same sequence above. In this reaction, 
several carboxylating reagents (BrCO2Et, (MeO)2CO and CO2) were examined in order to 
optimize the yield, and maximum yields were obtained by use of CO2, solid carbon dioxide.11 
In order to allow for the water in the solid carbon dioxide, more than one equivalent of the 








1. LDA (1.1 eq.)
2. TMSCl ( 1.05eq.)
    -78oC, THF







 LDA (1.5 eq.)
2-67 2-75 2-72
2-66  
Matthew Buck in this laboratory found that dibromination of the methyl ester 2-65 with 
2.0 equivalents of Br2 in CH2Cl2 for two days generated a dibromo compound, which was 
believed to be isomerized in refluxed THF for another two days to afford dibromo compound 
2-76. The elimination of 2-76 with DBU provided bromo-indenone 2-64. When this 
procedure was followed in the present study the result was a complex mixture. 



















2-76 2-64  
The unexpected long time and the difficulty of duplication of this procedure made us 
explore the reaction in more detail. After treatment of 2-65 with 2.0 equivalents of Br2 in 
CH2Cl2 at room temperature for three days, the major product was unexpectedly the desired 
bromoindenone 2-64 along with dibromoindanone 2-76 and 2-77, in whose proton NMR the 
shifts 5.23 ppm or 5.11 ppm referred to the proton α- to the ketone group in the 
dibromoindanone 2-76, and the shift 5.02 ppm might correspond to the proton β- to the 
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ketone group in the dibromoindanone 2-77. Following the time course of the reaction by 
proton NMR of the crude product it was found that after the first day of the reaction all 
starting material was consumed and no monobromo products appeared. The 
dibromoindanone 2-76 was the major product with a minor amount of dibromoindanone 2-77. 
After the second day, the ratio of 2-76 to 2-77 was lower and some bromoindenone 2-64 was 
observed. After the third day, the ratio of 2-76 to 2-77 kept going down and more 2-64 
appeared compared with the second day. We believed that dibromoindanones were the major 
products of this reaction in the first day. Meanwhile the reaction resulted in HBr formation in 
situ, which catalyzed the β-elimination of the dibromoindanone to generate bromoindenone 
2-64.  










































This reaction was found to be sensitive to the ratio of Br2 to starting material, the 
concentration of the Br2 in the reaction and the time of the reaction. Using 2.5 equivalents 
Br2 in CH2Cl2 (0.5 M in reaction solution) at room temperature for 24 hours, 2-65 was 
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converted to the mixture of 2-76 and 2-77. Treatment with DBU provided the desired 
bromoindenone 2-64 in 75% yield over two steps. 

























Thus, in the present project the synthesis of the AB ring synthon bromoindenone 2-64 was 
initiated from the dihydrocoumarin 2-70 via the sequence as presented in Scheme 2-19 and 














    K2CO3
1. LDA (1.1 eq.)
2. TMSCl (1.05 eq.)





1. Br2 (2.5 eq.)
2. CH2Cl2
         2-64
75% for two steps
         2-65
68% for two steps
2-66          2-67
65% for two steps
2-68
 
2.3.2 Synthesis of a Model of Isoprekinamycin 
With the AB ring building block 2-64 in hand, the palladium catalyzed Suzuki coupling 
between 2-64 and 2-79a-c using Pd(PPh3)4, KBr, Ba(OH)2 in DME and water was carried out 
by Matthew Buck in this laboratory, which generated diaryl compounds 2-80a-c smoothly 

















a  R = H
b  R = CHO






The biaryl compound 2-80c could be converted to benzo[a]fluorene 2-81 by an anionic 
cyclization using suitable base, which might be transformed to bromo precursor 2-82. Then 
the precursor 2-82 should be converted to the model of isoprekinamycin 2-58 via the same 


















Matthew Buck found that if LDA was used as a base for the anionic cyclization at 40 °C 
for 12 hours, only diisopropyl amide 2-83 was generated with some starting material 
remaining.   
In the present project, the cyclization of 2-80c was investigated using potassium 
hexamethyldisilazide (KHMDS) as base in THF with or without 18-crown-6 from 0 °C to 
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room temperature. However, the reaction always provided a complex mixture. Hence, it was 





















In 1987 Schwesinger and coworkers reported the extraordinarily basic uncharged 
polyaminophosphazenes 2-84a-d exhibiting MeCNpKBH values of up to 42.6.12 These 
polyaminophosphazenes were such strong bases because of the better charge delocalization 
of their cationic conjugated acids. With the exception of “proton sponges,” uncharged bases 
are kinetically highly active even towards weak acids, and naked anions thus generated are 
often extremely reactive. In reaction of such substrates with electrophiles, a low equilibrium 
concentration of the anion often suffices as long as the base is inert to the electrophile. Thus 












































2-84a  (t-Bu-P1): n = 0, MeCNpKBH = 26.89
2-84b  (t-Bu-P2): n = 1, MeCNpKBH = 33.45
2-84c  (t-Bu-P3): n = 2, MeCNpKBH = 38.60




Kraus and coworkers reported that the base 2-84d (P4-t-Bu) could efficiently deprotonate 
o-arylmethoxy benzaldehydes leading to a direct synthesis of benzofuranes.13 Treatment of 2-
85 with LDA in THF from -78 °C to 25 °C returned recovered starting material. The reaction 
of 2-85 with lithium tetramethylpiperidide (LiTMP) in THF from 0 °C to 25 °C afforded 
mostly recovered starting material. The 2-85 did not react with sodium hydride or potassium 
hydride in THF or DMF. However, the reaction of 2-85 with 1.1 equiv of 2-84d in 
pivalonitrile at 90–100 °C generated 2-(2-methoxylphenyl)benzofurane 2-86 in 49% isolated 
yield. Introducing an electron-withdrawing group in the system improved the cyclization 
such as the case of 2-87. Unfortunately with the present study, the cyclization of 2-80c with 
































Matthew Buck in this laboratory developed the sequence for the synthesis of 2-92 as 
shown in Scheme 2-25. Suzuki coupling between bromoindenone 2-64 and commercially 
available pinacol boronate 2-89 using Pd2(dba)3 as a catalyst, [(t-Bu)3PH]BF4 as a ligand 
with three equiv of KF as reported by Fu and coworkers14,15 provided diaryl compound 2-90 
smoothly. Cyclization of 2-90 with LDA, followed by methylation with CH3I/K2CO3, 
















   3.0 eq. KF
THF/H2O (19:1)












THF, 0oC to rt.
CH3I, K2CO3
DMF
2-91 2-92   85%  
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In this study, it proved possible to replicate the formation of 2-92 as achieved by M. Buck. 
With the benzofluorene 2-92 in hand, a path was investigated as presented in Scheme 2-26: It 
was felt that compound 2-92 might be hydrolyzed to the carboxamide 2-93, which might be 




















In the previous study, Matthew Buck found that heating 2-92 in ethanol with NaOH 
generated ethyl phenolate 2-96 resulting from the addition-elimination of the o-methoxyl 
group instead of the hydrolysis of the cyano group.  
In the present work an attempt to hydrolyze 2-92 with concentrated H2SO4 at 0 °C only 





















Hence, milder conditions were further explored. McKillop and Kemp reported a method 
for conversion aromatic nitriles to the corresponding amides using sodium perborate in 
aqueous methanol at 50 °C.16 Use of these conditions generated desired the amide 2-93, but 
in a low yield. Then treatment of 2-92 with hydrogen peroxide in the presence of aqueous 
NaOH in CH2Cl2 with phase transfer catalyst (n-Bu)4NHSO4 at room temperature overnight 
provided amide 2-93 with some starting material remaining. It seemed the reaction was clean 
but slow because of the two phase system. Changing these conditions by using H2O2 with 
K2CO3 in DMSO (a polar solvent) led to the conversion of 2-92 to 2-93 smoothly and 









































Hofmann rearrangements typically employ Br2 with NaOH or heavy metal reagents such 
as Pb(OAc)4 with NaOH or Hg(OAc)2 or AgOAc with NBS. Moriarty and coworkers, 
however, have reported the use of diacetoxyiodobenzene (DAIB), a stable and commercial 
available iodine (III) reagent, in methanolic KOH at 2–10 °C to generate methyl carbamates 
in good yields from the corresponding primary carboxamide.17 In our case, the carboxamide 
2-93 was transformed into the desired carbamate 2-94 using 1.0 equiv DAIB, 2.5 equiv KOH 















The mechanism proposed by Moriarty is shown in Scheme 2-30.17 Addition of DAIB 2-96 
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to methanolic KOH leads to the formation of PhI(OMe)2 2-97. Reaction of the amide 2-98 
with 2-97 probably provides N-(phenyliodonio) intermediate 2-99, which is subjected to 
rearrangement to generate isocyanate 2-101. Under acidic condition the isocyanate is readily 
hydrolyzed to amine but with basic condition in the presence of methanol it is converted to 

























Hydrolysis of methyl carbamate 2-104 using LiOH in refluxing ethanol and water 
provided the aniline 2-95 quantitatively. The reaction of aniline 2-95 with nitrous acid gave 
the corresponding diazonium salt which underwent demethylation in situ to generate o-
quinodiazde 2-58 in 59% yield, hence finishing the synthesis of the model of 
isoprekinamycin. The facile demethylation was believed to probably occur via a nucleophilic 
attack at the methyl ether group in the intermediate 2-103 resulting from the activating effect 















2-58   59%























In summary the Suzuki coupling of bromoindenone 2-64 and commercial available pinacol 
borate 2-89 afforded diaryl intermediate 2-90, which followed the sequence as presented in 
Scheme 2-32, seven steps, to achieve the synthesis of model compound 2-58 in 22% yield. If 
including the synthesis of bromoindenone 2-64, the longest linear path of this synthesis is 


















   3.0 eq. KF
THF/H2O (19:1)
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2-95   quant.









2-58   59%  
2.3.3 Spectroscopic Comparison of the Two Models and Isoprekinamycin 
The model compound 2-58 crystallized as fine dark red needles from CH2Cl2 by slowly 
evaporating the solvent during two weeks. The crystals were good enough quality to allow 
for X-ray diffraction analysis. A comparison of this structure with that of IPK is presented in 
Chapter 3. 




The compound was found to be stable in dilute acids and moderately inert to mildly 
alkaline conditions but basic conditions cause hydrodediazotization at higher temperature. 
High resolution mass spectrometry data for the compound 2-58 supports a molecular formula 
of C18H10 N2O3 as the observed exact mass is 302.0691. The 1H NMR spectrum of 2-58 
exhibits four doublets (δ 8.86 (J = 8.1 Hz), 7.40 (J = 8.0 Hz), 7.25 (J = 6.7 Hz), 7.13 (J = 8.1 
Hz)), one triplet (δ 7.51 (J = 7.4 Hz)), two protons that form a multiplet at δ 7.33, and a 
singlet at δ 3.96 representing the methoxy group. These signals can be observed as eight 
cross peaks in HMQC experiment at δ 8.86 (126.5), 7.51 (124.9), 7.40 (119.5), 7.33 (131.4), 
7.33 (125.7), 7.25 (117.0), 7.13 (121.2) and 3.96 (56.5). Because of the low solubility of 2-58, 
the 13C NMR signal corresponding to the carbon of the diazo group was not observable. 
However, the HMBC experiment indicated a three bond correlation from H-4 at δ 7.40 ppm 
to a 13C atom with a resonance at δ 90.0 ppm, assigned to the diazo group carbon atom. This 
result agrees with the value of δ 83.7 ppm for the isoprekinamycin diacetate. 
Other 13C NMR characteristics of model 2-58 are also in excellent agreement with the 
corresponding structural features of model 2-105 and IPK diacetate 2-106 (table 2-1). In 
particular, the carbonyl resonance at 196.2 ppm in spectrum of 2-58, assigned to the five 
member ring ketone, has counterparts at 196.77 ppm in model 2-105 and 192.48 ppm in IPK 
diacetate 2-106. In addition, the diazo group gives rise to a band at 2095 cm-1 in the IR 
spectrum of 2-58 as compared with a band at 2105 cm-1 in the spectrum of model 2-105 and 






















Table 2-1 Spectroscopic Data for 2-58, 2-105 and 2-106 
  2-58 2-105 2-106 
C-11 196.2 ppm 196.77 ppm 192.48 ppm 
C-6 170.5 ppm 176.33 ppm 174.14 ppm 
13C 
NMR 
C-5 90.0 ppm 82.64 ppm 83.17 ppm 
v (C-N2) 2095.7 cm–1 2105 cm–1 2119 cm–1 
v (CO) 1710.8 cm–1 1727 cm–1 1727 cm–1 IR 
v (CC) 1620.1 cm–1 1613 cm–1 1613 cm–1 
 
Further examination of the available data revealed an interesting inconsistency. That is, 
whereas the IR bands for the diazo groups in model 2-58 and 2-105 (2095.7 cm–1 and 2105 
cm–1, respectively) are in good agreement with that of the diacetate of isoprekinamycin 2-106 
(2119 cm-1), all these values differ considerably from that observed for isoprekinamycin 2-2 
(2162 -1cm). Ab intio calculations carried out previously in this group by Laufer for model 2-
105 and IPK 2-2 revealed that these discrepancies can be explained on the basis of 
intramolecular H-bonding to the ortho-quinodiazide oxygen in 2-2,8 which is absent in 2-105 
and also absent in the model 2-58. 
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2.4 Another Route to Diazobenzo[a]fluorenes 
With diaryl aldehyde 2-80b in hand, an alternative strategy as shown in Scheme 2-33 was 
explored briefly. The aldehyde 2-80b might be converted to the corresponding hydrazone 2-
107, which might be transferred to diazo compound 2-108 via hydrazone dehydrogenation or 

























Dehydrogenation of hydrazones is one of the oldest methods for the preparation of diazo 
compounds. For a long time, mercuric oxide was used almost exclusively as the oxidation 
agent. Since the 1960s, however, silver oxide, manganese dioxide, and lead(IV) acetate have 
been found to be efficient alternatives. This discovery has led to a renaissance of the method. 
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The limiting factor of this preparative method is, in some cases, the synthesis of the required 
hydrazone from a carbonyl compound and hydrazine. Hauser and coworkers reported the 
diazo transformation following the sequence as shown in Scheme 2-34: the ketone 2-109 was 
converted to a hydrazone 2-110, which was dehydrogenated using Ag2CO3 on Celite to 























In our case, the Suzuki coupling between bromoindenone and boronic acid 2-79b using 
Fu’s conditions generated the diaryl aldehyde 2-80b quantitatively. However, all the attempts 























   3.0 eq. KF
THF/H2O (19:1)




The Bamford-Stevens reaction is, next to hydrazone dehydrogenation, one of the most 
versatile methods to convert carbonyl compounds to diazo compounds. Starting compounds 
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are the tosyl hydrazine of aldehydes or ketones, which are then cleaved by base to give the 
diazoalkane and p-tolyl sulfinate. Kinetic investigations in the case of cyclohexanone 
hydrazone and camphor tosyl hydrazone support the E1 mechanism for the reaction with the 
















2-114 2-115  
The synthesis of tosyl hydrazone 2-116 from 2-80b using 1.1 equivalents of tosyl 
hydrazine was investigated. Almost no observable reaction was found in methylene chloride. 
In ethanol, the reaction was quite slow at room temperature, and provided a complex mixture 
at higher temperature (refluxing). In methanol, the reaction was very slow at room 
temperature, but was much faster after adding catalytic amount of AcOH to afford 2-116 in 
50% yield. Electrospray mass spectrometric analysis indicated that the product possessed the 
mass expected for the hydrazone 2-116.  The 1H NMR spectrum, however, was complicated 
by the fact that several key signals such as those from the methyl ether, the methyl ester and 
the tosyl group methyl were doubled up in approximately a 1:1 ratio.  This complexity likely 
arises from the fact that there is hindered rotation about the C-C bond linking the indenone to 
the aromatic hydrazone-bearing ring, giving rise to a chiral axis, and the fact that the tosyl 
hydrazone nitrogen is pyramidal, giving rise to a chiral center.  Thus the system consists of a 
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mixture of diastereomers.  In principle, the hydrazone might also exist as an E/Z mixture of 
stereoisomers about the C=N bond, but it seems likely that in that case the E isomers would 















An alternative procedure to synthesize tosyl hydrazone 2-116 was explored. The boronic 
acid 2-79b was converted to the tosyl hydrazone 2-117 with 1.1 equivalents of tosyl 
hydrazine in CH2Cl2 at room temperature quantitatively. The Suzuki coupling between 2-117 
and bromoindenone 2-64 using Pd(PPh3)4, Ba(OH)2, KBr, in refluxed DME and water 
afforded diaryl aldehyde 2-80b in 41%. It was concerned that, with a strong base Ba(OH)2 
under the elevated temperature, the tosyl hydrazone 2-117 was hydrolyzed to the 
corresponding aldehyde then coupled with 2-64. Further more, in the coupling using Fu’s 
condition at room temperature, almost all starting material remained. With heating at 55 °C 











































   3.0 eq. KF
THF/H2O (19:1)
     rt. or 55 oC





In their recent synthesis of prekinamycin, Birman and coworkers reported that a tosyl 
hydrazone 2-118 was converted to a diazo compound 2-119 using triethylamine in ethanol in 
the presence of air, in which the hydroquinone was oxidized in situ. Furhter more, a tosyl 
hydrazone 2-120 was demethylated to provide the intermediate 2-121, which was converted 































For our case, treatment of tosylhydrazone 2-116 with 1.0 equivalent of Et3N in THF at 
room temperature provided a complex mixture. A similar result was obtained upon changing 
the base to LDA. However, treatment of 2-116 on a small scale with Et3N in methanol at 
room temperature provided a crude product with 1NMR characterization compatible with a 
tosyldiazene 2-122a or a tosylhydrazone 2-122b rather than the desired diazo compound. 



































Kumamoto-Ishikawa and coworkers found that treatment of tosylhydrazone 2-123 with 
cerium ammonium nitrate (CAN) afforded methyl kinamycin C 2-124 , in which not only the 
expected oxidation to a naphthoquinone but also spontaneous desulfination leading to 
diazoalkane occurred.20 However, no reaction was observed when tosylhydrazone 2-116 was 
































Myers and co-workers developed a new method for the synthesis of diazoalkanes by 
oxidation of N-tert-butyldimethylsilylhydrazones (TBSHs) with difluoroiodobenzene.21,22 
The TBSHs was converted by the condensation of the corresponding ketone or aldehyde with 
1,2-bis(tert-butyldimethylsilyl)hydrazine (BTBSH) in the presence of a catalytic amount of 
scandium triflate. This method was used for the synthesis of kinamycin C 2-127 by Porco 
and coworkers.23 Unfortunately, treatment of diarylaldehyde 2-80b with BTBSH and 































































CH2Cl2, 0oC to rt. or ref.
starting materials
2-127   35% two steps
Kinamycin C
 
The alternative route to IPK model via the route in Scheme 2-33 was abandoned at this 
point. 
2.5 Experimental 
2.5.1 General Information 
1H NMR spectra were recorded on a Brüker AVANCE500 (500 MHz), Brüker AC300 (300 
MHz) or Brüker AVANCE300 (300 MHz) NMR spectrometer. Chemical shifts are reported 
in parts per million (ppm) relative to tetramethylsilane (TMS). The following abbreviations 
are used for NMR peak multiplicities: s, singlet; d, doublet; t, triplet; q, quartet; dd, doublet 
of doublets; dt, doublet of triplet; m, multiplet; b, broad; w, weak. 13C NMR spectra were 
broad band decoupled and recorded on a Brüker AVANCE500 (125.8 MHz), Brüker AC300 
(75.5 MHz) and Brüker AVANCE300 (75.5 MHz) NMR spectrometer using the carbon 
signal of the deuterated solvent as the internal standard. HMQC and HMBC experiments 
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were performed on a Brüker AVANCE500 spectrometer. IR spectra were determined on a 
Perkin-Elmer RX I FT-IR spectrometer. High/low resolution electron impact (EI or ESI) 
mass spectra (MS) were measured by the WATSPEC Mass Spectrometry Facility 
(Department of Chemistry, University of Waterloo, Waterloo, Ontario, Canada) and the 
McMaster Regional Center for Mass Spectrometry (Department of Chemistry, McMaster 
University, Hamilton, Ontario, Canada). Gas chromatography-mass spectrometry (GC-MS) 
was performed on a HP GCD 1800 with a column (HP5) length of 30.0 m and diameter of 
0.25 mm. The following temperature program was applied: initial temperature 70 °C, rising 
rate 10 °C/minute, final temperature 265 °C held for 20.0 minutes. Elemental analyses were 
performed by the M-H-W Laboratories (Phoenix, Arizona, USA). 
Anhydrous THF and Et2O were freshly distilled from sodium/benzophenone under nitrogen 
prior to use. Anhydrous CH2Cl2 was freshly distilled from CaH2 under nitrogen prior to use. 
All commercial reagents were purchased from Aldrich Chemical Co., Strem Chemicals Inc., 
Alfa Aesar, Lancaster Synthesis Ltd. or BDH Inc. and were used as received unless 
otherwise indicated. 
The –78 °C and 0 °C designations refer to solid carbon dioxide/acetone and ice/water slush, 
respectively. The room temperature refers to 22 °C to 25 °C. Flash column chromatography 
was carried out using the Merck silica gel (230–400 mesh) and SiliCycle silica gel (60 Å). 
Reactions were magnetically stirred and monitored by thin layer chromatography (TLC) with 
Merck pre-coated silica gel plates (silica gel 60 F254 on aluminum sheet). All reported yields 











    K2CO3
2-68   2-67  
4-Methoxy-2,3-dihydroindan-1-one (2-67) 
AlCl3 (58.19 g, 0.436 mol) and NaCl (12.03 g, 0.256 mol) were mixed and heated in an oil 
bath. When the bath temperature was about 150 ºC, dihydrocoumarin (10 mL, 0.079 mol) 
was added slowly while the bath temperature was maintained between 150 ºC and 180 ºC. 
The bath temperature was then raised to 200 °C and the mixture was stirred for 1 h. The 
mixture was cooled to room temperature and quenched with 100 g crushed ice and 50 mL 
conc. HCl at 0 °C. The suspension was stirred at room temperature for 30 min and the crude 
product (9.688 g) was obtained as a gray solid upon filtration. 
To a solution of the crude indanone (9.688 g, 0.065 mol) and K2CO3 (56.94 g, 0.411 mol) in 
acetone (667 mL) was added Me2SO4 (45.36 g, 0.360 mol) dropwise at room temperature 
and the reaction mixture was then refluxed for 2.5 h. The solution was cooled to room 
temperature, filtered and concentrated. The residue was mixed with water (100 mL) and 
triethylamine (100 mL), followed by stirring at room temperature for 1 h. The resulting 
solution was extracted with EtOAc (3 × 200 mL) and the organic phase was dried over 
Na2SO4 and concentrated. The residue was purified by flash chromatography 
(EtOAc:Hexanes = 1:9, v/v) to obtain the title compound as a white solid (8.317 g, 65%). 1H 
NMR (300 MHz, CDCl3): δ 7.30–7.34 (m, 2H), 6.96–7.01 (m, 1H), 2.97–3.01 (m, 2H), 2.62–
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2.66 (m, 2H); 13C NMR (75.5 MHz, CDCl3): δ 207.2, 156.9, 143.9, 138.5, 128.7, 115.1, 











2-66          2-67  
7-Methoxy-3-oxo-2, 3-dihydro-1H-indene-1-carboxylic acid (2-66)  
To a solution of 4-methoxy-1-indanone (2.000 g, 12.33 mmol) in anhydrous THF (25 mL) at 
–78 ºC was added freshly prepared LDA in THF (12.95 mmol in 65 mL) dropwise, and the 
reaction mixture was stirred for 1 h. TMSCl (1.64 mL, 12.95 mmol) was then added slowly 
at –78 °C and the reaction mixture was further stirred for 1 hour. The second batch of freshly 
prepared LDA in THF (18.50 mmol in 65 mL) was added at –78 °C and the reaction mixture 
was stirred for one more hour. Solid carbon dioxide (100 g) was added and the reaction 
mixture was stirred at room temperature for 1.5 hours. The reaction was quenched with 2 M 
HCl in an ice bath and then extracted with ether (3 × 150 mL). The ether phase was 
concentrated and the residue was redissolved in enough 2 M aqueous NaOH solution until 
the pH was ca. 12. The basic aqueous solution was washed with ether (3 × 20 mL) and then 
acidified with conc. HCl until the pH reached ca. 1. The resulting acidic aqueous solution 
was then extracted with a mixture of ether and THF (9:1, v/v, 4 × 100 mL). The resulting 
organic phase was dried over Na2SO4 and concentrated to give the crude product as a yellow 











         2-65  
Methyl 7-methoxy-3-oxo-2,3-dihydro-1H-indene-1-carboxylate (2-65) 
To a solution of the crude carboxylic acid (2.270 g) in methanol (50 mL) was added conc. 
H2SO4 (10 drops) and the reaction mixture was refluxed for 48 h. The solution was 
concentrated to ca. 5 mL, followed by addition of saturated aqueous NaHCO3 solution to 
adjust the pH to ca. 8. The solution was extracted with EtOAc (3 × 80 mL) and the organic 
phase was dried over Na2SO4 and concentrated. The residue was purified by flash 
chromatography (EtOAc:Hexanes = 1:4, v/v) to obtain the ester as a yellow solid (1.845 g, 
68% for two steps). 1H NMR (300 MHz, CDCl3): δ 7.40 (t, J = 7.7 Hz, 1H), 7.33 (d, J = 8.1 
Hz, 1H), 7.04 (d, J = 7.8 Hz, 1H), 4.19 (dd, J = 8.2, 3.5 Hz, 1 H), 3.85 (s, 3 H), 3.69 (s, 3 H), 
2.95 (dd, J = 11.7,  8.2 Hz, 1 H), 2.73 (dd, J = 11.7,  3.5 Hz, 1H); 13C NMR (75.5 MHz, 
CDCl3): δ 204.0, 173.4, 157.0, 140.5, 138.4, 130.6, 115.8, 115.5, 55.8, 52.4, 41.1, 41.0; 









         2-64         2-65  
Methyl 2-bromo-7-methoxy-3-oxo-3H-indene-1-carboxylate (2-64) 
To a solution of compound 2-65 (2.330 g, 10.59 mmol) in freshly distilled CH2Cl2 (46 mL) 
was added Br2 in CH2Cl2 (1 M, 26.5 mL) at room temperature and the solution was stirred 
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for 24 h. The solution was diluted with CH2Cl2 (300 mL) and washed with water (3 × 25 mL). 
The CH2Cl2 phase was dried over Na2SO4 and concentrated. The crude product was obtained 
as a red solid. 
To a solution of the above crude product in CH2Cl2 (100 mL) at 0 °C was added DBU (1.59 
mL, 10.59 mmol) slowly and the reaction mixture was stirred at this temperature for 1 h. The 
reaction solution was washed with water (3 × 15 mL), dried over Na2SO4 and concentrated. 
The residue was purified by flash chromatography (EtOAc:Hexanes = 1:5, v/v) to obtain the 
title compound as a red solid (2.365 g, 75% for two steps). Mp: 139–141 °C; 1H NMR (300 
MHz, CDCl3): δ 7.28 (t, J = 4.5 Hz, 1H), 7.18 (d, J = 7.2 Hz, 1H), 7.01 (d, J = 8.4 Hz, 1H), 
3.98 (s, 3H), 3.85(s, 3H); 13C NMR (75.5 MHz, CDCl3): δ 188.9, 164.9, 152.1, 148.4, 131.7, 
129.7, 128.0, 119.6, 117.8, 116.8, 56.4, 52.9; IR (KBr): 1737, 1723 cm–1; MS (GC-MS): 
18.52 minutes, m/z 296 (M+ containing 79Br) 298 (M+ containing 81Br) (1:1); Elemental 
analysis: calculated for C12H9BrO4: C, 48.51, H, 3.05; found: C, 48.70, H 3.02; HRMS: 


















Methyl 2-(2-(cyanomethyl)phenyl)-7-methoxy-3-oxo-3H-indene-1-carboxylate (2-90) 
A mixture of compound 2-64 (273 mg, 0.916 mmol), KF (160 mg, 2.49 mmol), 
Pd2(dba)3•CHCl3 (51 mg, 0.049 mmol) and [(t-Bu)3PH]BF4 (28 mg, 0.099 mmol) was 
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deoxygenated five times with an argon balloon and a vacuum pump. Pinacolboronate 2-89 
(200 mg, 0.824 mmol) was dissolved in a mixture of THF and water (19:1, v/v, 8 mL) and 
the solution was deoxygenated three times by a freeze-thaw process. The deoxygenated 
solution was then added to the solid mixture and stirred for 24 h at room temperature under 
an argon atmosphere. The solution was diluted with ether (100 mL) and washed with water 
(3 × 15 mL). The organic phase was dried over Na2SO4 and concentrated. The residue was 
purified by flash chromatography (Et2O:Hexanes = 1:1, v/v) to obtain the product as a red-
orange solid (255 mg, 93%). 1H NMR (500 MHz, CDCl3): δ 7.54 (d, J = 7.7 Hz, 1H), 7.4 (dt, 
J = 1.1 Hz, J = 7.5 Hz, 1H), 7.28 (m, 2H), 7.24 (d, J = 7.6 Hz, 1H), 7.18 (d, J = 6.80 Hz, 1H), 
7.03 (d, J = 8.4 Hz, 1H), 3.85 (s, 3H), 3.76 (s, 3H), 3.75 (s, 2H); 13C NMR (125.8 MHz, 
CDCl3): δ 194.76, 165.76, 152.95, 148.06, 132.24, 132.10, 130.46, 129.63, 129.49, 128.96, 
128.56, 127.93, 127.61, 119.12, 117.58, 117.11, 56.15, 52.40, 22.49; IR (KBr): 2246, 1735, 
1711 cm–1; Elemental analysis: calculated for C20H15NO4: C, 72.06, H, 4.54; found: C, 71.88, 














To a solution of compound 2-90 (255 mg, 0.766 mmol) in anhydrous THF (15 mL) at room 
temperature was added LDA in THF (0.781 mmol in 6 mL) slowly and the solution was 
stirred for 1 h. The reaction was quenched with saturated aqueous NH4Cl solution (15 mL) 
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leading to the formation of some red-orange precipitate. The precipitate was dissolved in 
EtOAc (600 mL) and then washed with H2O (3 × 30 mL). The organic phase was dried over 
Na2SO4 and concentrated to obtain the crude product as a red orange solid. 
To a solution of the above crude product in DMF (100 mL) was added K2CO3 (0.529 g, 3.83 
mmol) at room temperature and the mixture was stirred for 15 minutes, followed by addition 
of CH3I (0.48 mL, 7.66 mmol). The solution was heated at 80 °C for 45 min then filtered and 
concentrated. The solution residue was diluted with CHCl3 (300 mL) and washed with H2O 
(3 × 30 mL). The organic phase was dried over Na2SO4 and concentrated. The residue was 
purified by flash chromatography (CHCl3:Hexanes = 3:1, v/v) to give the product as an 
orange solid (140 mg, 58% for two steps). 1H NMR (300MHz, CDCl3): δ 9.05 (m, 1H), 8.03 
(m, 1H), 7.58 (m, 2H), 7.32 (m, 2H), 7.15 (d, J = 8.4 Hz, 1H), 4.04 (s, 3H), 4.00 (s, 3H); 13C 
NMR (75.5 MHz, CDCl3): δ 194.1, 157.8, 154.8, 139.2, 135.6, 135.0, 132.0, 129.2, 129.1, 
127.5, 126.8, 124.7, 124.6, 120.2, 117.0, 115.1, 110.8, 63.9, 56.3; HRMS: calculated for 














To a solution of compound 2-92 (140 mg, 0.443 mmol) and K2CO3 (95 mg, 0.687 mmol) in 
DMSO (55 mL) at 0 °C was added 30% H2O2 (10 mL) slowly, then the mixture was stirred at 
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room temperature for 21 h. The reaction was quenched with water (60 mL), followed by 
extraction with EtOAc (300 mL). The organic phase was washed with water (3 × 30 mL), 
dried over Na2SO4 and concentrated. The residue was purified by flash chromatography 
(EtOAc:Hexanes = 3:1, v/v) to give the product as an orange solid (151 mg, 100%). 1H NMR 
(300 MHz, DMSO-d6): δ 8.88 (d, J = 8.3 Hz, 1H), 8.12 (s, br, 1H), 7.88(s, br, 1H), 7.67 (d, J 
= 8.3 Hz, 1H), 7.52 (m, 2H), 7.34 (m, 2H), 7.20 (d, J = 6.6 Hz, 1H), 3.93 (s, 3H), 3.75 (s, 3H); 
13C NMR (75.5 MHz, DMSO-d6): δ 194.4, 168.2, 154.8, 149.2, 140.7, 138.7, 135.9, 132.4, 
131.7, 129.1, 127.7, 127.6, 127.4, 127.3, 125.5, 123.7, 121.2, 116.7, 63.9, 56.5; IR (film): 













Methyl 6,7-dimethoxy-11-oxo-11H-benzo[a]fluoren-5-ylcarbamate (2-94) 
To a solution of compound 2-93 (151 mg, 0.453 mmol) in methanol (160 mL) was added 
KOH (64 mg, 1.13 mmol) at rt. The solution was cooled to 0 °C and stirred for 10 minutes. 
PhI(OAc)2 (146 mg, 0.453 mmol) was added and the mixture was stirred at 0 °C for 
additional 15 min. The solution was then warmed to rt and further stirred for 7 h. The 
solution was concentrated and the residue was mixed with CH2Cl2 (200 mL) and water (100 
mL). The aqueous phase was extracted with CH2Cl2 (2 × 100 mL). The combined organic 
phase was dried over Na2SO4 and concentrated. The residue was purified by flash 
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chromatography (EtOAc:Hexanes = 3:1, v/v) to give the title compound as an orange solid 
(115 mg, 70%). 1H NMR (300 MHz, CDCl3): δ 9.05 (d, J = 8.4 Hz, 1H), 7.77 (d, J = 8.5 Hz, 
1H), 7.49 (t, J = 7.5 Hz, 1H), 7.40 (t, J = 7.5 Hz, 1H), 7.29 (m, 2H), 7.07 (m, 1H), 6.81 (s, br, 
1H), 3.98 (s, 3H), 3.81 (s, 3H), 3.80 (s, 3H); 13C NMR (75.5 MHz, CDCl3): δ 194.2, 155.6, 
154,3, 147.5, 139.8, 136.7, 133.6, 131.3, 130.8, 128.6, 128.3, 128.0, 126.6, 124.4, 123.9, 
119.5, 116.8, 62.6, 56.3, 53.1; IR (film): 3275.8, 1730.0, 1690.0, 1283.6, 1261.9, 1238.0 cm–
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5-Amino-6, 7-dimethoxy-11H-benzo[a]fluoren-11-one (2-95) 
To a solution of compound 2-94 (115 mg, 0.317 mmol) in ethanol (125 mL) was added 
aqueous LiOH solution (2 M, 0.79 mL) slowly at room temperature and the reaction mixture 
was refluxed for 21 h. The solution was concentrated and the residue was dissolved in EtOAc 
(300 mL) and washed with water (3 × 30 mL). The organic phase was dried over Na2SO4 and 
concentrated. The residue was purified by flash chromatography (EtOAc:Hexanes = 2:3, v/v) 
to give the product as a red solid (99 mg, 100%). 1H NMR (300 MHz, DMSO-d6): δ 8.85 (d, 
J = 8.4 Hz, 1H), 8.12 (d, J = 8.6 Hz, 1H), 7.44 (t, J = 7.6 Hz, 1H), 7.27 (m, 2H), 7.18 (s, 1H), 
7.15 (m, 2H), 7.06 (d, J = 6.9 Hz, 1H), 3.91 (s, 3H), 3.66 (s, 3H); 13C NMR (75.5 MHz, 
DMSO-d6): δ 190.8, 154.7, 148.0, 140.5, 139.1, 136.7, 131.9, 130.2, 129.4, 126.6, 124.2, 
123.9, 123.6, 121.3, 119.3, 115.2, 112.9, 61.7, 56.5; IR (film): 3315.8, 3216.1, 1654.0, 
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5-Diazo-5H-7-methoxy-11H-benzo[a]fluoren-6, 11-dione (2-58) 
To a solution of compound 2-95 (99 mg, 0.33 mmol) in ethanol (150 mL) was added conc. 
HCl (2.5 mL) at room temperature. The solution was cooled to 0 ºC, and an aqueous NaNO2 
solution (28 mg, 0.41 mmol in 5 mL) was added slowly. The solution was stirred at 0 °C for 
4 h, followed by addition of NaHCO3 powder (2.5 g), and the mixture was stirred for 
additional 20 min. The remained NaHCO3 was filtered and the filtrate was concentrated. The 
residue was dissolved in EtOAc (300 mL) and washed with water (3 × 30 mL). The organic 
phase was dried over Na2SO4 and concentrated. The residue was purified by flash 
chromatography (EtOAc:Hexanes = 1:1, v/v) to obtain the title compound as a purple solid 
(58 mg, 59%). 1H NMR (500 MHz, CD2Cl2): δ 8.86 (d, J = 8.1 Hz, 1H), 7.51 (t, J = 7.4 Hz, 
1H), 7.40 (d, J = 8.0 Hz, 1H), 7.33 (m, 2H), 7.25 (d, J = 6.7 Hz, 1H), 7.13 (d, J = 8.1 Hz, 1H), 
3.96 (s, 3H); 13C NMR (125.8 MHz, CD2Cl2)*: δ 196.2, 170.5, 154.8, 133.7, 133.6, 131.4, 
129.4, 128.6, 127.5, 126.5, 125.7, 122.2, 121.2, 119.5, 117.0, 56.5; IR (CH2Cl2 solution): 
3061.0, 2945.0, 2838.1, 2095.7, 1710.8, 1620.1, 1480.1 1336.0 cm-1; MS (EI): m/z 302.1 (30, 
M+), 274.1 (96), 259.1 (100), 231.1 (25), 187.1 (24), 175.1 (23); HRMS (EI): calculated for 
C18H10 N2O3: 302.0691, found: 302.0691. 
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*As a result of low solubility of the title compound in CD2Cl2, no 13C NMR signal was 
observed for the quaternary carbon attached to the diazo group. A cross peak at 90.0 ppm, 
assignable to the carbon atom attached to the diazo group, is a clear evidence, however, in 



















Methyl 2-(2-formylphenyl)-7-methoxy-3-oxo-3H-indene-1-carboxylate (2-80b) 
A mixture of compound 2-64 (230.7 mg, 0.774 mmol), KF (135 mg, 2.32 mmol), 
Pd2(dba)3·CHCl3 (40.1 mg, 0.039 mmol) and [(t-Bu)3PH]BF4 (22.5 mg, 0.077 mmol) was 
deoxygenated five times with an argon balloon and a vacuum pump. 2-formylphenylboronic 
acid 2-79b (200 mg, 0.697 mmol) was dissolved in a mixture of THF and water (19:1, v/v, 6 
mL) and the solution was deoxygenated three times by the thaw-freeze process. The 
deoxygenated solution was then added to the solid mixture and stirred for 24 h at rt under 
argon atmosphere. The solution was diluted with ether (150 mL) and washed with water (3 × 
15 mL). The water phase was then extracted by Et2O (2 ×50 mL), and the ether phase was 
combined.  The ether phase was dried over Na2SO4 and concentrated. The residue was 
purified by flash chromatography (EtOAc:Hexanes = 1:3, v/v) to obtain the product as a red-
orange solid (238.2 mg, 100%). 1H NMR (500 MHz, CDCl3): δ 9.97 (s, 1H), 7.98 (d, J = 7.7 
Hz, 1H), 7.62 (t, J = 7.5 Hz, 1H), 7.55 (t, J = 7.6 Hz, 1H), 7.40 (d, J = 7.5 Hz, 1H), 7.32 (t, J 
= 8.37 Hz, 1H), 7.24 (d, J = 7.1 Hz, 1H), 7.05 (d, J = 8.4 Hz, 1H), 3.89 (s, 3H), 3.78 (s, 3H); 
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13C NMR (125.8 MHz, CDCl3): δ 194.42, 190.83, 165.99, 153.04, 146.11, 135.37, 133.61, 
132.52, 131.92, 131.35, 130.87, 130.82, 130.35, 129.31, 128.13, 119.11, 117.39, 56.29, 52.42; 















p-Tolunesulfonylhydrazone of methyl 2-(2-formylphenyl)-7-methoxy-3-oxo-3H-indene-
1-carboxylate (2-116) 
To a solution of compound 2-80b (68.4 mg, 0.212 mmol) in anhydrous methanol (20 mL) 
was added TsNHNH2 (43.5 mg, 0.234 mmol) at room temperature, and then two drops 
AcOH. The reaction was stirred at room temperature for 24 hours. The solution was 
concentrated, and the residue was purified by flash chromatography (EtOAc:Hexanes = 1:2, 
v/v) to obtain a red orange solid (51.8 mg, 50%). MS (ESI): Calcd for C26H23N2O6+ 491.13; 
Found 491.12 (100, (M+H)+). 1H NMR (300 MHz, CDCl3): The proton NMR was complex 
and exhibited an approximate doubling up of key signals suggesting the presence of isomers 
or conformers: δ 6.8 – 7.8 (m, 11H), 3.95 (s, approx. 1.5H), 3.85 (s, approx. 1.5H), 3.69 (s, 













p-Toluenesulfonylhydrazone of 2-formylphenylboronic acid (2-117) 
To a solution of 2-formylphenylboronic acid (100 mg, 0.667 mmol) in CH2Cl2 (20 mL) was 
added TsNHNH2 (136.6 mg, 0.734 mmol) at room temperature. The reaction was stirred at 
room temperature for 3 hours. The solution was concentrated, and the residue was purified by 
flash chromatography (EtOAc:Hexanes = 1:3, v/v) to obtain the title compound as a white 
solid (193.2 mg, 100%).1H NMR (300 MHz, CDCl3): δ 8.17 (d, J = 7.2 Hz, 1H), 7.99 (s, 1H), 
7.90 (d, J = 8.2 Hz, 1H), 7.65 (m, 2H), 7.52 (d, J = 7.5 Hz, 1H), 7.42 (s, 1H), 7.30 (d, J = 8.0 
Hz, 1H), 2.39 (s, 3H); 13C NMR (75.5 MHz, CDCl3): δ 145.1, 143.6, 134.7, 134.0, 132.7, 




Chapter 3 Total Synthesis of Isoprekinamycin 
With the successful synthesis of an isoprekinamycin model, the same strategy was 
explored for the total synthesis of isoprekinamycin 3-1 (Scheme 3-1). Thus, it was hoped that 
isoprekinamycin could be obtained from the O,O-dimethyl isoprekinamycin 3-2 by 
demethylation, and the diazo group could be installed via demethylative diazotization of the 
aniline 3-3. The formation of the aniline could be achieved by the functional group 
interconversion from the corresponding carbonitrile 3-4, and this benzo[a]fluorene 3-4 might 
be formed from an anionic cyclization of 3-5. The diaryl compound 3-5 could be constructed 
by a Suzuki coupling involving bromoindenone 3-6 and the substituted phenyl acetonitrile 3-






























































3.1 Synthesis of a Precursor to the D Ring of Isoprekinamycin 
It was intended that target boronate 3-7 could be produced from iodophenyl acetonitrile 3-
8 and it was thought that 3-8 could be generated from the known o-iodobenzylic alcohol 3-9, 
which could be derived from the benzyl alcohol 3-10. A retrosynthetic analysis for 

























Jones and coworkers reported that the bromination of dimethylanisole using NBS in CCl4 
provided the benzyl bromide 3-12, which was hydrolyzed to generate alcohol 3-10 (Scheme 
3-3).1  However, all attempts in this laboratory at duplication and modification of the 
procedure to obtain benzyl bromide 3-12 had failed. Treatment of dimethylanisole 3-11 with 
1.05 equivalent of NBS, 2.0% of benzoyl peroxide in refluxing anhydrous benzene provided 
2-bromo-5-methoxy-1,3-dimethylbenzene (3-13) as a major product, as well as minor 
amounts of mono and dibromo compounds 3-12 and 3-14 and remaining starting material 
based on by NMR analysis; Treatment of the same system with light generated p-bromo 
compound 3-13 in 67% yield and a small amount of 3-12, 3-14 and starting material. Even 
upon changing the solvent to CCl4, the reaction still afforded 3-13 as a major product. It was 
concluded that since the dimethylanisole is quite electron-rich, the reaction went mostly 
through electrophilic aromatic substitution rather than substitution at the benzylic position 
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2.0% benzoyl peroxide
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      1.05 eq. NBS
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3-13 3-12 3-14+ + 3-11
major SM
+3-13 3-12 3-14+ + 3-11
CCl4
 
Jung and coworkers reported that methylation of available 3-hydroxy-5-methylbenzoic 
acid (3-15) with MeI in acetone provided the methyl protected acid 3-16, which was reduced 
by lithium aluminum hydride to provide benzyl alcohol 3-10 (Scheme 3-4).2 In that study, the 
synthesis of 3-15 was accomplished according to Gearien’s procedure.3 Claisen condensation 
of acetone and diethyl oxalate 3-18 generated ethyl sodium acetopyruvate (3-19) in 50% 
yield. Treatment of 3-19 with AcOH provided 3-20 in 80% yield, which was then converted 
to 3-hydroxy-5-methylbenzoic acid (3-15) in 42% yield. The whole procedure involved three 
steps with 17% yield overall, but this was considered to be inadequate for preparing the 

































3-15  42%3-17 3-18 3-19   50% 3-20   80%  
  The selective catalytic oxidation of alkylbenzenes with O2 is a very important reaction for 
the production of bulk chemicals such as benzoic acids and terephthalic acids. For example, 
the oxidation of toluene is currently carried out in the presence of a catalytic amount of 
cobalt(II) 2-ethylhexanoate under a pressure of 10 atm of air at 140–190 °C.4 However, 
examples of the direct aerobic oxidation of alkylbenzenes under normal pressure and 
temperature are relatively rare.  
Sakaguchi and coworkers developed a new strategy for alkylbenzene oxidations with O2 
using N-hydroxyphthalimide (NHPI) as a catalyst.5 They found that the oxidation of toluene 
3-21 in the presence of 10 mol% of NHPI and 0.5 mol% of Co(OAc)2 in acetic acid under an 
atmosphere of O2 at 25 °C for 20 hours generated benzaldehyde (3-22) and benzoic acid (3-
23) in 2% and 81% yield, respectively. The oxidation of 3-21 in acetonitrile resulted in lower 
yield. Various alkylbenzenes were investigated and some representative cases were shown in 
Scheme 3-5. Both p-xylene (3-24) and mesitylene (3-27) were oxidized to the corresponding 
aldehyde and benzoic acid smoothly in either acetic acid or acetonitrile. Conversion of 4-
methylanisole (3-30) into the benzoic acid proceeded in 80% yield in acetonitrile but did not 
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proceed as well in acetic acid. p-Nitrotoluene (3-33), which contains a strong electron-
withdrawing group, was not oxidized under these conditions. 




AcOH   3-22  2%;  3-23  81%
3-21 3-22 3-23




AcOH   3-25  2%;  3-26  85%
3-24 3-25 3-26




AcOH   3-28  21%;  3-29  51%
3-27 3-28 3-29




AcOH   3-31  20%;  3-32  0%
3-30 3-31 3-32





AcOH   no reaction
3-33 3-34 3-35




In order to obtain further information on the role of Co(II) species in the reaction, the 
Sakaguchi group carried out ESR measurements under the same conditions as those for the 
oxidation of 3-21.5 When an acetonitrile solution of NHPI and 3-21 was exposed to an 
oxygen atmosphere, no ESR signal was observed over 10 hours. However, when a very small 
amount of Co(OAc)2  was added to the solution, an ESR signal of the phthalimido-N-oxy 
(PINO) radical was observed. These observations suggested that the complexation of Co(II) 
with O2 to generate a labile dioxygen complex such as superoxocobalt(III) 3-37 or µ-
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peroxocobalt(III) complex 3-38, which had been reported to be easily formed by the one 
electron reduction of O2 by Co(II) species,6–9 is present during the oxidation step (Scheme 3-
6). 
Scheme 3-6 
LnCoII O2 LnCoIII O O




3-37 3-36 3-38  
A plausible reaction pathway for the aerobic oxidation of alkanes is as presented in Figure 
3-1. The generation of PINO by the reaction of the NHPI with the cobalt(III)-oxygen 
complex would be the most important step in the present oxidation. The next step in the 
oxidation involves the hydrogen abstraction from RH by PINO to form R·, which is readily 
trapped by dioxygen to provide ROO· followed by ROOH and eventually the formation of 
alcohols, ketones and/or carboxylic acids. 
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In this laboratory, the oxidation of 1,3-dimethylanisole (3-11) with NHPI and Co(OAc)2 
was investigated. Treatment of 3-11 with 0.1 equivalent of NHPI and 0.5 mol % of Co(OAc)2 
in acetonitrile under one atm of O2 at room temperature for 24 hours provided mostly starting 
material with small amounts of the aldehyde and benzoic acid 3-16. It was found that the 
conversion ratio was very low after one day under these conditions, and increased catalyst 
loading and elevation of the reaction temperature did not significantly improve the rate of 
reaction. Improvement in the conversion ratio was observed, however, when the reaction was 





















28% over 2 steps,




The reaction, which was optimized by increasing the amount of Co(OAc)2 to 2.0 mol% 
and reaction time to 72 hours, generated the mixture of aldehyde and benzoic acid 3-16, 
which could be cleanly reduced to the corresponding benzyl alcohol 3-10 with an excess of 
LiAlH4. Since this two-step procedure proved to be relatively clean and the unreacted starting 
material 3-11 could be easily recovered after the first step (36%), it was felt that this process 
was suitable for the large-scale preparation of starting materials for the proposed synthetic 
project (Scheme 3-7). 
Treatment of 3-10 with 2.2 equivalents of n-BuLi from –78 °C to room temperature for 4 
hours, followed by treatment with 1.2 equivalents of iodine in THF at 0 °C for 30 minutes, 
generated the desired iodobenzyl alcohol 3-9 in 74% yield and high regioselectively. As 
intended, the regioselectivity likely arises from the inductive effect of the o-methoxy group 
and the coordination of the Li+ of the base with benzylic alkoxide oxygen, and the structure 
of 3-9 was later confirmed indirectly through further transformations (vide infra). The 
addition of TMEDA was not helpful as it gave rise to a complex mixture and did not improve 











I1. n-BuLi (2.2 equiv)
    Et2O, -78 °C to rt, 4 h
2. I2 (1.2 equiv)
    THF, 0 °C, 30 min
 
Treatment of the iodobenzyl alcohol 3-9 with 1.05 equivalents of CBr4 and 1.05 
equivalents of PPh3 in CH2Cl2 at room temperature smoothly provided the benzylic bromide 
3-39, which was subjected to an SN2 reaction with 1.5 equivalents of NaCN in DMSO to 












CH2Cl2, rt DMSO, rt
3-39 3-8
69% over 2 steps
NaCN
 
While classical methods for the synthesis of aryl boronic acids or their esters involve the 
use of Grignard reagents 3-40 or lithium reagents 3-42, these conditions could not be used for 
the borylation of 3-8, due to the acidic benzylic protons activated by the cyano group. 
Miyaura and co-workers reported a palladium-catalyzed cross-coupling reaction of the 
tetraalkoxydiboron 3-44, which provides a one-step procedure for generating 






























    KOAc
DMSO, 90oC3-44
X = I, Br  
Masuda and coworkers reported that a palladium-catalyzed coupling reaction of the 
dialkoxyhydroborane 3-48 with aryl halides or aryl triflates 3-47 afforded the corresponding 
arylboronates (e.g. 3-49 or 3-52) in high yield as presented in Scheme 3-11.14 To explore 
optimal borylation conditions, the reaction of 1-iodonaphthalene 3-51 with pinacolborane (3-
48) was carried out under various conditions. The reaction was efficiently catalyzed by the 
palladium(II) complexes with 2 equivalents of phosphine ligands, such as PdCl2(dppf) and 
PdCl2(PPh3)2. However, an additional phosphine ligand tended to retard the reaction. In 
general, tertiary amines are known to not contribute to coupling reactions with boron 
compounds, and triethylamine was found to be most effective for the selective formation of 
3-52. In the presence of other bases such as pyridine, DBU and KOAc, the formation of the 
undesirable reduction product 3-53 predominated. The reaction was not sensitive to different 
solvents (dioxane, toluene, MeCN, and ClCH2CH2Cl), but the use of the polar solvent DMF 
did result in both lower yields and poorer selectivity due to a decomposition of the 
dialkoxyborane to diborane (B2H6).15  
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3-51 3-52 3-53  
The order of relative reactivity for this reaction was aryl iodide > aryl triflate > aryl 
bromide. The differences in the yields and in the selectivity among aryl iodides having 
electron-donating or electron-withdrawing groups were not particularly large such as in the 
case of 3-56. The product yields of the borylation of aryl triflates also were not substantially 
affected by substituents, but the reaction of those having electron-withdrawing groups was 
sluggish at 80 °C. A more elevated temperature (100 °C) was needed in the case of 3-58. In 
addition, the borylation of aryl bromides with electron-donating groups proceeded smoothly 
at 100 °C; however, the presence of electron-withdrawing substituents decreased the yield 
such as 3-55c.  
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3-55a  X = I          79%
3-55b  X = OTf     77%




































In this laboratory, the borylation of iodophenylacetonitrile 3-8 with 1.5 equivalents of 
pinacol borane (3-48), 3 mol% of PdCl2(dppf), and 3.0 equivalents of Et3N in dioxane at 80 
°C, unfortunately, provided a complex mixture. A possible problem was that, although the 3-
8 is an electron-rich species, it did include a sterically hindered di-ortho-substituted structure, 
which might hinder the reaction. Guéritte and coworkers extended this reaction to ortho-
substituted aryl bromides or iodides.16 For example, treatment of 2-bromoaniline (3-60) with 
3 equivalents of pinacolborane 3-48, 4.0 equivalents of Et3N using Pd(OAc)2 as a catalyst in 
the presence of the 20 mol % of biphenylphosphine ligand 3-66 in dioxane at 80 °C 
generated piancol boronate 3-61 in much higher yield (81%) than that of the original 
condition. For the aryl iodide, even for the more sterically hindered species such as 3-62 and 
3-64, the borylation proceeded smoothly under same conditions. For our case, the borylation 




























































































Guéritte et al. proposed a possible mechanism and catalytic cycle for the borylation that 
involves a boryl anion, generated by the combination of Et3N and the dialkoxyborane 3-48 
(Figure 3-2).16 Initially, the aryl electrophile would add oxidatively to the palladium catalyst 
to give arylpalladium(II) species Ar–PdII–X. A subsequent ligand exchange between X of 
Ar–PdII–X and the boryl anion would produce the Ar–PdII–B(OR)2 intermediate and 
Et3NH·X, followed by reductive elimination that would give the arylboronate ArB(OR)2 and 
regenerate the palladium catalyst. 
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Ar PdII X Ar PdII B(OR)2
Pd0







Overall, the synthesis of pinacol boronate 3-7, the D-ring building block for the synthesis 
of isoprekinamycin, was achieved in seven steps from commercial available 1,3-
dimethylanisole 3-11 following the sequence as shown in Scheme 3-14, was achieved in six 




3-10   28%
OMe
OH




























OMe 1. NHPI, Co(OAc)2




3.2 The Total Synthesis of Isoprekinamycin 
With the D ring synthon pinacol boronate 3-7 in hand, Suzuki coupling between 3-7 and 
bromoindenone 3-6 was explored as shown in Scheme 3-15. The desired diaryl compound 3-
5 was obtained in 85% by using 5 mol% of Pd2(dba)3·CH3Cl, 10 mol% of [(t-Bu)3PH]BF4 


























Cyclization of diaryl compound 3-5 using 1.1 equivalents of LDA in THF unfortunately 





















rt, 3 h major trace
rt, 24 h 2 1
-78 °C to rt, 72 h 3 1  
 Treatment of 3-5 with 1.1 equivalents of LDA in THF at room temperature for 3 hours, 
the conditions under which the cyclization of the model compound was completed, generated 
only trace amounts of the desired phenol 3-67, but more of the aldol product 3-66 and a 
substantial amount of un-reacted starting material. Increasing the reaction time to 24 hours 
led to a higher conversion of starting material, but 3-66 remained the major product. 
Cyclization of diaryl compound 3-5 was clearly much slower than the simpler model 
compound and the aldol reaction was the favoured reaction, in comparison to the desired 
Dieckmann-like cyclization. Since the aldol reaction is reversible, it was hoped that the 
conjugate base of phenol 3-67 (phenolic anion) is the thermodynamically more stable product 
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so that the yield of phenol 3-67 might be improved by increasing the reaction time. However, 
even increasing the reaction time to three days, the ratio of the desired Dieckmann product 3-
67 to aldol product 3-66 was not improved (3-66:3-67 ≈ 3:1), and small amounts of starting 
material remained. 
Cyclization of the diaryl compound 3-5 using bases other than LDA was investigated as 
shown in Scheme 3-17. Treatment of 3-5 with two equivalents of DBU in refluxing THF 
afforded aldol product 3-66 in 60% yield with some remaining starting material. A reaction 
carried out in DMF at room temperature overnight generated the aldol product 3-66 cleanly 
in 66% yield with some starting material left. However, at 80 °C the reaction provided a 
complex mixture possibly resulting from the decomposition of 3-66 at elevated temperature 
in a polar solvent such as DMF. A similar result was obtained when using 1.1 equivalents of 
sodium hydride. Meanwhile, treatment of 3-5 with 1.1 equivalents of sodium methoxide in 
methanol at room temperature also provided the aldol product 3-66 as a major product with 



















DBU (2.0 eq.), THF, reflux
DBU (2.0 eq.), DMF, rt
DBU (2.0 eq.), DMF, 80 °C
NaH (1.1 eq.), DMF, 80 °C








Hence, a computational analysis of the aldol versus Dieckmann cyclizations was carried 
out.  
It was decided that the analysis would be restricted to a ground state calculation of the 
initial tetrahedral addition product between the cyano-stabilized anion and the ester group.  In 
considering a computational analysis of the Dieckmann cyclization a number of issues had to 
be considered. To begin with, two conformations of the C-ring had to be considered as well 
as the relative configurations of the two chiral centers created in the initial reaction. The two 
conformations are labeled A and B in Figure 3-3.  Calculations were done for the two ring 
conformations of the two relative configurations (RR and RS) as shown in Figure 3-3. 













































Additionally, the ring-A methoxy group has some conformational options. Two starting 
geometries with the methyl group of the methyl ether oriented at 90° relative to the aromatic 
ring (up and down) as well as one starting geometry with the O-Me bond in the aromatic 
plane and away from the ortho-substituent were considered. The other planar geometry was 
clearly too sterically strained and was not minimized. Given the substantial number of 
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starting geometries that had to be probed, the computational study was restricted to the AM1 
semi-empirical method. In each case, a full geometry optimization was performed and 
frequencies were calculated. All structures obtained had no imaginary frequencies suggesting 
that they were true energy minima. The lowest energy minima were found for the RR isomer 
in the B-type conformation.  With total electronic energy of –0.0202 a.u. = –12.7 kcal/mol. 
In the case of the aldol condensation, the most stable initial adduct has the alkoxide and 
the cyano group syn such that the lithium ion is shared between the alkoxide oxygen and the 
cyano nitrogen and has a total electronic energy of –0.01470649 a.u. = –9.22 kcal/mol. 
If one assumes that the reaction proceeds in each case via the most stable initial adduct 
then the above analysis predicts that the Dieckmann cyclization should be favoured by 
approximately 3.5 kcal/mol. This would be consistent with the observation that in this model 
series the Dieckmann-like cyclization appears to occur essentially to the exclusion of the 
intramolecular aldol condensation. Models of the computed lowest energy structures for the 
aldol and Dieckmann cyclizations are shown in Figure 3-4. 
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Figure 3-4 Comparison of the Minimum Energy with Aldol and Dieckmann 
Intermediates for the Model 
Model –Aldol Intermediate 
 
Total Electronic Energy: –9.22 kcal/mol 
Model – Dieckmann Intermediate 
 
Total Electronic Energy = –12.80 kcal/mol 
For computational analysis of the intermediates in the IPK synthesis, the starting 
geometries were constructed by modifying the lowest energy structures shown above for the 
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model series. The computed optimized geometries for the Dieckmann and aldol intermediates 
are shown in Figure 3-5. 
Figure 3-5 Comparison of the Minimum Energy with Aldol and Dieckmann 
Intermediates for the IPK 
IPK-Dieckmann Intermediate 
 
Total Electronic Energy = -51.47 kcal/mol 
 
IPK –Aldol Intermediate 
 




These semi-empirical calculations do predict that the degree to which the Dieckmann 
condensation is favoured over the intramolecular aldol is substantially diminished (less that 
0.5 kcal/mol) in the case of the IPK synthesis versus the case in the model synthesis, where 
the Dieckmann condensation intermediate is favoured by about 3.5 kcal/mol.  
These calculations are in the gas phase and clearly could be influenced by solvent effects. 
Examination of the computed models of the intermediates reveals that some steric 
interaction is expected between the ring D OMe group and the ester group in forming the 
aldol intermediate. Likewise, some steric interactions are expected between the ketone 
oxygen atom and the ring D OMe group in forming the initial Dieckmann intermediate. 
However, in the initial Dieckmann product the steric clash between the oxygen atoms of the 
ketone and the methyl ether is at an O–O distance of 2.38 Å whereas the O–C clash in the 
aldol intermediate is at a distance of 3.14 Å. Furthermore, as indicated in the figure below, 
the partial charges on the atoms involved in the in the steric contacts in the Dieckmann 
intermediate are both partially negative (–0.25 and –0.19) whereas the partial charges on the 




Figure 3-6 Comparison of the Steric and Electronic Effects with Aldol and Dieckmann 






See Appendix 3-10 for a more detailed description of the computational method and a 
reference for the Gaussian 03 program. 
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Since the cyclization of the diaryl compound with various bases generated the aldol 
product, the conversion of 3-5 to the corresponding cyclic ketal was explored as shown in 
Scheme 3-18, in order to control the regioselectivity of the cyclization. It has been observed 












O O OH OH
p-TsOH, benzene
          reflux
3-5
O O OH OH
p-TsOH, benzene





O O OH OH
p-TsOH, benzene
          reflux
starting material










In practice, heating diaryl compound 3-5 with ethylene glycol in benzene in the presence 
of p-toluenesulfonic acid (p-TsOH) led to no reaction. Paquette and coworkers reported an 
essentially quantitative conversion to 3-74 under transacetalization conditions, in which the 
ketone 3-73 was unresponsive to normal ketalization involving ethylene glycol.18 For our 
case, heating the 3-5 with 0.1 equivalent of 2,2-dimethyl-1,3-propanediol and 3 equivalents 
of 2,2,5,5-tetramethyl-1,3-dioxane in the presence of p-TsOH in benzene provided only the 
starting materials. Attempted ketalization of the bromoindenone 3-6 (i.e. prior to Suzuki 
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coupling) also failed. 
Attempts were also made to protect the ketone as an N,N-dimethyl hydrazone derivative. 
Corey and coworkers reported that (–)-carvone was converted to the dimethylhydrazone 3-76 
in 95% yield using 1.5 equivalents of dimethyhydrazine in the presence of 0.05 equivalent of 
trifluoroacetic acid in refluxing toluene.19 No reaction was observed under such conditions 
applied to 3-5. Evans and coworkers reported a mild condition for converting ketones to N,N-
dimethyl hydrazones20 using an excess of dimethylhydrazine with TMSCl to synthesize 




 0.05 eq. CF3COOH


























3-75 3-76   95%
















An alternative way of improving the regioselectivity of the cyclization was considered, 
and involved conversion of the diaryl compound 3-5 to the corresponding carboxylic acid 3-
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79. In this way, the system could be activated by introducing a good leaving group to the 
carbonyl group, and was investigated as presented in Scheme 3-20. Attempted hydrolysis of 
diaryl compound 3-5 with lithium hydroxide in refluxing THF, water and methanol provided 
aldol compound 3-66. On the other hand, attempted hydrolysis of the bromoindenone 3-6 
using different bases such as LiOH and NaOH led to complex mixtures of products. Heating 
3-6 with HCl in refluxing THF and water still afforded a complex mixture. Meanwhile, 




























































Evans and coworkers developed a procedure to generate titanium enolates from the β-
ketone imides such as 3-82, which reacted with electrophiles diastereoselectively.21–23 TiCl4 
and i-Pr2NEt or Et3N were used for this system and isopropoxytitanium trichloride Ti(Oi-
Pr)Cl3 could be used in place of TiCl4. Increasing the number of the alkoxy substituents on 
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the titanium reagent decreases its enolization potential, but the coordination between the 
oxygenated titanium reagent and i-Pr2NEt or Et3N is reversible, which means that the 
sequence of the addition of reagents does not need to be controlled.  
















































CH2Cl2, -78oC to rt.
1. 2.2 eq. TiCl3(Oi-Pr)


























The possibility was considered that such conditions might be applied to the cyclization of 
3-5 such that the titanium reagent would complex to the carbonyl group of the B ring and the 
nearest methoxy group and also to the carbonyl group of the ester to its nearest methoxy 
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group to form an intermediate such as 3-85. It was hoped that such a species could undergo 
deprotonation and then cyclized selectively by reaction with the titanium-complexed ester 
group. In practice, no reaction was observed when 3-5 was treated with 2.2 equivalents of 
Ti(Oi-Pr)Cl3, 1.1 equivalents of i-Pr2NEt in CH2Cl2, or when DBU, a stronger base, was used 
(Scheme 3-22). 
Since it was difficult to directly protect the keto group of 3-5 as either a ketal or a 
hydrazone derivative, the reduction of it was investigated. Treatment of ketone 3-5 with 2.0 
equivalents of NaBH4 in the presence of 1.0 equivalent of cerium (III) chloride hydrate to 
favour 1,2-reduction of the unsaturated ketone in a 1:1 mixture of methylene chloride and 
methanol at room temperature generated the corresponding alcohol 3-86 in 99% yield. 
However, treatment of alcohol 3-86 with 2.0 equivalents of DBU in DMF at room 
temperature provided the aldol product 3-87 accompanied by a complex mixture of products. 
Replacement of DBU with 2.5 equivalents of LDA in THF at room temperature led to a 
mixture of the aldol-dehydration product 3-66, the desired phenol 3-67, and the ketone 3-5. It 
is not clear what the oxidant is in this procedure. Perhaps the oxidation involves traces of 
desolved oxygen or, perhaps the oxidation occures at the expense of reduction of another 


















































It was then thought that the alcohol 3-86 could be protected prior to cyclization, as 
presented in Scheme 3-24. Treatment of 3-86 with one equivalent of LDA, followed by one 
equivalent of TMSCl, generated the TMS-protected ether 3-88, which was treated in situ 
with 1.25 equivalents of LDA, and worked up with saturated aqueous ammonium chloride to 
afford a mixture of the phenols 3-89 and 3-67. Methylation of this mixture provided 3-4 in 
60% yield in two steps, and with the benzo[a]fluorene skeleton built up, the carbonitrile 
functionality was converted to the corresponding carboxamide 3-90 smoothly in 97% yield. 
Similar to the attempted cyclizations mentioned above, it was noticed that the benzylic 
alcohol was oxidized in situ by air during the methylation. A similar sensitivity to oxidation 
of the related TBS-protected alcohol 3-91 was previously observed in this group in a 















1. LDA (1.0 eq.)
    THF, -78 °C, 1 h
2. TMSCl (1.0 eq.)
    THF, -78 °C, 1 h
1. LDA (1.25 eq.)













































   BINAP, PhMe
 
It was found later that the yield of the sequence from 3-86 to 3-4 was difficult to achieve 
reproducibly on different scales, perhaps because of instability of the TMS ether or the 
tendency of the alkoxide derived from 3-86 to undergo oxidation. 
Hence, treatment of ketone 3-5 with one equivalent of lithium tri-tert-butoxyaluminum 
hydride, which resembles sodium borohydride in terms of its selectivity for functional groups, 
in THF at room temperature overnight led to alcohol 3-86 and a small amount of starting 
material. Although the reaction seemed clean, it seemed too slow to be practical for large-
scale preparations. (Scheme 3-25) 
Exploration of the literature revealed that Kim and coworkers reported that an ate complex, 
LiAlH(n-Bu)i-Bu2, generated from diisobutylaluminum hydride and n-butyllithium in an 
equimolar ratio in tetrahydrofuran-hexane could reduce the keto group in an enone 
selectively while tolerating ester or cyano groups.25 Reduction of 3-5 with one equivalent of 
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LiAlH(n-Bu)i-Bu2 in THF at –78 °C for one hour, followed by treatment with one equivalent 
of TMSCl in THF at –78 °C for one hour, and treatment with 1.25 equivalents of LDA in 
THF from –78 °C to room temperature for six hours provided a mixture of alcohol 3-86 and 
the desired cyclization product 3-89. It was considered that the trialkylaluminate 3-93 (in 
Scheme 3-26), generated from the reduction of 3-5 using LiAlH(n-Bu)i-Bu2, was relatively 
stable and that its reaction with TMSCl was slower than expected. However, elevation of the 
reaction temperature to room temperature after the addition of TMSCl did not improve the 








1. LiAlH(n-Bu)i-Bu2 (1.0 eq.)
    THF, -78 °C, 1 h
3-88
1. LDA (1.25 eq.)
    -78 °C to rt, 6 h
2. H3O+2. TMSCl (1.0 eq.)



























It was decided that, since the trialkylaluminate 3-93 is bulky and relatively stable, it could 
be viewed as a protecting group for the alcohol 3-86. Thus, treatment of 3-5 with the same 
sequence as above, without the TMSCl, afforded a mixture of the desired phenol 3-89 and its 
oxidized product 3-67 (as expected), which were methylated to provide the mixture of 3-94 
and 3-4. Since the next step in the planned sequence was hydrolysis of the cyano group by 
H2O2/K2CO3/DMSO, it was assumed that the alcohol 3-94 would be oxidized in this step. In 
























1. LDA (1.25 eq.)
    -78 °C to rt, 6 h





































Thus, this sequence provides 3-90 via a convenient and reproducible protocol. To our 
knowledge, the use of an aluminate intermediate such as 3-93 for protection of an alcohol is 
new and this way offers an advantage over trialkylsilyl protection when the alcohol is very 
base sensitive. 
With carboxamide 3-90 in hand, the modified Hofmann rearrangement of 3-90 using 1.0 
equivalent of PhI(OAc)2 and 2.5 equivalents of KOH in methanol at room temperature 
provided the carbamate 3-95 in 99% yield. This reaction is sensitive to the amount of 
PhI(OAc)2, and more than one equivalent of this oxidative reagent led to complex mixtures 
of byproducts, perhaps resulting from the oxidation of the electron rich D ring of 3-90. 
Hydrolysis of the 3-95 afforded an aniline 3-3 quantitatively, which was subjected to the 
demethylative diazotization conditions to generate dimethyl isoprekinamycin 3-2 in a yield 
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of 63%. Fortunately, the demethylation of dimethyl IPK 3-2 using four equivalents of BCl3 in 
methylene chloride proceeded well and provided IPK 3-1 in 64% yield. This contrasts with 
reported conversion of the dimethyl prekinamycin 3-96, which was decomposed with BCl3 
and other Lewis acids such as BBr3, TMSI, and MgI2·Et2O during the attempted 

































  MeOH, rt.
LiOH (4 M)
EtOH, reflux
1.  1.25 eq. NaNO2
    HCl, EtOH, 0oC, 2 h
2. NaHCO3, 0oC
4.0 eq. BCl3
   CH2Cl2
 -40oC to rt.











Thus, the first total synthesis of IPK was achieved via the sequence as presented in 
Scheme 3-28. The synthesis was initiated from the commercially available dihydrocoumarin 
3-97 through six steps to generate the AB ring synthon, bromoindenone 3-6, in 33% yield. 
Suzuki coupling between 3-6 and a D ring building block pinacol boronate 3-7, which was 
obtained from the known benzyl alcohol 3-10 through four steps in 42% yield, gave 3-5 in 
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85% yield. IPK was obtained in another seven steps, and overall, the longest linear sequence 




























3.3 Comparison between the Synthetic Compounds and Natural IPK 
Although the synthetic route that was followed and the detailed characterization of the 
intermediates gave us confirmation that we had indeed synthesized the structure assigned to 
IPK, it was felt that a rigorous comparison to establish that the synthetic material was 
identical to the natural product remained important. 
High resolution mass spectrometry data for the synthetic dimethylisoprekinamycin 3-2 
supports the molecular formula as C20H14O4N2 with an exact mass of 346.0953. The proton 
NMR spectrum of 3-2 exhibits one multiplet at δ 7.33, two doublets at δ 7.27 (J = 6.5 Hz) 
and 7.16 (J = 8.2 Hz) and two singlets at δ 6.86, 6.69 representing the aromatic protons and 
three singlets at δ 3.99, 3.98, 2.48 representing the two methoxy groups and one methyl 
group respectively. 2-Dimensional HMQC NMR experiments showed cross peaks at δ 7.33 
(130.9), 7.27 (120.5), 7.16 (116.7), 6.86 (112.5), 6.69 (109.1), 3.99 (56.7), 3.98 (55.8) and 
2.48 (21.7). As a result of the low solubility of 3-2, the 13C NMR signal corresponding to the 
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carbon of the diazo group was not observable directly. However, the HMBC experiment 
indicated a three bond correlation from H-4 at 6.86 ppm to a 13C atom with a resonance at δ 
88.0 ppm, which was then assigned to the carbon attached to the diazo group. This result 























Table 3-1 Spectroscopic Data for Compounds 3-98, 3-2, and 3-99 
  3-98 3-2 3-99 
C-11 196.2 ppm 192.2 ppm 192.48 ppm 
C-6 170.5 ppm 171.2 ppm 174.14 ppm 
13C 
NMR 
C-5 90.0 ppm 88.0 ppm 83.17 ppm 
v (C-N2) 2095.7 cm–1 2112.6 cm–1 2119 cm–1 
v (CO) 1710.8 cm–1 1722.3cm–1 1727 cm–1 IR 
v (CC) 1620.1 cm–1 1608.6 cm–1 1613 cm–1 
 
Other 13C NMR characteristics of dimethyl IPK 3-2 are also in excellent agreement with 
the corresponding structural features of model 3-98 and IPK diacetate 3-99 (Table 3-1). In 
particular, the carbonyl resonance at 192.2 ppm in the spectrum of 3-2, assigned to the five-
membered ring ketone, has counterparts at 196.2 ppm in the model 3-98 and 192.48 ppm in 
IPK diacetate 3-99. In addition, the diazo group gives rise to a band at 2112.6 cm–1 in the IR 
spectrum of 3-2 as compared with a band at 2095.7 cm–1 in the spectrum of the model 3-98 
and at 2119 cm–1 for IPK diacetate 3-99. 
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Spectroscopic comparison of the synthetic and natural IPK was then carried out in the 
following manner: (1) for 1H NMR spectral comparison, saturated CD2Cl2 solutions of the 
synthetic and natural IPK were examined on a 500 MHz NMR spectrometer; (2) for IR 
spectral comparison, saturated CH2Cl2 solutions of the synthetic and natural IPK were 
examined on an FT-IR spectrometer using a demountable liquid-cell IR kit (Aldrich Z11200-
3) with two CaF2 windows (32 mm × 3 mm) and a light path of 0.1 mm, and the solvent and 
air backgrounds were deducted from the recorded spectra; (3) for HPLC retention time and 
UV-vis spectra comparison,  the synthetic and natural IPK and also a mixture of both 
compounds were analyzed with a Waters HPLC system equipped with a photodiode array 
detector.  
Table 3-2 Comparison of 1H NMR with Natural and Synthetic IPK (500 MHz in CD2Cl2) 
Natural IPK (ppm) Synthetic IPK (ppm) 
12.32 (s, 1H) 12.32 (s, 1H) 
11.61 (s, 1H) 11.61 (s, 1H) 
7.26 (dd, J = 7.0 Hz, 0.7 Hz, 1H) 7.26 (d, J = 6.7 Hz, 1H) 
7.18 (t, J = 7.6 Hz, 1H) 7.18 (t, J = 7.6 Hz, 1H) 
7.06 (dd, J = 8.3 Hz, 0.8 Hz, 1H) 7.06 (d, J = 8.3 Hz, 1H) 
6.71 (s, 1H) 6.72 (s, 1H) 
6.69 (s, 1H) 6.69 (s, 1H) 




Table 3-3 Comparison of IR Frequencies of Natural and Synthetic IPK (saturated 
CH2Cl2 solution) 











 * Absorption of the diazo group 
 
Table 3-4 Comparison of UV-vis with Natural and Synthetic IPK (HPLC) 






Synthetic and natural isoprekinamycin exhibited the same Rf values in the following three 
different TLC solvent systems: Rf = 0.80 (EtOAc:Hexanes = 3:2), Rf = 0.38 (Et2O:Hexanes = 
1:1), Rf = 0.14 (CH2Cl2:Hexanes = 2:1). 
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Slow crystallization of IPK by Nan Chen in this group, provided crystals for an X-ray 
diffraction study that confirmed the assigned structure 3-1. Comparison of structures of the 
synthetic model compound 3-98 and IPK 3-1 reveals increased diazonium ion character in 
IPK as evidenced by the alternating shorter N–N (1.104 versus 1.116 Å), longer C5–N (1.362 
versus 1.334 Å), shorter C5–C6 (1.424 versus 1.457 Å) , and longer C6–O (1.246 versus 
1.227 Å) bond lengths in the IPK structure which are entirely consistent with an increased 
diazonium ion contribution to the resonance hybrid representing the o-quinodiazide 
functionality in IPK relative to that 3-98. 
The increased availability of IPK opens the door to more extensive biological studies. We 
have now found that IPK, previously shown to exhibit modest antibacterial activity, 
significantly inhibits the growth of CHO (IC50 = 5.8 µM) and K562 human leukemia cells 




Figure 3-8 Structural Comparison of the Diazobenzo[a]fluorene and 
Diazobenzo[b]fluorene Systems 
 
Superimposition of a computed model of isoprekinamycin (RHF/6-31G) on a model of 
prekinamycin(RHF/6-31G) reveals that the oxygen and nitrogen atoms on the periphery align 
well despite the rearranged carbon skeleton, suggesting that the diazobenzo[a]- and 
diazobenzo[b]fluorenes are variants of the same pharmacophore. Consistent with this 
hypothesis is our finding that IPK-diacetate 3-99, which is more soluble than IPK, inhibits 
the topoisomerase IIα-catalyzed decatenation of kDNA (IC50 = 9.7 µM) just as was observed 
recently for kinamycin A and kinamycin C (IC50 = 3.2 and 43 µM, respectively) in the 
laboratory of  our collaborators in the Faculty of Pharmacy at the University of Manitoba.29 
The ease of synthesis of IPK relative to the kinamycins and lomaiviticins makes the 
diazobenzo[a]fluorene system attractive for generation of synthetic analogues. Efforts to 
create other benzo[a]fluorenes and congeners of IPK with improved solubility and drug-like 




3.4.1 General Information 
 
1H NMR spectra were recorded on a Brüker AVANCE 500 (500 MHz), Brüker AC 300 (300 
MHz) and Brüker AVANCE 300 (300 MHz) NMR spectrometer. Chemical shifts are 
reported in parts per million (ppm) relative to tetramethylsilane (TMS). The following 
abbreviations are used for NMR peak multiplicities: s, singlet; d, doublet; t, triplet; q, quartet; 
dd, doublet of doublets; dt, doublet of triplets; m, multiplet; b, broad; w, weak. 13C NMR 
spectra were broad band decoupled and recorded on a Brüker AVANCE 500 (125.8 MHz), 
Brüker AC 300 (75.5 MHz) and Brüker AVANCE 300 (75.5 MHz) NMR spectrometer using 
the carbon signal of the deuterated solvent as the internal standard. HMQC and HMBC 
experiments were performed on a Brüker AVANCE 500 spectrometer. IR spectra were 
determined on a Perkin-Elmer RX I FT-IR spectrometer as KBr discs unless otherwise 
indicated. High- and low resolution electron impact or electrospray ionization (EI or ESI) 
mass spectra (MS) were measured by the WATSPEC Mass Spectrometry Facility 
(Department of Chemistry, University of Waterloo, Waterloo, Ontario, Canada). Elemental 
analyses were performed by the M-H-W Laboratories (Phoenix, Arizona, USA).  
Anhydrous THF and Et2O were freshly distilled from sodium/benzophenone under nitrogen 
prior to use. Anhydrous CH2Cl2 was freshly distilled from CaH2 under nitrogen prior to use. 
All commercial reagents were purchased from Aldrich Chemical Co., Strem Chemicals Inc., 
Alfa Aesar, Lancaster Synthesis Ltd. or BDH Inc. and were used as received unless 
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otherwise indicated. Deionized water was supplied by a Biolab vertical series reverse 
osmosis system. 
The –78 °C and 0 °C designations refer to solid carbon dioxide/acetone and ice/water slush 
respectively. The room temperature refers to 22 °C to 25 °C. Flash column chromatography 
was carried out using the Merck silica gel (230–400 mesh) and SiliCycle silica gel (60 Å). 
Reactions were magnetically stirred and monitored by thin layer chromatography (TLC) with 
Merck pre-coated silica gel plates (silica gel 60 F254 on aluminum sheet). All reported yields 
are isolated yields. 
 


















 (3-Methoxy-5-methylphenyl)methanol (3-10) 
To a solution of 3,5-dimethylanisole 3-11 (4.752 g, 34.90 mmol) in HOAc (50 mL) were 
added N-hydroxyphthalimide (0.569 g, 3.490 mmol) and Co(OAc)2•4 H2O (0.174 g, 0.698 
mmol). The solution was stirred at 100 °C for 72 h. The solution was concentrated, and 1 M 
aqueous NaOH solution was added to the residue to adjust the pH to ca. 12. The resulting 
solution was extracted with CH2Cl2 (3 × 100 mL), and the organic phase was dried over 
Na2SO4 and concentrated. The residue was purified by flash chromatography 
(EtOAc:Hexanes = 1:20, v/v) to recover the starting material 3,5-dimethylanisole (1.712 g, 
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36%) and meanwhile to obtain the crude aldehyde. The pH of the basic aqueous phase was 
adjusted to ca. 1 with conc. HCl and the resulting solution was extracted with EtOAc (4 × 
100 mL). The EtOAc phase was dried over Na2SO4 and concentrated to obtain the crude 
carboxylic acid 3-16. The crude aldehyde and carboxylic acid 3-16 were combined (3.425 g) 
and subjected to the next reduction step.  
To a suspension of LiAlH4 (1.299 g, 34.25 mmol) in anhydrous THF (75 mL) at 0 °C was 
added slowly a solution of the crude aldehyde and acid in anhydrous THF (3.425 g in 9 mL), 
and the reaction mixture was further stirred at 0 °C for 15 min. The solution was then 
warmed to room temperature and stirred for 20 h. Excess LiAlH4 was quenched with the 
addition of saturated aqueous NH4Cl solution at 0 ºC and the suspension was filtered, dried 
over Na2SO4, and concentrated. The residue was purified by flash chromatography 
(EtOAc:Hexanes = 1:5, v/v) to obtain the title compound as a white solid (1.487 g, 28% for 
two steps). 1H NMR (300 MHz, CDCl3): δ 6.71 (s, 1H), 6.68 (s, 1H), 6.62 (s, 1H), 4.53 (s, 
2H), 3.74 (s, 3H), 3.08 (s, 1H), 2.30 (s, 3H); 13C NMR (75.5 MHz, CDCl3): δ 159.7, 142.4, 
139.5, 120.0, 113.9, 109.2, 64.9, 55.1, 21.4; IR (film): 3366.1, 2999.8, 2940.0, 2871.3, 
2839.1, 1613.5, 1462.7, 1325.3, 1295.3, 1193.6, 1152.5, 1068.2 cm–1; MS (EI): m/z 152.09 




















To a solution of compound 3-10 (3.743 g, 24.62 mmol) in anhydrous diethyl ether (160 mL) 
was added n-BuLi (1.6 M in hexane, 33.86 mL) slowly, and the solution was warmed to 
room temperature and stirred for 4 hours, after which the solution was again cooled to 0 °C. 
Anhydrous THF (80 ml) was then added to the solution and the reaction mixture was stirred 
for 1 h, followed by slow addition of I2 (7.687 g, 30.29 mmol) dissolved in minimum amount 
of THF and the mixture was further stirred for 30 min at 0 ºC. The reaction mixture was 
washed with 10% aqueous Na2S2O3 solution and then mixed with saturated aqueous NH4Cl 
solution (50 mL), followed by extraction with Et2O (3 × 100 mL). The organic phase was 
dried over Na2SO4 and concentrated. The residue was purified by flash chromatography 
(EtOAc:Hexanes = 1:5, v/v) to obtain the title compound as a white solid (5.068 g, 74%). 1H 
NMR (300 MHz, CDCl3): δ 6.86 (s, 1H), 6.54 (s, 1H), 4.59 (s, 2H), 3.83 (s, 3H), 2.60 (s, 1H), 
2.30 (s, 3H); 13C NMR (75.5 MHz, CDCl3): δ 157.7, 144.0, 139.7, 121.7, 111.1, 85.2, 69.4, 
56.5, 21.4; IR (film): 3262.1, 2902.6, 1651.8, 1575.5, 1457.7, 1433.9, 1409.8, 1356.2, 1307.6, 























To a solution of compound 3-9 (5.068 g, 18.23 mmol) in anhydrous CH2Cl2 (100 mL) was 
added CBr4 (6.348 g, 19.14 mmol) at room temperature. The solution was cooled to 0 ºC and 
PPh3 (5.021 g, 19.14 mmol) was added slowly. The solution was then warmed to room 
temperature and stirred for 6 h. The solution was concentrated and the residue was purified 
by flash chromatography (EtOAc:Hexanes = 1:50, v/v) to obtain the intermediate benzyl 
bromide as a white solid. 
To a solution of the above white solid in anhydrous DMSO (30 mL) was added NaCN (1.340 
g, 27.35 mmol) and the mixture was stirred for 36 h. The reaction mixture was diluted with 
water (150 ml) and extracted with CH2Cl2 (2 x 100mL). The organic phase was dried over 
Na2SO4 and concentrated. The residue was purified by flash chromatography 
(EtOAc:Hexanes = 1:20, v/v) to obtain the title compound as a white solid (3.606 g, 69% for 
two steps). 1H NMR (300 MHz, CDCl3): δ 6.91 (s, 1H), 6.55 (s, 1H), 3.82 (s, 3H), 3.73 (s, 
2H), 2.30 (s, 3H); 13C NMR (75.5 MHz, CDCl3): δ 158.4, 140.3, 134.5, 122.2, 117.6, 111.4, 
87.4, 56.6, 30.2, 21.4; IR (film): 3020.3, 2968.7, 2942.4, 2920.1, 2250.9, 1572.7, 1458.9, 
1408.0, 1391.9, 1319.7, 1298.3, 1243.0, 1184.4, 1081.5, 1015.7 cm–1; MS (EI): m/z 287.0 





















To a solution of compound 3-8 (1.500 g, 5.226 mmol) in anhydrous dioxane (18 mL) were 
added pinacolborane (2.28 mL, 15.98 mmol) and Et3N (2.91 mL, 20.91 mmol), and the 
mixture was degassed three times by the thaw-freeze process. Pd(OAc)2 (59 mg, 0.2613 
mmol) and (2-biphenyl)dicyclohexylphosphine (366 mg, 1.045 mmol) were added to the 
mixture then the reaction mixture was degassed again by a freeze-thaw process. The mixture 
was stirred at 100 ºC for 4 h. Saturated aqueous NH4Cl solution (20 mL) was added to the 
solution at 0 ºC followed by extraction with CH2Cl2 (2 × 100 mL). The organic phase was 
dried over Na2SO4 and concentrated, and the residue was purified by flash chromatography 
(EtOAc:Hexanes = 1:10, v/v) to obtain the title compound as a white solid (1.229 g, 82%). 
1H NMR (300 MHz, CDCl3): δ 6.77 (s, 1H), 6.56 (s, 1H), 3.76 (s, 2H), 3.71 (s, 3H), 2.28 (s, 
3H), 1.31 (s, 12H); 13C NMR (75.5 MHz, CDCl3): δ 164.2, 142.3, 135.7, 121.6, 118.5, 110.8, 
83.8, 55.8, 24.7, 23.4, 21.7; IR (film): 3458.1, 2978.7, 2935.6, 2838.5, 2249.0, 1612.1, 
1567.3, 1144.2, 1084.9, 1063.8 cm–1; MS (EI): m/z 287.2 (100, M+), 286.2 (27), 272.2 (26), 
228.2 (38), 214.2 (25), 200.2 (37), 187.1 (99), 186.1 (32), 161.1 (18), 131.1 (26), 130.1 (12); 



























Compound 3-6 (132 mg, 0.443 mmol) was mixed with KF (77 mg, 1.329 mmol), 
Pd2(dba)3·CHCl3 (23 mg, 0.022 mmol) and [(t-Bu)3PH]BF4 (13 mg, 0.044 mmol) and the 
mixture was deoxygenated five times with an argon balloon and vacuum pump. Compound 
3-7 (114 mg, 0.339 mmol) was dissolved in a mixture of THF and water (19:1, v/v, 4 mL) 
and the solution was deoxygenated three times using a freeze-thaw process. The 
deoxygenated solution was then added to the mixture of solids and the reaction mixture was 
stirred at room temperature for 24 hours under an argon atmosphere. The solution was then 
diluted with Et2O (100 mL) and washed with H2O (3 × 10 mL). The aqueous phase was 
extracted with Et2O (2 × 50 mL) and all Et2O phases were combined. The organic phase was 
dried over Na2SO4 and concentrated. The residue was purified by flash chromatography 
(EtOAc:Hexanes = 1:3, v/v) to obtain the title compound as an orange solid (127 mg, 85%). 
1H NMR (300 MHz, CDCl3): δ 7.27 (m, 1H), 7.16 (d, J = 6.8 Hz, 1H), 7.01 (d, J = 8.3 Hz, 
1H), 6.93 (s, 1H), 6.67 (s, 1H), 3.83 (s, 3H), 3.75 (s, 3H), 3.73 (d, J = 19.0 Hz, 1H), 3.69 (s, 
3H), 3.64 (d, J = 19.0 Hz, 1H), 2.35 (s, 3H); 13C NMR (75.5 MHz, CDCl3): δ 195.1, 166.0, 
158.1, 152.8, 148.3, 141.0, 131.8, 131.1, 130.8, 130.4, 128.0, 121.2, 119.0, 118.0, 117.0, 
115.1, 111.4, 56.2, 55.8, 52.4, 22.0, 21.8; IR (film): 2950.0, 2842.3, 2251.6, 1733.1, 1717.1, 
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1610.0, 1575.8, 1479.4, 1464.0, 1337.9, 1274.2, 1242.6, 1202.1, 1173.8, 1092.5, 1055.1 cm–1; 
MS (EI): m/z 377.2 (100, M+), 345.1 (25), 318.1 (40), 286.1 (65), 59.2 (12); HRMS (EI): 
















1, 6, 7-Trimethoxy-3-methyl-11-oxo-11H-benzo[a]fluorene-5-carboxamide (3-90) 
Preparation of lithium complex solution: To a solution of i-Bu2AlH (1.75 mL of a 1.0 M 
solution, 1.75 mmol) in anhydrous THF (2.05 mL) at –78 °C was added n-BuLi in hexane 
(1.20 mL, 1.75 mmol) slowly, the mixture was further stirred for 1 hour. 
Preparation of LDA: To a solution of i-Pr2NH (0.26 mL, 1.834 mmol) in anhydrous THF 
(8.54 mL) at 0 ºC was added n-BuLi in hexane (1.20 mL, 1.75 mmol) slowly, and the 
mixture was further stirred for 30 minutes.  
To a solution of compound 3-5 (66 mg, 0.175 mmol) in anhydrous THF (4 mL) at –78 ºC 
was added the above lithium complex solution (0.5 mL) slowly, and the reaction mixture was 
further stirred for 1 hour, followed by slow addition of the freshly prepared LDA solution 
(1.25 mL). The solution was stirred for 1 hour at –78 ºC and then warmed to room 
temperature to be further stirred for 5 hours. Saturated aqueous NH4Cl solution (10 mL) was 
added to quench the reaction and the mixture was stirred for 20 minutes at 0 ºC. The resulting 
solution was extracted with CH2Cl2 (3 × 50 mL). The organic phase was dried over Na2SO4 
and concentrated to obtain the crude product as a red-orange solid (75 mg). 
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To a solution of the above crude product (75 mg) in anhydrous DMF (10 mL) was added 
K2CO3 (121 mg) and the reaction mixture was stirred at room temperature for 10 min, 
followed by addition of CH3I (0.11 mL). The reaction mixture was heated and stirred at 80 
ºC for 45 minutes. The solution was cooled to room temperature and diluted with H2O (100 
mL), followed by extraction with Et2O (3 × 100 mL). The organic phase was washed with 
H2O (3 × 30 mL), dried over Na2SO4 and concentrated to obtain the crude product as a red-
orange solid (63 mg). 
To a solution of the above crude product (63 mg) and K2CO3 (37 mg) in DMSO (25 ml) at 0 
ºC was added slowly 30% H2O2 (5 mL). The solution was warmed to room temperature and 
stirred for 24 h. The reaction mixture was diluted with H2O (100 mL) and then extracted with 
EtOAc (3 × 100 mL). The EtOAc phase was washed with H2O (3 × 30 mL), dried over 
Na2SO4 and concentrated. The residue was purified by flash chromatography 
(EtOAc:Hexanes = 2:1, v/v) to obtain the title compound as a red orange solid (34 mg, 51% 
for three steps). 1H NMR (300 MHz, DMSO-d6): δ 8.04 (s, 1H), 7.78 (s, 1H), 7.35 (m, 1H), 
7.26 (d, J = 8.2 Hz, 1H), 7.15 (d, J = 6.8 Hz, 1H), 7.00 (s, 1H), 6.83 (s, 1H), 3.91 (s, 3H), 
3.87 (s, 3H), 3.70 (s, 3H), 2.38 (s, 3H); 13C NMR (75.5 MHz, DMSO-d6): δ 190.4, 168.5, 
156.2, 154.4, 149.5, 140.1, 138.0, 137.3, 135.8, 133.6, 131.8, 131.6, 126.9, 120.2, 118.4, 
116.5, 116.4, 110.1, 63.5, 56.1, 55.6, 22.2; IR (film): 3425.0, 3337.5, 2937.5, 2837.5, 1706.3, 
1670.9, 1605.8, 1554.6, 1483.8, 1355.5, 1266.3, 1047.6 cm–1; MS (EI): m/z 377.2 (100, M+); 



















Methyl 1, 6, 7-trimethoxy-3-methyl-11-oxo-11H-benzo[a]fluoren-5-ylcarbamate (3-95) 
To a solution of compound 3-90 (24 mg, 0.065 mmol) and KOH (9 mg, 0.16 mmol) in 
anhydrous methanol (14 mL) at 0 ºC was added PhI(OAc)2 (21 mg, 0.065 mmol). The 
reaction mixture was stirred for 30 minutes at 0 ºC, then warmed to rt and stirred for 3 h. The 
solution was diluted with EtOAc (150 mL) and washed with brine (3 x 15 mL). The organic 
phase was dried over Na2SO4 and concentrated. The residue was purified by flash 
chromatography (EtOAc:Hexanes = 1:1, v/v) to obtain the title compound as a red orange 
solid (26 mg, 99%). 1H NMR (300MHz, CD2Cl2): δ 7.24 (m, 2H), 7.12 (s, 1H), 7.06 (d, J = 
7.9 Hz, 1H), 6.82 (s, 1H), 6.66 (s, 1H), 3.94 (s, 6H), 3.78 (s, 3H), 3.73 (s, 3H), 2.37 (s, 3H); 
13C NMR (75.5 MHz, CD2Cl2): δ 190.3, 156.3, 155.6, 153.9, 149.0, 139.8, 137.6, 136.4, 
133.7, 132.1, 130.7, 130.5, 127. 3, 118.9, 118.6, 116.1, 114.8, 109.6, 61.8, 56.0, 55.6, 52.7, 
21.8; IR (film): 3304.4, 2939.3, 1706.2, 1605.5, 1559.8, 1483.9, 1273.5, 1045.8 cm–1; MS 






















To a solution of compound 3-95 (26 mg, 0.065 mmol) in ethanol (16 mL) was added aqueous 
LiOH solution (4 M, 0.16 mL, 0.65 mmol) and the mixture was refluxed for 24 h. The 
solution was concentrated to ca. 5 mL and then diluted with CH2Cl2 (100 mL). The resulting 
solution was washed with H2O (3 × 10 mL), and the aqueous phase was extracted with 
CH2Cl2 (2 × 50 mL). The combined CH2Cl2 phase was dried over Na2SO4 and concentrated. 
The residue was purified by flash chromatography (EtOAc:Hexanes = 1:1, v/v) to obtain the 
title compound as a dark red solid (23 mg, 100%). 1H NMR (300 MHz, DMSO-d6): δ 7.46 (s, 
1H), 7.26 (m, 1H), 7.13 (d, J = 8.3 Hz, 1H), 7.02 (d, J = 6.9 Hz, 1H), 6.75 (m, br, 3H), 3.88 
(s, 3H), 3.82 (s, 3H), 3.62 (s, 3H), 2.36 (s, 3H); 13C NMR (75.5 MHz, DMSO-d6): δ 187.5, 
156.6, 154.2, 146.1, 140.8, 138.9, 136.8, 134.6, 131.3, 126.6, 123.8, 120.7, 118.7, 115.9, 
115.1, 114.6, 110.7, 61.1, 56.6, 55.8, 22.0; IR (film): 3394.6, 1627.8, 1513.1, 1457.0, 1269.9 
cm–1; MS (EI): m/z 349.1 (100, M+), 334.1 (27), 319.1 (18); HRMS (EI): calculated for 





















To a solution of compound 3-3 (15 mg, 0.044 mmol) in ethanol and water (5:1, v/v, 12 mL) 
at 0 ºC was added dilute HCl (1.2 M, 0.91 mL) slowly and the mixture was stirred for 10 
minutes. An aqueous solution of NaNO2 (4 mg/0.044 mmol in 0.5 mL) was added and the 
reaction was stirred at 0 ºC for 1 h, followed by addition of aqueous NaHCO3 solution (150 
mg in 2.0 mL), and the mixture was stirred at 0 ºC for additional 20 minutes. The reaction 
mixture was diluted with EtOAc (150 mL) and washed with H2O (3 × 20 mL). The organic 
phase was dried over Na2SO4 and concentrated. The residue was purified by flash 
chromatography (EtOAc:Hexanes = 1:2, v/v) to obtain the title compound as a dark purple 
solid (10 mg, 63%). 1H NMR (500 MHz, CD2Cl2): δ 7.33 (m, 1H), 7.27 (d, J = 6.5 Hz, 1H), 
7.16 (d, J = 8.2 Hz, 1H), 6.86 (s, 1H), 6.69 (s, 1H), 3.99 (s, 3H), 3.98 (s, 3H), 2.48 (s, 3H); 
13C NMR (125.8 MHz, CD2Cl2)*: δ 192.2, 171.2, 158.3, 154.4, 142.1, 140.9, 139.2, 133.9, 
130.9, 130.4, 127.4, 120.5, 116.7, 112.5, 110.7, 109.1, 56.7, 55.8, 21.7; IR (CH2Cl2 solution): 
2996.6, 2926.9, 2852.8, 2112.6, 1722.3, 1608.6, 1563.4, 1483.9, 1468.0, 1361.4 cm–1; MS 
(EI): m/z 346.1 (78, M+), 318.1 (100), 303.1 (97), 275.1 (27), 247.1 (22), 219.1 (15), 189.1 
(23), 187.1 (12); HRMS (EI): calculated for C20H14N2O4: 346.0954, found: 346.0953. 
*As the result of low solubility of the title compound in CD2Cl2, no 13C NMR signal was 
observed for the quaternary carbon attached to the diazo group. A cross peak at 88.0 ppm, 
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Isoprekinamycin (3-1) 
To a solution of compound 3-2 (8 mg, 0.022 mmol) in anhydrous CH2Cl2 (2 mL) at –78 °C 
was added slowly a CH2Cl2 solution of BCl3 (1 M, 0.09 mL, 0.09 mmol), and the reaction 
mixture was stirred for 30 minutes. The reaction mixture was warmed to rt and further stirred 
for 90 minutes, followed by addition of ice (1 g) and CH2Cl2 (100 mL). The CH2Cl2 solution 
was washed with water (3 × 10 mL), dried over Na2SO4 and concentrated. The residue was 
purified by flash chromatography (Et2O:CH2Cl2 = 1:200, v/v) to obtain the title compound as 
a dark purple solid (5 mg, 64%). 1H NMR (500 MHz, CD2Cl2): δ 12.32 (s, 1H), 11.61 (s, 1H), 
7.26 (d, J = 6.7 Hz, 1H), 7.1 8 (t, J = 7.6 Hz, 1H), 7.06 (d, J = 8.3 Hz, 1H), 6.72 (s, 1H), 6.69 
(s, 1H), 2.41 (s, 1H); IR (CH2Cl2 solution): 3686.1, 3600.7, 2926.6, 2855.0, 2126.1, 1733.9, 




Chapter 4 Design and Synthesis of Analogues of Isoprekinamycin 
The general methodology that had been established for the synthesis of 
diazobenzo[a]fluorenes systems, including the model compound 4-1 and isoprekinamycin (4-
2), allowed the design of analogues of isoprekinamycin. Functionalities that were considered 
for analoging of the core structure of 4-3 included OH groups, for example, which could be 
introduced at C1, C7, or C10 in order to increase the diazonium ion character of the diazo 
group as a result of intramolecular hydrogen bonding. The solubility of analogues might also 
be improved with the introduction of polar groups such as carboxylic acids, amides, or 
amines in a side chain, at the R3 or R4 positions of 4-3. An amino group could also possibly 
increase the affinity of the analogues for DNA. The introduction of a polar group such as a 
phenol at C4 could potentially increase the diazonium ion characteristics of the diazo group in 
the analogues because of the dipole-dipole interactions as shown in 4-5. Ab initio molecular 
orbital calculations by R.S. Laufer in this group support the existence of such an interaction.1 
Thus a study of the design and synthesis of the analogues was initiated in this laboratory, and 
is discussed in this and the following chapters. It was hoped that this work would open the 
door for further exploration of the structure and activity relationship of these compounds and 
would lead to more clues concerning the mode of action of isoprekinamycin and the related 


















R3 = H, CH3, CH2X, O(CH2)nNRR'
R4 = H, OH, O(CH2)nNRR'















R1 = H, OH
R7 = H, OH
R10 = H, OH
 
4.1 Studies Toward the Synthesis of the Analogues from the Corresponding 
Phenol Precursor 
It was felt that one series of analogues might be constructed by O-alkylation of a phenol 
group present at C3 of the D ring (e.g. 4-6, R = H). Retrosynthetic reasoning suggested that 
such system might be prepared from the aniline 4-7 via demethylative diazotization. The 
aniline 4-7 might be transformed from the corresponding benzyl group protected phenol ether 
4-8, which might be obtained from benzo[a]fluorene 4-9. The intermediate 4-9 might be 
formed via anionic cyclization of diaryl compound 4-10, which could be provided by the 
Suzuki coupling between bromoindenone 4-11 and pinacolboronate 4-12. The boronate 4-12 
might be formed from the triflate 4-13, which might be synthesized from the commercially 


























































Another analogue of interest was 4-15, in which a side chain OR is present at C4. This 
might be synthesized by a sequence similar to 4-6 as presented in Scheme 4-2. The synthesis 















































Salvadori and coworkers reported that treatment of 2,5-dihydroxybenzoic acid 4-14 with 
2.2 equivalents of sodium hydride, followed by treatment of one equivalent of benzyl 
bromide, provided mono-benzyl protected phenol ether 4-23 regioslectively.2 In this 
laboratory, this procedure was duplicated to convert 4-14 to 4-23 in 72% yield, which was 
reduced by three equivalents of lithium aluminium hydride in THF from 0 °C to room 








1. 2.2 eq. NaH
    0oC to rt.
2. 1.0 eq. BnBr
     DMF, rt.





THF, 0oC to rt.
4-24   73%  
Unfortunately, Salvadori’s procedure was unsuccessful for the analogous transformation 
with 2,6-dihydroxybenzoic acid 4-22, and no obvious reaction occurred under these 
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conditions. Increasing the temperature of the reaction from room temperature to 80 °C 
provided a complex mixture with small amounts of starting material. Increasing the amount 
of BnBr to two equivalents did not lead to the desired dibenzyl protected product 4-25. 
Treatment of 4-22 with two equivalents of K2CO3 and two equivalents of benzyl bromide in 
refluxing acetone led to a tribenzyl-protected product 4-26 as the major product. However, 
decreasing the amount of K2CO3 to one equivalent provided the desired dibenzyl protected 
product 4-25. Unfortunately, attempted reduction using four equivalents of lithium 






1. 2.2 eq. NaH
    0oC to rt.
2. 1.0 eq. BnBr
     DMF, rt.
Starting material
4-22
1. 2.2 eq. NaH
       0oC to rt.
2. 1.0 eq. BnBr
    DMF, 80oC
Starting material + complex mixture
4-22
1. 2.2 eq. NaH
    0oC to rt.
2. 2.0 eq. BnBr
    DMF, 80oC
4-22
2.0 eq. K2CO3





4-26   major
4-22
1.0 eq. K2CO3





4-25   major
4.0 eq. LiAlH4










Jennings and coworkers developed a general method which allowed for the synthesis of 
either substituted salicylaldehydes or the corresponding 2-hydroxybenzyl alcohols upon 
treatment of the 2,2-dimethyl-1,3-benzo-dioxan-4-one functional group with DIBAL-H or 
LAH, respectively.3 Treatment of 2,6-dihydroxybenzoic acid 4-22 with 1.5 equivalents of 
SOCl2 and acetone in the presence of 5 mol% of DMAP in DME from 0 °C to room 
temperature afforded the 5-hydroxy-2,2-dimethyl-1,3-benzo-dioxan-4-one 4-30, which was 
protected with benzyl bromide to provide benzyl protected phenol ether 4-31 in 63% yield 
overall. Then 4-31 was reduced smoothly to the corresponding benzyl alcohol 4-32 in 74% 




















5 mol % DMAP
DME, 0oC to rt.
2.0 eq. K2CO3
























Treatment of diol 4-24 with three equivalents of triflic anhydride in the presence of 2.5 
equivalents of 4-dimethylaminopyridine (DMAP) in methylene chloride at 0 °C provided the 
quaternary ammonium salt 4-34, suggesting that the desired ditriflate 4-33 was unstable and 
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underwent substitution by DMAP. Replacement of the base of this reaction with 




























Treatment of diol 4-24 with 2.5 equivalents of triflic anhydride and diisopropylethylamine 
(DIPEA) in the presence of 1.25 equivalents of tetrabutylammonium iodide (TBAI) and 
sodium cyanide in methylene chloride at 0 °C generated benzyl iodide 4-35 in 6% yield from 
a complex mixture, but none of the desired product 4-36 was observed. This was possibly the 
result of the low stability of 4-35 and low solubility of NaCN in CH2Cl2. Attempts were then 
made to achieve the transformation stepwise, such that the triflate could be prepared in 
CH2Cl2 and NaCN could be used in DMSO in the second step, but this also resulted in a 
complex mixture. Since the instability of the benzyl triflate intermediate was thought to be 
problematic, the conversion of the diol 4-24 to the salt 4-34 was considered since DMAP 
could also potentially act as a leaving group. The salt 4-34 was treated with NaCN in DMSO, 








1. Tf2O (2.1 eq)
    i-Pr2NEt (2.1 eq)
    TBAI (2.1 eq)
     CH2Cl2, 0 °C
2. NaCN (1.25 eq)








































Since it was difficult to obtain the ditriflate from diol 4-24, the substitution was 
investigated from the phenol 4-36. The alcohol 4-24 was treated with 1.05 equivalents of 
CBr4 and PPh3 in CH2Cl2 from 0 °C to room temperature to generate benzyl bromide as an 
intermediate. Conversion to the corresponding phenyl acetonitrile 4-36 was accomplished 
using 1.25 equivalents of NaCN in DMSO in 43% overall yield. However, increasing the 
amount of CBr4 and PPh3 did not improve the bromination and led to a complex mixture. 
Unfortunately, this procedure was unsuccessful with the diol 4-32. Schwartz and coworkers, 
however, reported the conversion of phenolic benzyl alcohols to the corresponding phenolic 
phenylacetonitriles by direct treatment with cyanide ion, presumably by way of a quinone 
methide intermediate.4 This method proved successful for diol 4-32 and the corresponding 
phenylacetonitrile 4-37 was obtained in 74% yield by using 1.2 equivalents of NaCN in DMF 








1. 1.05 eq. CBr4
    1.05 eq. PPh3
    CH2Cl2, 0oC to rt.
2. 1.25 eq. NaCN









 6.0 eq. CBr4
 6.0 eq. PPh3






1. 1.05 eq. CBr4
    1.05 eq. PPh3
    CH2Cl2, 0oC to rt.
2. 1.25 eq. NaCN
























The phenols 4-36 or 4-37 could then be protected with 1.5 equivalents of triflic anhydride 
in the presence of triethylamine in CH2Cl2 from 0 °C to room temperature to provide the 



























Unfortunately, the palladium-catalyzed borylation of triflates 4-13 and 4-21 did not 
proceed well. Treatment of 4-13 with 3 equivalents of pinacolborane (4-38), 4.0 equivalents 
of Et3N, and Pd(OAc)2 as a catalyst, in the presence of the 20 mol% of biphenylphosphine 
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ligand 4-39 in dioxane at 110 °C for four hours led to hydrogenated product 4-40 along with 
starting material and a complex mixture. Increasing the reaction time improved the formation 
of 4-40 according to the 1H NMR of the crude product. Furthermore, the borylation of the 
bromoindenone 4-11 under these conditions was also unsuccessful, but this is not surprising 
in retrospect since similar reactions are known to be ineffective with substrates that possess 











































Difficulties with the borylation of triflates 4-41 and 4-44 was reported by Taylor et al. with 
pinacolborane (4-38), but conversion to the corresponding pinacol boronates occurred 
smoothly with the use of diborane 4-42.6,7 However, treatment of 4-13 with 1.1 equivalents 
of 4-42 and three equivalents of KOAc in the presence of 5 mol% of Pd(dppf)Cl2 in dioxane 
at 85 °C for 24 hours generated a complex mixture that did not include the desired product. 




















4-41 4-43   83%



























It has been reported that the cross-coupling reaction between haloarenes and 4-42 can be 
enhanced by electron-withdrawing substituents sufficiently so as to permit the use of less 
reactive aryl bromides.6 However, treatment of bromoindenone 4-11 with 1.1 equivalents of 
4-42 and 3.0 equivalents of KOAc in the presence of 5 mol% of Pd(dppf)Cl2 in dioxane at 90 
°C over 16 hours provided a complex mixture without the desired product. The reaction was 
also attempted in DMSO and DMF since polar solvents have been known to enhance the rate 

















dioxane 90 °C 16h,
or DMSO 80 °C 4 h,
or DMF 85 °C 4 h
complex mixture
 
In contrast to that described above for the borylations of 4-41 and 4-44, Joachim and 
coworkers reported that no reaction was observed upon treatment of triflate 4-46 with 
diborane 4-42 (1.1 eq. 4-42, 3 eq. KOAc, 3 mol% Pd(dppf)Cl2 in DMF or DMSO at 80 °C), 
but the cross-coupling was achieved in 88% yield when using pinacol borane 4-38 (3 eq. 
pinacol borane, 3 eq. Et3N, 5 mol% Pd(PPh3)4, dioxane, 80 °C, 2 h).8 Unfortunately, attempts 
in our laboratory with 4-21 led to the hydrogenated product 4-48 rather than the desired 










3 mol % Pd(dppf)Cl2
    3.0 eq. KOAc
DMF or DMSO








5 mol % Pd(PPh3)4
    3.0 eq. Et3N















5 mol % Pd(PPh3)4
    3.0 eq. Et3N













The Buchwald phosphine ligand9 4-39 and DPEphos10 4-49 have been used as efficient 
supporting ligands for the palladium-catalyzed borylation of aryl bromides. Although the 
scope of the aryl halides in the palladium-catalyzed borylation has been improved, these 
catalyst systems still have some drawbacks. For example, reactions of electron-deficient or 
ortho, ortho′-substituted bromides produce relatively poor yields, and no examples of the 
borylation of aryl chlorides have been provided. Murata and coworkers developed a catalyst 
system using Pd2(dba)3 and the electron-rich bis-phosphine ligand bis(2-di-tert-
butylphosphinophenyl)ether 4-50, which overcame many limitations of the previous methods. 
It is felt that this system could possibly be used for the borylation of triflate 4-13 and 4-21 or 
even the bromoindenone 4-11, but these reactions have not yet been explored in this 




Br NO2 B NO2
O
O
5 mol % Pd2(dba)3
    3.0 eq. Et3N








5 mol % ligand 4-50
4-50  t-Bu-DPEphos
4-51 4-52   76%
Br iPr B iPr
O
O
5 mol % Pd2(dba)3
    3.0 eq. Et3N
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5 mol % Pd2(dba)3
    3.0 eq. Et3N
5 mol % ligand 4-50
 
Porco and coworkers reported11 that stannylation of aryl bromide 4-57 provided the 
arylstannane 4-58,12 which was subjected to the cross-coupling with vinyl bromide 4-59 to 
generate 4-60.13 Thus, the triflate 4-13 or 4-21 could potentially be converted to the 
corresponding arylstannane 4-61, and 4-61 might be suitable for the cross-coupling with 
bromoindenone 4-11 to produce the diaryl 4-62. While this strategy was acknowledged as a 




















































4.2 Studies Toward the Synthesis of Analogues from an Aniline Precursor 
Since the borylation of triflate 4-13 proved difficult, the synthesis of the same synthon but 
in the form of more active iodophenylacetonitrile 4-63 was considered (Scheme 4-16). Thus, 
it was felt that 4-63 might be formed from the corresponding iodobenzyl alcohol 4-64 by 
substitution, and that 4-64 might be achieved by selective protection of the phenol group of 
diol 4-65, which might come from the iodobenzoic acid 4-66 by reduction. The acid 4-66 































In practice, treatment of 2-amino-5-hydroxybenzoic acid (4-67) with 1.01 equivalents of 
sodium nitrite and concentrated H2SO4 in water at 0 °C for 30 minutes generated diazonium 
salt 4-68, which was subjected to the substitution with 1.5 equivalents of potassium iodide 
and 1 M H2SO4 at 100 °C for one hour to produce the aryl iodide 4-66 in 82% yield.14 The 
benzoic acid 4-66 was then reduced with borane in THF to give the diol 4-65,15 and the 
phenolic group of the diol was selectively protected with benzyl bromide to afford the 























       H2SO4











All attempts to convert the 4-65 to the benzylic bromide 4-69 with 48% aqueous HBr 
failed. The reaction in ether at room temperature over 19 hours led to a small amount of the 
desired bromo compound 4-69, but much starting material remained. It was considered that 
the reaction was slow possibly because of the two-phase system. However, replacement of 
the ether by methanol to give a one-phase system made no difference. Elevating the 


































It was found that treatment of benzyl alcohol 4-64 with 1.05 equivalents of CBr4 and PPh3 
in CH2Cl2 at room temperature for one day led to a low ratio of conversion from 4-64 to 




























An alternative procedure16 for conversion of the alcohol to the bromide using PBr3 was 
investigated after all previous failure. Treatment of the iodobenzyl alcohol 4-64 with two 
equivalents of PBr3 in anhydrous methylene chloride from 0 °C to room temperature over 
night provided benzyl bromide 4-70, which was subjected directly to the substitution by 
NaCN to generate the desired iodophenyl acetonitrile 4-63 in 64% yield over all. This 
reaction was not perfect, partially because of the instability of the bromo intermediate 4-70. 
Meanwhile, treatment of 4-64 with 1.25 equivalents of mesyl chloride and triethylamine in 
CH2Cl2 at 0 °C provided the corresponding mesylate 4-71, which was unexpectedly stable 














4-63   61%
CN2.0 eq. PBr3





















Treatment of iodophenylacetonitrile 4-63 with three equivalents of pinacol borane 4-38 
and four equivalents of triethylamine and 20 mol% of ligand 4-39 in the presence of 5 mol % 
of Pd(OAc)2 in dioxane for 4 hours provided the desired pinacol boronate 4-12 in 73% yield. 
However the same procedure did not work for the triflate 4-13 possibly because of a lower 











5 mol % Pd(OAc)2
4.0 eq. Et3N



















5 mol % Pd(OAc)2
4.0 eq. Et3N










Hence, the synthesis of the D ring building block pinacol boronate 4-12 initiated from 2-
amino-5-hydroxybenzoic acid 4-67, following the sequence as shown in Scheme 4-22 was 








1. NaNO2, conc. H2SO4 
            H2O, 0oC
2. KI, H2SO4 (1 M) 











4-64   82%
OH










4-63   69%
CN
MsCl, Et3N
CH2Cl2, 0oC DMSO, rt.
NaCN
PCy2
 Et3N, dioxane, 100oC
B OBn
CN









With the AB ring and D ring building blocks 4-11 and 4-12 of the analogue of 
isoprekinamycin in hand, the Suzuki cross coupling between them using the same conditions 
as before provided the diaryl 4-10 compound in 76% yield. Without any group at C1 of the D 
ring in 4-10, the cyclization of it with 1.1 equivalents of LDA in THF from 0 °C to room 
temperature for three hours afforded the desired phenol 4-72 smoothly without competition 
from the aldol reaction. The product was methylated to generate the carbonitrile 4-9 in 63% 
yield over two steps. Here the solvent of the methylation was changed from DMF to acetone 












   3.0 eq. KF
THF/H2O (19:1)
      rt., 24 h






















THF, 0oC to rt.




        15 h
4-72 4-9   63%  
Hydrolysis of carbonitrile 4-9 with 30% aqueous hydrogen peroxide and 1.55 equivalents 
of potassium carbonate in DMSO, as used in the synthesis of IPK, did not proceed well in 
this case. Since the conversion of 4-9 to the desired carboxamide 4-73 was low, it was 
thought that the low solubility of the starting materials in DMSO was the major cause. 
Conducting the reaction in ethanol and increasing the temperature led to no improvement, but 
it was found that treatment of 4-9 with excess sodium hydroxide in the presence of the 30% 

















































Solubility of the starting materials was also problematic in the modified Hofmann 
rearrangement of 4-73, in which one equivalent of PhI(OAc)2 and 2.5 equivalents of KOH 
was used in methanol. Since 4-73 seemed to have low solubility in methanol, the reaction 
was attempted with a 1:1 mixture of methanol and methylene chloride, and the desired 


































The synthesis of the analogues in which a group was introduced at C3 of the D ring was 
stopped at this stage because of time limitations. However, the planned sequence for the 
synthesis to follow is shown in Scheme 4-26. Cleavage of the benzyl group of 4-74 via 
hydrogenation or treatment with BCl3 at low temperature would provide phenol 4-75, which 
might be alkylated with BrCH2CO2t-Bu to generate ether 4-76. Hydrolysis of 4-76 would 
afford corresponding aniline, which might be subjected to demethylative diazotization 
conditions that simultaneously cleave the tert-butyl group in situ. Thus, this represents a 
potential route for the synthesis of an analogue of isoprekinamycin such as 4-78, which 
























LiOH 1. NaNO2, HCl
2. NaHCO3






  The acid group in 4-78 could then be used as a handle for the introduction of a variety of 




4.3.1 General information  
1H NMR spectra were recorded on a Brüker AVANCE 500 (500 MHz), Brüker AC 300 (300 
MHz) or Brüker AVANCE 300 (300 MHz) NMR spectrometer. Chemical shifts are reported 
in parts per million (ppm) relative to tetramethylsilane (TMS). The following abbreviations 
are used for NMR peak multiplicities: s, singlet; d, doublet; t, triplet; q, quartet; dd, doublet 
of doublets; dt, doublet of triplet; m, multiplet; b, broad; w, weak. 13C NMR spectra were 
broad band decoupled and recorded on a Brüker AVANCE 500 (125.8 MHz), Brüker AC 
300 (75.5 MHz) and Brüker AVANCE 300 (75.5 MHz) NMR spectrometer using the carbon 
signal of the deuterated solvent as the internal standard. HMQC and HMBC experiments 
were performed on a Brüker AVANCE 500 spectrometer. IR spectra were determined on a 
Perkin-Elmer RX I FT-IR spectrometer as KBr discs unless otherwise indicated. High/low 
resolution electron impact or electrospray ionization (EI or ESI) mass spectra (MS) were 
measured by the WATSPEC Mass Spectrometry Facility (Department of Chemistry, 
University of Waterloo, Waterloo, Ontario, Canada). Elemental analyses were performed by 
the M-H-W Laboratories (Phoenix, Arizona, USA).  
Anhydrous THF and Et2O were freshly distilled from sodium/benzophenone under nitrogen 
prior to use. Anhydrous CH2Cl2 was freshly distilled from CaH2 under nitrogen prior to use. 
All commercial reagents were purchased from Aldrich Chemical Co., Strem Chemicals Inc., 
Alfa Aesar, Lancaster Synthesis Ltd. or BDH Inc. and were used as received unless 




The –78 ºC and 0 ºC designations refer to solid carbon dioxide/acetone and ice/water slush 
respectively. The room temperature refers to 22 °C to 25 °C. Flash column chromatography 
was carried out using the Merck silica gel (230-400 mesh) and SiliCycle silica gel (60 Å). 
Reactions were magnetically stirred and monitored by thin layer chromatography (TLC) with 
Merck pre-coated silica gel plates (silica gel 60 F254 on aluminum sheet). All reported yields 
are isolated yields. 
 










4-14 4-23  
5-(Benzyloxy)-2-hydroxybenzoic acid (4-23) 
To a suspension of NaH (0.528 g, 13.20 mmol) in DMF (5 mL) was added 2,5-
dihydroxybezoic acid (0.924 g, 6.0 mmol) at 0 °C dropwise. The reaction was then warmed 
up to room temperature and stirring was continued at this temperature for another 2 hours. 
Benzyl bromide (0.71 mL, 6.0 mmol) in DMF (1.5 mL) was added, and the reaction was 
continued 23 hours at room temperature. Water (10 mL) was added at 0 °C and the pH value 
of the solution was adjusted to 1 with 1 M HCl. Then the resulting solution was extracted 
with Et2O (3 × 100 mL) and the organic phase was washed with H2O (3 × 30 mL). The 
combined organic phase was dried over Na2SO4 and concentrated. The residue was purified 
by recrystallization from chloroform to obtain the title compound as a white solid (1.061 g, 
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72%). 1H NMR (300 MHz, DMSO-d6): δ 10.01 (s, 1H), 7.38 (m, 6H), 7.21 (m, 1H), 6.93 (d, 













To a suspension of LiAlH4 (0.494 g, 13.23 mmol) in anhydrous THF (30 mL) was added 5-
(benzyloxy)-2-hydroxybenzoic acid (1.061 g, 4.34 mmol) slowly at 0 °C. The reaction was 
warmed up to room temperature and stirring was continued at this temperature for 20 hours. 
The solution was diluted with ether (20 mL). Saturated aqueous ammonium chloride solution 
was added until no bubbling was observed. The solution was filtered through Celite.  The 
filtrate was then extracted with CH2Cl2 (3 × 100 mL), and the organic phase was washed 
with water (3 × 30 mL). Then the resulting CH2Cl2 solution was dried over Na2SO4 and 
concentrated. The residue was purified by flash chromatography (EtOAc:Hexanes = 1:2, v/v) 
to obtain the title compound as a white solid (0.726 g, 73%).1H NMR (300 MHz, CDCl3): δ 
7.35 (m, 5H), 6.79 (m, 3H), 6.67 (s, 1 H), 4.97 (s, 2H), 4.79(d, J = 4.0 Hz, 2H), 2.15 (s, 1H); 
MS (EI): m/z 230.2 (29, M+), 212.2 (7), 139.1 (4), 121.1 (5),  91.1 (100), 84.0 (3), 65.1 (9); 















To a colled (ice-bath) solution of 4-(benzyloxy)-2-(hydroxymethyl)phenol (100 mg, 0.43 
mmol) and CBr4 (151.2 mg, 0.46 mmol) in CH2Cl2 (10 mL) was added PPh3 (119.6mg, 0.46 
mmol) under ice-bath dropwise. Then the reaction was warmed up to room temperature and 
stirring was continued at this temperature over 7 hours. 
The solvent was evaporated and the residue was dissolved in DMSO (5 mL). NaCN (26.6 mg, 
0.54 mmol) was added and the solution was stirred at room temperature for 17 hours. 
Saturated aqueous NH4Cl (10 mL) and water (40 mL) were added sequentially, and the 
resulting solution was extracted with EtOAc (3 × 50 mL). Then the organic phase was 
washed with water (3 × 20 mL), dried over Na2SO4 and concentrated. The residue was 
purified by flash chromatography (EtOAc:Hexanes = 1:3, v/v) to obtain the title compound 
as a white solid (45.0 mg, 43%).1H NMR (300 MHz, CDCl3): δ 7.36 (m, 6H), 6.99 (s, 1H), 
















4-(Benzyloxy)-2-(cyanomethyl)phenyl trifluoromethanesulfonate (4-13) 
To a stirred solution of 2-(5-(benzyloxy)-2-hydroxyphenyl)acetonitrile (67.6 mg, 0.28 mmol) 
and Et3N (0.059 ml, 0.42 mmol) in anhydrous CH2Cl2 (4 mL) cooled by an ice-bath was 
added Tf2O (0.071 ml, 0.42 mmol) dropwise under ice-bath. The reaction was stirred at 0 °C 
for 2 hours. Then saturated aqueous NH4Cl (10 mL) was added. The resulting solution was 
extracted with CH2Cl2 (3 × 50 mL) and the organic phase was dried and concentrated. The 
residue was purified by flash chromatography (EtOAc:Hexanes = 1:3, v/v) to obtain the title 
compound as a white solid (79.1 mg, 75%). 1H NMR (300 MHz, CDCl3): δ 7.40 (m, 5H), 
7.26 (d, J = 9.1 Hz, 1H), 7.21 (d, J = 2.7 Hz, 1H), 6.98 (dd, J = 9.1, 2.9 Hz, 1H), 5.08 (s, 2H), 
3.78 (s, 2H); 13C NMR (75.5 MHz, CDCl3): δ 158.6, 140.1, 135.8, 128.8, 128.4, 127.6, 124.8, 
123.1, 118.6 (q, J = 320.5 Hz, CF3), 116.5, 116.1, 115.9, 70.7, 19.1; IR (film): 3035.6, 
2937.6, 2261.9, 1591.1, 1495.2, 1423.9, 1250.2, 1216.9, 1171.6, 1138.7, 1025.4, 871.1, 612.0 
























To a stirred solution of 2,6-dihydroxybenzoic acid (1.54 g, 10 mmol), DMAP (61.1 mg, 0.5 
mmol) and acetone (1.1 ml, 15 mmol) in DME (8 mL) cooled by an ice-bath was added 
SOCl2 ( 1.1 ml, 15 mmol) dropwise. The reaction was stirred at 0 °C for 1 hour and then 
warmed up to room temperature. Stirring was continued at this temperature for 23 hours. 
Water (10 mL) was added and the resulting solution was extracted with ether (3 × 50 mL). 
The organic phase was washed with water (3 × 15 mL) and dried over Na2SO4. 
Concentration of this organic phase afforded a crude product as a white solid. 
The a solution of the crude product in acetone (20 mL) was added solid K2CO3 (2.764 g, 20 
mmol). The reaction mixture was stirred at room temperature for 10 minutes. Then benzyl 
bromide (4.76 ml, 40 mmol) was added and the temperature was increased to reflux and the 
reaction was continued at this temperature for 19 hours. The resulting solution was filtered 
and the precipitate was washed with EtOAc. The combined organic phase was dried over 
Na2SO4 and concentrated. The residue was purified by flash chromatography 
(EtOAc:Hexanes = 1:3, v/v) to obtain the title compound as a white solid (1.781 g, 63%). 1H 
NMR (300 MHz, CDCl3): δ 7.53 (d, 7.4 Hz, 2H), 7.37 (m, 3H), 7.29 (d, J = 7.2 Hz, 1H), 6.63 















To a suspension of LiAlH4 (676.1 mg, 17.82 mmol) in anhydrous THF (7 mL) was added 5-
(benzyloxy)-2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one (1.013 g, 3.56 mmol) in anhydrous 
THF (14 mL) slowly at –78 °C. Then the reaction was warm up to room temperature and 
stirred at this temperature for 14 hours. The solution was diluted with ether (25 mL). 
Saturated aqueous NH4Cl was added until bubbling ceased. Then the pH of the solution was 
adjusted to 1 and the resulting solution was filtered through Celite. The filtrate was dried 
over Na2SO4 and concentrated. The residue was purified by flash chromatography 
(EtOAc:Hexanes = 1:3, v/v) to obtain the title compound as a white solid (607.3 mg, 74%). 
1H NMR (300 MHz, CDCl3): δ 8.31 (s, 1 H), 7.37 (m, 5H), 7.07 (t, J = 8.2 Hz, 1H), 6.50 (t, J 
= 8.7 Hz, 1H), 5.01 (s, 2H), 4.98 (s, 2H), 3.43 (s, 1H); MS (EI): m/z 230.1 (23, M+), 212.1 
(15), 122.1 (15), 91.1 (100), 84.0 (13), 65.1 (8), 51.1 (4); HRMS (EI): calculated for 
















The 3-(benzyloxy)-2-(hydroxymethyl)phenol (100 mg, 0.43 mmol) was dissolved in DMF (5 
mL). NaCN (25.5 mg, 0.52 mmol) was added and the reaction was stirred at 110 °C for 15 
hours. The resulting solution was cooled by an ice-bath and the pH was adjusted to 5 with 
HCl (1 M). The solution was extracted with EtOAc (3 × 50 mL). The organic phase was 
separated, washed with brine (3 × 10 mL), dried over Na2SO4 and concentrated. The residue 
was purified by flash chromatography (EtOAc:Hexanes = 1:4, v/v) to obtain the title 
compound as a white solid (76.9 mg, 74%).  1H NMR (300 MHz, CDCl3): δ 7.40 (m, 5H), 
7.08 (t, J = 8.3 Hz, 1H), 6.53 (d, J = 8.3 Hz, 1H), 6.44 (d, J = 8.2 Hz, 1H), 5.94 (s, 1H), 5.10 












3-(Benzyloxy)-2-(cyanomethyl)phenyl trifluoromethanesulfonate (4-21) 
To a solution of 2-(2-(benzyloxy)-6-hydroxyphenyl)acetonitrile (76.9 mg, 0.32 mmol) and 
Et3N (0.067 ml, 0.48 mmol) in anhydrous CH2Cl2 (4 mL) cooled by an ice-bath was added 
Tf2O (0.081 ml, 0.48 mmol) dropwise and the reaction was stirred with cooling for 2 hours. 
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Saturated aqueous NH4Cl (10 mL) was added. The resulting solution was extracted with 
CH2Cl2 (3 × 50 mL) and the combined organic phase was dried and concentrated. The 
residue was purified by flash chromatography (EtOAc:Hexanes = 1:6, v/v) to obtain the title 
compound as a white solid (105.8 mg, 89%). 1H NMR (300 MHz, CDCl3): δ 7.51 (m, 2H), 
7.40 (m, 4H), 7.03 (d, J = 4.0 Hz, 1H), 7.00 (d, J = 4.2 Hz, 1H), 5.17 (s, 2H), 3.77 (s, 2H); 
13C NMR (75.5 MHz, CDCl3): δ 157.8, 147.7, 135.6, 130.6, 128.8, 128.5, 127.5, 118.6 (q, J 
= 320.5 Hz, CF3), 116.3, 113.9, 112.9, 112.1, 71.2, 13.0; IR (film): 3035.3, 2938.6, 2258.6, 
1613.9, 1585.0, 1466.1, 1454.3, 1424.2, 1276.9, 1216.2, 1138.3, 1047.4, 887.4, 810.7, 605.8 






1. NaNO2, H2SO4 






5-Hydroxy-2-iodobenzoic acid (4-66) 
To a solution of 2-amino-5-hydroxybenzoic acid (1.53 g, 10 mmol) in water (10 mL) was 
added conc. H2SO4 (1.4 mL) slowly. Then NaNO2 (0.697 g, 10.1 mmol) in water (3 mL) was 
added dropwise over 15 minutes and the reaction mixture was stirred with cooling for 
another 30 minutes. The patasium iodide (2.49 g, 15 mmol) in H2SO4 (5 mL, 1 M) was added 
slowly with ice-bath cooling. The reaction was heated to 100 °C and was continued at this 
temperature for 1 hour. The resulting solution was cooled to room temperature and left over 
night. A lot of precipitate came out, which was filtered and washed with water to obtain the 
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title compound as a brown solid (2.159 g, 82%). Mp: 188–199 °C; 1H NMR (300 MHz, 
DMSO-d6): δ 13.1 (s, br, 1H), 9.93 (s, br, 1H), 7.67 (d, J = 8.6 Hz, 1H), 7.13 (d, J = 2.9 Hz, 
1H), 6.66 (dd, J = 8.6, 2.9 Hz, 1H); 13C NMR (75.5 MHz, DMSO-d6): δ 168.3, 157.8, 141.7, 
137.9, 120.6, 117.8, 80.5; IR (KBr): 3254.9, 1695.5, 1594.3, 1439.0, 1285.6, 1253.8, 1233.3, 
1143.4, 1014.5, 827.8, 759.8, 659.5 cm–1; MS (EI): m/z 263.9 (100, M+), 246.9 (35), 218.9 













To a ice-bath cooled solution of 5-hydroxy-2-iodobenzoic acid (500 mg, 1.89 mmol) in 
anhydrous THF (5 mL) was added a THF solution of BH3 (5.7 ml, 1 M, 5.7 mmol) dropwise. 
The reaction was warmed up to room temperature and stirred at this temperature for 20 hours. 
The reaction was quenched with THF and H2O (1:1, 20 mL) with ice-bath cooling. The 
resulting solution was extracted with EtOAc (100 mL). The organic phase washed with brine 
(3 × 10 mL), dried over Na2SO4 and concentrated. The residue was purified by flash 
chromatography (EtOAc) to obtain the title compound as a white solid (462.8 mg, 98%). Mp: 
145–146 °C; 1H NMR (300 MHz, DMSO-d6): δ 9.56 (s, 1H), 7.49 (d, J = 8.4 Hz, 1H), 6.97 
(d, J = 2.9 Hz, 1H), 6.45 (dd, J = 8.4, 2.9 Hz, 1H), 5.32 (s, br, 1H), 4.29 (s, 2H); 13C NMR 
(75.5 MHz, DMSO-d6): δ 158.3, 145.1, 139.3, 116.6, 115.7, 82.9, 67.6; IR (KBr): 3359.9, 
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3164.9, 1590.2, 1572.9, 1463.6, 1437.1, 1321.9, 1283.0, 1235.8, 1162.6, 1042.6, 1009.8, 
851.7, 800.1, 613.9 cm–1; MS (EI): m/z 249.9 (100, M+), 121.0 (13), 95.0 (15), 94.0 (12), 













 (5-(Benzyloxy)-2-iodophenyl)methanol (4-64) 
To a solution of 3-(hydroxymethyl)-4-iodophenol (462.8 mg, 1.85 mmol) in acetone (10 mL) 
was added solid K2CO3 (319.8 mg, 2.31 mmol). The reaction mixture was stirred at room 
temperature for 10 minutes. Benzyl bromide (0.28 mL, 2.31 mmol) was added and the 
temperature was heated to reflux and was continued at this temperature for 18 hours. The 
resulting solution was filtered and the precipitate was washed with CH2Cl2. The combined 
organic phase was dried over Na2SO4 and concentrated. The residue was purified by flash 
chromatography (EtOAc:Hexanes = 1:4, v/v) to obtain the title compound as a white solid 
(515.3 mg, 82%).  Mp: 103–104 °C; 1H NMR (300 MHz, CDCl3): δ 7.64 (d, J = 8.6 Hz, 1 H), 
7.36 (m, 5H), 7.13 (d, J = 2.4 Hz, 1H), 6.65 (dd, J = 8.6, 2.5 Hz, 1H), 5.04 (s, 2H), 4.59 (s, 
2H), 2.13 (s, 1H); 13C NMR (75.5 MHz, CDCl3): δ 159.5, 143.8, 139.7, 136.6, 128.8, 128.2, 
127.6, 116.2, 115.3, 85.8, 70.2, 69.3; IR (film): 3305.5, 2869.0, 1587.8, 1567.3, 1461.8, 
1292.9, 1233.8, 1165.2, 1005.1, 794.1, 732.8, 695.5 cm–1; MS (EI): m/z 340.0 (36, M+), 91.1 





















To a ice-bath cooled solution of (5-(benzyloxy)-2-iodophenyl)methanol (8.84g, 25.99 mmol) 
and Et3N (4.6 ml, 32.49 mmol) in anhydrous CH2Cl2 (200 mL) was added MsCl (2.6 mL, 
32.49 mmol) slowly at 0 °C and the reaction was stirred with cooling for 3 hours.  
The solution was concentrated and the residue was dissolved in DMSO (80 mL). Solid NaCN 
(3.821 g, 77.97 mmol) was added and the reaction was stirred at room temperature for 16 
hours. Water (20 mL) was added to the ice-bath cooled solution which was then extracted 
with EtOAc (3 × 300 mL). The combined organic phase was washed with water (3 × 90 mL), 
dried over Na2SO4 and concentrated. The residue was purified by flash chromatography 
(EtOAc:Hexanes = 1:20, v/v) to obtain the title compound as a white solid (6.256 g, 69%). 
Mp: 114–115 °C; 1H NMR (300 MHz, CDCl3): δ 7.69 (d, J = 8.7 Hz, 1H), 7.36 (m, 5H), 7.18 
(d, J = 2.4 Hz, 1H), 6.68 (dd, J = 8.7, 2.5 Hz, 1H), 5.06 (s, 2H), 3.74 (s, 2H); 13C NMR (75.5 
MHz, CDCl3): δ 159.6, 140.3, 136.2, 134.3, 128.8, 128.4, 127.6, 117.2, 116.8, 116.3, 87.5, 
70.3, 30.0; IR (film): 3032.4, 2924.1, 2249.0, 1590.1, 1568.6, 1467.1, 1411.8, 1316.7, 1292.4, 
1237.3, 1171.6, 1027.8, 1007.4, 806.0, 736.4, 696.9 cm–1; MS (EI): m/z 349.0 (44, M+), 91.1 























A mixture of Pd(OAc)2 (19.4 mg, 0.086 mmol) and (2-biphenyl)dicyclohexyl-phosphine 
(120.8 mg, 0.344 mmol) was deoxygenated five times with an argon balloon and a vacuum 
pump. To a solution of 2-(5-(benzyloxy)-2-iodophenyl)acetonitrile (601.3 mg, 1.722 mmol)  
in dioxane (8 mL) was added pinacol borane (0.75 mL, 5.166 mmol) and Et3N (0.96 mL, 
6.888 mmol) and the solution was deoxygenated three times by a freeze-thaw process. The 
deoxygenated solution was then added to the solid mixture of the catalyst and ligand and 
stirred at 100 °C for 4 hours in an argon atmosphere. The reaction was quenched with 
saturated aqueous NH4Cl (10 ml) and extracted with CH2Cl2 (2 × 50 mL). The organic phase 
was dried over Na2SO4 and concentrated. The residue was purified by flash chromatography 
(EtOAc:Hexanes = 1:20, v/v) to obtain the title compound as a white solid (437.7 mg, 73%). 
1H NMR (300 MHz, CDCl3): δ 7.82 (d, J = 8.3 Hz, 1H), 7.38 (m, 5H), 7.09 (d, J = 2.3 Hz, 
1H), 6.91 (dd, J = 8.3, 2.4 Hz, 1H), 5.10 (s, 2H), 4.08 (s, 2H), 1.34 (s, 12H); 13C NMR (75.5 
MHz, CDCl3): δ 161.6, 138.8, 138.7, 136.5, 128.7, 128.2, 127.5, 118.9, 115.5, 113.4, 83.9, 
69.9, 24.9, 23.7; IR (film): 3011.9, 2978.4, 2261.9, 1603.2, 1566.5, 1381.4, 1350.4, 1322.9, 
1292.1, 1232.3, 1168.1, 1144.5, 1125.4, 1025.20, 857.9, 668.2 cm–1; MS (EI): m/z 349.2 (33, 
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M+), 348.2 (9), 249.1 (3), 91.1 (100), 65.1 (3); HRMS (EI): calculated for C21H24BNO3: 






















A mixture of bromoindenone 4-11 (2.73 g, 9.16 mmol), KF (1.597 g, 27.49 mmol), Pd2(dba)3 
(419.5 mg, 0.458 mmol) and [(t-Bu)3PH]BF4 (265.9 mg, 0.916 mmol) was deoxygenated five 
times with an argon balloon and a vacuum pump. Pinacolboronate 4-12 (2.880 g, 8.246 mmol) 
was dissolved in a mixture (19:1) of THF and water (100 mL) and the solution was 
deoxygenated three times by a freeze-thaw process. The deoxygenated solution was then 
added to the solid mixture and stirring was continued for 24 hours at room temperature in an 
argon atmosphere. The solution was concentrated and the residue was dissolved in CH2Cl2 
(150 mL). The organic phase was washed with water (3 × 20 mL), dried over Na2SO4 and 
concentrated. The residue was purified by flash chromatography (EtOAc:Hexanes = 1:3, v/v) 
to obtain the product as a red orange solid (2.75 g, 76%). 1H NMR (300 MHz, CDCl3): δ 
7.34 (m, 6H), 7.17 (m, 3H), 7.01 (d, J = 8.4 Hz, 1H); 6.92 (dd, J = 8.5, 2.4 Hz, 1H), 5.08 (s, 
2H), 3.84 (s, 3H), 3.77 (s, 3H) 3.73 (s, 2H); 13C NMR (75.5 MHz, CDCl3): δ 195.4, 166.2, 
159.9, 153.0, 147.9, 136.4, 132.3, 132.1, 132.0, 131.3, 130.7, 128.7, 128.3, 128.0, 127.6, 
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121.3, 119.3, 117.7, 117.3, 115.5, 114.3, 70.2, 56.4, 52.6, 22.7; IR (film): 3035.7, 2950.2, 
2261.9, 1734.8, 1711.4, 1610.3, 1498.0, 1479.7, 1274.1, 1241.4, 1202.1, 1171.0, 1055.3, 
932.6, 766.5, 738.2, 698.0 cm–1; MS (EI): m/z 439.2 (94, M+), 408.2 (8), 348.2 (38), 320.2 





















To a solution of methyl 2-(4-(benzyloxy)-2-(cyanomethyl)phenyl)-7-methoxy-3-oxo-3H-
indene-1-carboxylate (348.1 mg, 0.792 mmol) in anhydrous THF (10 mL) was added LDA 
(0.871 mmol) in THF (2 mL) slowly with ice-bath cooling. The solution was warmed up to 
room temperature and stirring was continued for 2 hour. The reaction was quenched with 
saturated aqueous NH4Cl (10 mL) solution leading to the formation of some red-orange 
precipitate. The suspension was extracted with CH2Cl2 (3 × 50 mL) and the combined 
organic phase was washed with H2O (3 × 15 mL). The organic phase was dried over Na2SO4 
and concentrated to obtain the crude product as a red-orange solid.  
To a solution of the crude product in acetone (100 mL) was added solid K2CO3 (547.4 mg, 
3.96 mmol) at room temperature and the mixture was stirred for 15 minutes. CH3I (0.50 mL, 
7.92 mmol) was added and the reaction mixture was heated to reflux and stirred at this 
temperature for 13 hours. The solution was filtered and the precipitate was washed with 
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CH2Cl2. The filtrate was dried over Na2SO4 and concentrated. The residue was purified by 
flash chromatography (CH2Cl2: Hexanes = 1:1, v/v) to give the product as an orange solid 
(211.2 mg, 63% for two steps). Mp: 187–188 °C; 1H NMR (300 MHz, CDCl3): δ 8.98 (d, J = 
9.3 Hz, 1 H), 7.50 (d, J = 6.9 Hz, 2H), 7.39 (m, 4H), 7.29 (m, 3H), 7.10 (dd, J = 7.3, 1.8 Hz, 
1H), 5.20 (s, 2H), 4.04 (s, 3H), 3.99 (s, 3H); 13C NMR (75.5 MHz, CDCl3): δ 194.4, 159.6, 
158.2, 154.6, 137.5, 136.0, 135.7, 132.3, 131.5, 128.9, 128.5, 128.4, 128.0, 126.7, 123.1, 
122.8, 120.4, 117.5, 115.7, 109.2, 103.9, 70.5, 64.1, 56.6 (missing one peak); IR (film): 
3023.8, 2940.5, 2219.8, 1705.4, 1621.1, 1602.4, 1484.8, 1442.0, 1376.7, 1281.6, 1226.3, 
1202.2, 1052.6, 1023.9, 967.8, 833.4, 750.7, 694.1 cm–1; MS (EI): m/z 421.1 (100, M+), 
330.1 (15), 302.1 (7), 229.1 (7), 201.1 (6), 91.1 (84); HRMS (EI): calculated for C27H19NO4: 
















To a solution of 3-(benzyloxy)-6,7-dimethoxy-11-oxo-11H-benzo[a]fluorene-5-carbonitrile 
(46.5 mg, 0.11 mmol) and NaOH (91.3 mg, 1.10 mmol) in a mixture of EtOH (10 mL) and 
THF (20 mL) was added 30% H2O2 (10 mL) slowly at room temperature, then the mixture 
was stirred this temperature for 72 hours. The solution was concentrated to recover the 
organic solvents and extracted with CH2Cl2 (3 × 50 mL).  The combined organic phase was 
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washed with water (3 × 15 mL), dried over Na2SO4 and concentrated. The residue was 
purified by flash chromatograph (EtOAc:Hexanes = 3:1, v/v) to give the product as an orange 
solid (51.1 mg, quant.). 1H NMR (300 MHz, DMSO-d6): δ 8.80 (d, J = 9.3 Hz, 1 H), 8.06 (s, 
1H), 7.82 (s, 1H), 7.37 (m, 8H), 7.17 (d, J = 6.7 Hz, 1 H), 7.07 (d, J = 2.1 Hz, 1H), 5.12 (s, 
2H), 3.91 (s, 3H), 3.73 (s, 3H); 13C NMR (75.5 MHz, DMSO-d6): δ 194.1, 167.8, 156.9, 
154.2, 149.5, 137.3, 136.8, 136.4, 135.3, 132.9, 131.4, 128.5, 128.0, 127.9, 127.5, 127.4, 
124.9, 122.6, 121.5, 120.8, 116.3, 104.7, 69.3, 63.4, 56.1; IR (film): 3416.7, 3333.3, 3178.6, 
2916.8, 1700.0, 1660.7, 1602.9, 1482.9, 1275.6, 1228.0, 1049.7, 754.4 cm–1; MS (EI): m/z 
439.2 (100, M+), 422.2 (17), 394.2 (7), 348.2 (57), 320.2 (18), 277.2 (6), 91.1 (53); HRMS 















Methyl 3-(benzyloxy)-6,7-dimethoxy-11-oxo-11H-benzo[a]fluoren-5-ylcarbamate (4-74) 
To a solution of 3-(benzyloxy)-6,7-dimethoxy-11-oxo-11H-benzo[a]fluorene-5-carboxamide 
(32.7 mg, 0.074 mmol) in a mixture of methanol (70 mL) and CH2Cl2 (30 mL) in an ice-bath 
was added solid KOH (10.4 mg, 0.19 mmol) at room temperature. The solution was cooled to 
0 ºC and stirred for 10 minutes. Solid PhI(OAc)2 (24 mg, 0.074 mmol) was added and the 
mixture was stirred with cooling for an additional 15 minutes. The solution was then warmed 
to room temperature and further stirred for 20 hours. The solution was concentrated and the 
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residue was dissolved in CH2Cl2 (150 mL) which was washed with water (3 × 15 mL). The 
aqueous phase was extracted with CH2Cl2 (2 × 50 mL). The combined organic phase was 
dried over Na2SO4 and concentrated. The residue was purified by flash chromatography 
(EtOAc:Hexanes = 2:1, v/v) to give the title compound as an orange solid (31.3 mg, 90%). 
1H NMR (300 MHz, DMSO-d6): δ 9.20 (s, 1H), 8.82 (d, J = 9.0 Hz, 1H), 7.48 (m, 2 H), 7.33 
(m, 6H), 7.19 (m, 2H), 5.19 (s, 2H), 3.93 (s, 3H), 3.69 (s, 3H), 3.64 (s, 2H); 13C NMR (75.5 
MHz, DMSO-d6): δ 194.4, 157.4, 155.8, 154.7, 150.6, 138.1, 137.0, 136.0, 134.2, 133.8, 
131.8, 129.0, 128.5, 128.3, 128.0, 126.2, 125.5, 123.2, 122.1, 121.3, 116.7, 104.0, 69.9, 62.4, 
56.6, 52.6; IR (film): 3250.0, 2904.8, 1697.5, 1624.7, 1528.3, 1257.7, 1050.7, 755.0 cm–1; 













Chapter 5 Studies Toward the Total Synthesis of Fluostatin A and 
C4 Substituted IPK 
5.1 Introduction 
As indicated in the introduction, isoprekinamycin (IPK), first assigned a 
diazobenzo[b]fluorene,1 is now recognized to be the diazobenzo[a]fluorene 5-1.2 Actually, 
IPK was the only known member of the benzo[a]fluorene class of natural products until 
recently, when the fluostatin class of natural products was discovered in 1998.3 Fluostatins 
A–E (5-2–5-6)3–6 possess various degrees of oxygenation in ring D but lack the diazo 

































Isoprekinamycin Fluostatin A Fluostatin B




When this project began, there were no reports related to the total synthesis of any of the 
fluostatins. Very recently, Danishefsky and coworkers achieved a concise total synthesis of 
fluostatin C and E.7 The strategy of Danishefsky’s synthesis is shown in Scheme 5-1. The 
Diels-Alder cycloaddition between diene 5-7 and dienophile quinoneketal 5-8 provided 
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cycloadduct 5-9a or 5-9b. Regardless of the regioselectivity of the cycloaddition, either 






















5-7 5-8 5-9a   X1 = O, X2 = O(CH2)2O
5-9b   X1 = O(CH2)2O, X1 = O
5-4   Fluostatin C 5-6   Fluostatin E
PGO
 
The Diels-Alder reaction between 5-10 and 5-11 under Mikami-Corey protocols8-10 
provided 5-12, in which the CD junction was isomerized with NaOMe in methanol to 
generate 5-13. The keto group of 5-13 was reduced with superhydride then protected with 
TIPSOTf  to produce triisopropyl silyl derivative 5-14, which was transformed to the 
corresponding α,β-unsaturated ketone 5-15 with PPTS in acetone. The nucleophilic 
epoxidation of 5-15 with triton B and t-BuOOH in THF generated epoxide 5-16 
stereospecifically, in which the trans-junction was partially isomerized. Oxidation of 5-16 
with osmium tetroxide afforded diol 5-17, which was further oxidized to hydroxylketone 5-













































5-12   93%, 65% ee
       (i-PrO)2TiCl2
(R)-1,1'-Bi-2-naphthol
M.S., CH2Cl2
     -15oC
NaOMe
1. superhydride
    -78oC, THF
MeOH
2. TIPSOTf
    2,6-lutidine
    CH2Cl2
5-13   92%
PPTS
acetone, H2O





     H2O, 0oC
TPAP, NMO
CH2Cl2, rt.
5-14   86% 5-15   88%









5-18  39% or 22%
H
 
Removal of the MOM protecting group and dehydration of 5-18 with TsOH in benzene 
generated 5-19, which was converted to 5-20 via benzylic oxidation with SeO2. The 
dehydrogenation-tautomerization of 5-20 with Hünig’s base in the presence of air afforded 5-
21. Cleavage of the TIPS protecting group in 5-21 with HF produced fluostatin C (5-4), 




























































5-21   47% or 38% from 5-18 5-4   Fluostatin C   85%  
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5.2 Studies Toward the Total Synthesis of Fluostatin A 
Given the similarities in the structures of the fluostatins and isoprekinamycin, it was 
considered that fluostatin A (5-2) might be synthesized with the same strategy used for the 
synthesis of IPK (5-1) and its model compound (Scheme 5-5). In this plan, fluostatin A 
would be formed via demethylation of 5-22, which might be obtained from the diazo 
compound 5-23 by hydrodediazotization. The o-quinodiazide 5-23 might be achieved via 
demethylative diazotization of the aniline 5-24, which would come from the corresponding 
carbamate 5-25 via hydrolysis. The quinone 5-25 would be obtained by oxidation of the 
phenol 5-26, which might come from the benzylic ether 5-27 via hydrogenolysis. The 
compound 5-27 might be obtained from the carbonitrile 5-28, which would be achieved from 
the anionic cyclization of diaryl compound 5-29. Compound 5-29 would be obtained from 
the Suzuki coupling between bromoindenone 5-30 and pinacol boronate 5-31, which might 
be formed from the iodophenylacetonitrile 5-32 by palladium-catalyzed borylation. 



























































5-2   Fluostatin A
BCl3 dediazotization diazotization








5-30 5-31 5-32 5-33  
It was also felt that the key intermediate 5-27 might serve as a precursor to a series of IPK 
analogues in which substituents could be attached to the oxygen atom at C4. For example, a 
compound such as 5-34 might be generated with side chain incorporating amino group which 












R = H, CH2(CH2)nNR1R2 etc.
 
In practice, treatment of 3-methylsalicylic acid 5-33 with 2.2 equivalents of benzyl 
bromide in the presence of 2.1 equivalents of K2CO3 in refluxing acetone gave the di-benzyl 
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adduct 5-35, which was hydrolyzed with 1 M aqueous NaOH in THF and methanol to 











1. 1.5 eq. NaOH (1 M)
THF-MeOH, rt.
5-33 5-35 5-36   92%
2. H3O+
 
Palladium-catalyzed iodination of 5-44 using the protocol of Kodama and coworkers11 (10 
mol% of Pd(OAc)2 and 1.1 equivalents of N-iodosuccinimide (NIS) in DMF at 120 °C for 24 
hours) generated a mixture of the desired iodobenzoic acid 5-45 and starting materials in 4:1 
ratio. The reaction seemed clean, but various attempts to improve the conversion ratio of the 
starting material to product, either by increasing the reaction time or the amount of the 











NIS (1.1 eq.), DMF




Since it was difficult to separate 5-37 and 5-36, the reduction of this mixture was 
investigated. Treatment of the mixture of 5-37 and 5-36 with six equivalents of borane in 
THF from 0 °C to room temperature provided unexpectedly the diol 5-38 in a low yield, in 
which the cleavage of the benzyl group in the presence of large excess of borane had 
occurred. Replacement of the reducing agent by a less active borane species BH3·SMe2 did 
 
 189
not improve the selectivity of the reaction. Furthermore, controlling the amount of borane in 


















3.0 eq. BH3 SMe2
10 eq. B(OMe)3


















Since the benzyl ether was sensitive to borane, the methyl ether 5-40 was synthesized from 
5-33 by methylation and hydrolysis. Nguyen and coworkers reported that orthometalation of 
benzoic acid 5-41 followed by treatment with I2 generated o-iodobenzoic acid 5-42 
regioselectively.12 However, treatment of 5-33 with 2.2 equivalents of s-BuLi and TMEDA 
followed by trapping with I2 provided a complex mixture. Meanwhile, palladium-catalyzed 
iodination of 5-40 produced a mixture of the desired iodobenzoic acid 5-43 along with 
starting material. Reduction of the mixture by borane without purification afforded the 















22.5 eq. NaOH (5 M)
THF, reflux



























15 mol % Pd(OAC)2
1.1 eq. NIS, DMF
     120oC, 24 h
4 : 1
4.0 eq. BH3
THF, rt. 17 h
OMe
Me





It was decided that the system 5-44 might be too electron rich and possibly prone to 





















Thus, the mesyl protected phenol 5-45 was synthesized from 5-33 by treatment with 2.5 
equivalents of CaO and 1.2 equivalent of mesyl chloride in THF at room temperature in 76% 


















Palladium-catalyzed iodination of 5-45 with 10 mol % of Pd(OAc)2 and 1.1 equivalents of 
NIS in DMF at 120 °C for 24 hours provided iodobenzoic acid 5-47 in 65% yield. More 
recently, Yu and coworkers observed the carboxylate-directed C-H iodination using 
Pd(OAc)2 and IOAc (Eq. I, Scheme 5-12),13 which was a special case of the palladium-





10 mol % Pd(OAC)2
1.1 eq. NIS, DMF
     120oC, 24 h
OMs
Me COOH





























Palladium Catalyzed Ligand-Directed C-H Bond Halogenation






Brown and coworkers reported many years ago that the o-iodobenzoic acid (5-48) was 
reduced with four equivalents of borane in THF smoothly to the corresponding alcohol 5-49. 
Salicylic acid 5-50 was also reduced but required more borane and longer reaction time 
(Scheme 5-13).15 However, treatment of iodobenzoic acid 5-47 with ten equivalents of 
borane in THF at room temperature led only to partial conversion of the starting material to 
the desired iodobenzyl alcohol 5-52, even though a similar reaction of 5-45 worked quite 
well. Apparently, the di-o-substituted benzoic acid is a much more sterically hindered species 
than the other benzoic acids above. Thus, the reaction was run at a higher temperature with 

















COOH 4.0 eq. BH3
THF, rt., 1 h
OH
I I
5-48 5-49   92%
OH
COOH 5.0 eq. BH3
THF, rt., 3 h
OH
OH






THF, ref., 6 h
OMs
Me







Since it was intended that 5-52 would be produced eventually on large scale, a less 
expensive route was sought. Periasamy and coworkers developed a general method by which 
a carboxylic acid could be selectively reduced to an alcohol by NaBH4 and I2.16 The 
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conversion ratio of the starting material was low when 5-47 was treated with five equivalents 
of NaBH4 and one equivalent of iodine in THF at room temperature over one day. Hence, the 
amount of iodine was increased and was run at an elevated temperature, leading to 5-52 in 
57% yield. Since both the reaction with borane and NaBH4 in THF in a high temperature led 
to contamination by byproducts, derived by decomposition of THF, that was difficult to 
























THF, reflux, 24 h
OMs
Me

















Hydrolysis of mesylate 5-52 with aqueous NaOH in refluxing methanol led to diol 5-53, 
which was converted to the benzyl ether 5-54 in 76% yield over two steps. Treatment of 
iodobenzyl alcohol 5-54 with two equivalents of PBr3 in methylene chloride provided the 
corresponding bromo compound 5-55, which was subjected to a substitution with NaCN in 
DMSO to generate iodophenyl acetonitrile 5-32 in 47% yield over all. Alternatively, 
mesylation of the benzylic alcohol 5-54 with mesyl chloride and triethylamine produced the 
corresponding mesylate 5-56, which was converted to the desired product 5-32 in 87% yield 
















5-54   76%
I
OH









































CH2Cl2, 0 oC, 3 h
3.0 eq. NaCN
DMSO, rt., 13 h
 
With 5-32 in hand, the palladium-catalyzed borylation of 5-32 with pinacolborane (5-57) 
using 20 mol% ligand 5-58 and 5 mol% Pd(OAc)2 and four equivalents of triethylamine in 
dioxane at 100 °C for 4 hours provided a mixture of the desired pinacol boronate 5-31 and 
the reduction product 5-59 (7:1, respectively). Since the separation of 5-31 and 5-59 was 
difficult, the mixture was subjected to the Suzuki coupling with bromoindenone 5-30 using 5 
mol% Pd2(dba)3, 10 mol% [(t-Bu)3PH]BF4, and three equivalents of KF in THF and water 
(19:1) at room temperature over one day to generate the diaryl adduct 5-29 in 75% yield for 
two steps. The diaryl compound 5-29 was cyclized with LDA then protected by CH3I to 







































[(t-Bu)3PH]BF4 (10 mol%), KF (3.0 eq.) 
THF/H2O (19:1), rt, 24 h
5-30













5-28   48% two steps
LDA (1.1 eq.)
THF, 0 °C to rt.









However, the hydrolysis of carbonitrile 5-28 to the corresponding carboxamide did not 
work well. Treatment of 5-28 with 1.55 equivalents of K2CO3 and excess 30% H2O2 in 
DMSO at room temperature provided nothing but starting material over one day. The failure 
of the reaction likely arose, at least partially, because of the poor solubility of 5-28 in DMSO. 
Thus, co-solvent THF or CH2Cl2 was used, but no obvious reaction was observed. Although 
methylene chloride is the best solvent for 5-28, but the two phase condition using 10% n-
Bu4NHSO4 as a phase transfer catalyst did not work. Even though hydrolysis of 5-61 with 
excess NaOH and H2O2 in THF and ethanol afforded the carboxamide 5-62 smoothly as 
described in chapter 4, this condition did not work for 5-28. The OBn group at C4 of D ring 










1.55 eq.  K2CO3
    H2O2 (30%)
         DMSO, rt.
with or without cosolvent
no reaction 5-28
excess  NaOH (1M )
 n-Bu4NHSO4 (10%)
 H2O2 (30%), CH2Cl2
                rt.
no reaction
5-28
excess NaOH (1M) 

















Alternatively, heating of 5-28 with KOH in refluxing t-BuOH, common conditions for the 
hydrolysis of nitriles, unexpectedly generated phenol 5-60, likely, resulting from an addition-
elimination reaction rather than the desired hydrolysis of the nitrile. Treatment of 5-28 with 6 



























Ruano and coworkers reported hydrolysis of cyanohydrins to the corresponding hydroxyl 
amides with HCl in ether.17 However, no reaction was observed when a solution of 5-28 in 
methylene chloride was treated with a 2 M solution of HCl in ether. Alternative methods for 
the acid-catalyzed hydrolysis of 5-28 were considered, but the use of concentrated HCl and 
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AcOH (1:1) at 100 °C led to cleavage of the benzyl group, with no detectable hydrolysis of 
the nitrile, and the use of concentrated H2SO4 provided a complex mixture. Treatment of 5-

























           rt.
complex mixture




Maffioli and coworkers reported the palladium-catalyzed reversible dehydration of 
primary amides in aqueous organic solvents under mild conditions (Scheme 5-20).18 
However, attempts to apply these conditions to the desired hydrolysis were not successful as 
no reaction was observed when 5-36 was treated with one equivalent of Pd(OAc)2 and five 
equivalents of acetamide in THF and water (3:1) at room temperature or at elevated 
temperature. The use of excess acetamide was also ineffective for pushing the equilibrium in 


























  rt. or reflux
no reaction
 
Luo and Jeevanandam19 reported a method for transformation of nitriles into esters by 
heating with a 1:2 mixture of TMSCl and alcohol to give an O-alkyl imidate intermediate, 
which then reacted with water upon aqueous workup. However, no reaction was observed 





















Since it was difficult to hydrolyze the carbonitrile 5-28 to the corresponding carboxamide, 
the reduction of 5-28 to an aldehyde, which might possibly be further functionalized, was 
investigated. Treatment of 5-28 with 1.1 equivalents of DIBAL in methylene chloride from –
78 °C to room temperature led to partial reduction of 5-28 to the secondary alcohol 5-64. 
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Increasing the amount of DIBAL to six equivalents, the reaction provided some desired 
aldehyde 5-65 along with alcohol 5-64 and starting material. It was felt that, on the small 
scale being studied, dissolved O2 might oxidize the alcohol 5-64 back to 5-36, leading to 






























































  Hence, 5-28 was degassed and then treated with four equivalents of DIBAL. In this case, all 
starting material was consumed and the reaction generated a mixture of 5-64 and 5-65 (5:1, 
respectively). Increasing the amount of DIBAL to six equivalents did not improve the ratio of 
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5-65 to 5-64. Furthermore, increasing the amount of DIBAL to ten equivalents led to a 
complex mixture. 
The synthesis was stopped at this stage because of the limitation of time. In summary, the 
benzo[a]fluorene 5-36, which is a potential intermediate for the total synthesis of fluostatin A 
and analogs of isoprekinamycin, was synthesized from commercial available 3-
methylsalicylic acid (5-33) as the sequence shown in scheme 5-23 through eleven steps in 






































































5-28   48%
1. LDA
2. CH3I, 
    K2CO3






Future work beyond 5-28 may involve removal of the o-benzyl group which interferes 
with further reactions of the cyano group sterically and which also creates problems 
associated with poor solubility. 
Additionally, some variations during the DIBAL reduction of the cyano group in 5-28 
might be explored. It is possible that in the DIBAL reduction both the ketone and nitrile 























Conversion of 5-67 to the desired aldehyde requires hydrolysis of the hindered imine 









It was possible that this process is very slow and that a competing air oxidation may occur 
in the workup leading to conversion not only the alcohol to ketone but also perhaps the 















The precise mechanism for this process is unknown. 
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If this is true, then future work might involve reduction with DIBAL in O2-free medium as 
done above, but followed by aqueous workup also under air free condition so that hydrolysis 
might compete with air oxidation. 
5.3 Experimental 
5.3.1 General Information 
 
1H NMR spectra were recorded on a Brüker AVANCE500 (500 MHz), Brüker AC300 (300 
MHz) and Brüker AVANCE300 (300 MHz) NMR spectrometer. Chemical shifts are reported 
in parts per million (ppm) relative to tetramethylsilane (TMS). The following abbreviations 
are used for NMR peak multiplicities: s, singlet; d, doublet; t, triplet; q, quartet; dd, doublet 
of doublets; dt, doublet of triplet; m, multiplet; b, broad; w, weak. 13C NMR spectra were 
broad band decoupled and recorded on a Brüker AVANCE500 (125.8 MHz), Brüker AC300 
(75.5 MHz) and Brüker AVANCE300 (75.5 MHz) NMR spectrometer using the carbon 
signal of the deuterated solvent as the internal standard. HMQC and HMBC experiments 
were performed on a Brüker AVANCE500 spectrometer. IR spectra were determined on a 
Perkin-Elmer RX I FT-IR spectrometer as KBr discs unless otherwise indicated. High/low 
resolution electron impact or electrospray ionization (EI or ESI) mass spectra (MS) were 
measured by the WATSPEC Mass Spectrometry Facility (Department of Chemistry, 
University of Waterloo, Waterloo, Ontario, Canada). Elemental analyses were performed by 
the M-H-W Laboratories (Phoenix, Arizona, USA).  
Anhydrous THF and Et2O were freshly distilled from sodium/benzophenone under nitrogen 
prior to use. Anhydrous CH2Cl2 was freshly distilled from CaH2 under nitrogen prior to use. 
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All commercial reagents were purchased from Aldrich Chemical Co., Strem Chemicals Inc., 
Alfa Aesar, Lancaster Synthesis Ltd. or BDH Inc. and were used as received unless 
otherwise indicated. Deionized water was supplied by a Biolab vertical series reverse 
osmosis system. 
The –78 ºC and 0 ºC designations refer to solid carbon dioxide/acetone and ice/water slush 
respectively. The room temperature refers to 22 °C to 25 °C. Flash column chromatography 
was carried out using the Merck silica gel (230-400 mesh) and SiliCycle silica gel (60 Å). 
Reactions were magnetically stirred and monitored by thin layer chromatography (TLC) with 
Merck pre-coated silica gel plates (silica gel 60 F254 on aluminum sheet). All reported yields 
are isolated yields. 
 











3-Methyl-2-(methylsulfonyloxy)benzoic acid (5-45) 
To a mixture of 3-methylsalicylic acid (15.52 g, 100 mmol) and CaO (14.02, 250 mmol) in 
THF (150 mL) was added MsCl (9.4 ml, 120 mmol) at room temperature slowly, and  the 
reaction was stirred at this temperature for 48 hours. With ice-bath cooling, conc. HCl was 
added until the pH value of the solution was near 1 (pH page). Then the resulting solution 
was extracted by ether (3 × 200 mL), and the combined organic phase was dried over Na2SO4 
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and concentrated. The residue was washed with ether several times to provide the title 
compound as a white solid (17.48 g, 76%). Mp: 147–148 °C; 1H NMR (300 MHz, CDCl3): δ 
7.87 (d, J = 7.7 Hz, 1H), 7.50 (d, J = 7.6 Hz, 1H), 7.29 (t, J = 7.7 Hz, 1H), 3.34 (s, 3 H), 2.47 
(s, 3 H); 13C NMR (75.5 MHz, CDCl3): δ 170.2, 146.2, 136.8, 134.3, 130.1, 126.9, 124.4, 
39.4, 17.4; IR (film): 3027.5, 1688.2, 1606.4, 1586.0, 1465.3, 1419.0, 1335.5, 1298.8, 1206.9, 
1189.2, 1169.9, 1142.7, 1087.5, 975.0, 868.1, 768.7, 701.6 cm–1; MS (EI): m/z 230.05 (13, 
M+), 151.05 (9), 134.05 (100), 133.04 (27), 106.05 (36), 105.04 (13), 77.01 (13), 51.19 (7); 












6-Iodo-3-methyl-2-(methylsulfonyloxy)benzoic acid (5-47) 
To a solution of 3-methyl-2-(methylsulfonyloxy)benzoic acid (4.0 g, 17.37 mmol) and NIS 
(4.30 g, 19.11 mmol) in 12 ml DMF was added Pd(OAc)2 (0.39 g, 1.74 mmol) and the 
reaction was stirred at 120 °C for 24 hours. The reaction mixture was filtered through a plug 
of silica gel, and washed with ether (2 L). The filtrate was concentrated to 500 mL and then 
washed with water (6 × 50 mL). The organic phase was dried over Na2SO4 and concentrated. 
The residue was recrystallized from THF to obtain the title compound as a white solid (4.025 
g, 65%). 1H NMR (300 MHz, CDCl3): δ 11.32 (s, 1H), 7.69 (d, 8.1 Hz, 1H), 7.06 (d, J = 8.1 
Hz, 1H), 3.29 (s, 3H), 2.39 (s, 3H); 13C NMR (75.5 MHz, CDCl3): δ 170.4, 144.7, 138.2, 
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134.7, 134.0, 133.5, 88.9, 39.6, 17.6; IR (film): 3037.5, 2939.0, 1711.9, 1593.1, 1562.6, 
1454.7, 1359.5, 1250.9, 1190.0, 1150.1, 1116.7, 972.6, 886.5, 815.7, 792.8, 727.8 cm–1; MS 
(EI): m/z 355.9 (56, M+), 337.9 (7), 276.9 (18), 259.9 (100), 231.9 (34), 230.9 (13), 134.0 















2-(Hydroxymethyl)-3-iodo-6-methylphenyl methanesulfonate (5-52) 
To a solution of 6-iodo-3-methyl-2-(methylsulfonyloxy)benzoic acid (435.2 mg, 1.22 mmol) 
in anhydrous DME (12 mL) was added NaBH4 ( 232.2 mg, 6.11 mmol) followed by adding 
I2 ( 620.3 mg, 2.44 mmol) in anhydrous DME (12 mL) slowly at room temperature. The 
reaction was stirred at 80 °C for 24 hours. At 0 °C, 1 M HCl (20 mL) was added, and the 
resulting solution was extracted with EtOAc (3 × 50 mL). The organic phase was washed 
with water (3 × 15 mL), dried over Na2SO4 and concentrated. The residue was purified by 
flash chromatography (EtOAc:Hexanes = 1:2, v/v) to obtain the title compound as a white 
solid (273.6 mg, 65%). 1H NMR (300 MHz, CDCl3): δ 7.70 (d, J = 8.1 Hz, 1H), 6.93 (d, J = 
8.0 Hz, 1H), 4.75 (d, J = 6.3 Hz, 2H), 3.38 (s, 3 H), 2.65 (t, J = 6.8 Hz, 1H), 2.35 (s, 3H); 13C 
NMR (75.5 MHz, CDCl3): δ 145.8, 138.6, 136.7, 133.6, 133.2, 98.3, 64.0, 38.8, 17.6; IR 
(film): 3341.5, 3021.9, 2952.4, 1563.4, 1454.6, 1386.6, 1360.5, 1184.3, 1153.4, 1118.0, 
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974.4, 878.5, 793.0 cm-1; MS (EI): m/z 342.0 (55, M+), 324.0 (5), 264.0 (10), 263.0 (100), 
246.0 (36), 136.1 (7), 108.1 (34), 107.1 (13), 77.0 (8), 51.2 (5); HRMS (EI): calculated for 
















 (2-(Benzyloxy)-6-iodo-3-methylphenyl)methanol (5-54) 
To a solution of 2-(hydroxymethyl)-3-iodo-6-methylphenyl methanesulfonate (219.3 mg, 
0.64 mmol) in MeOH (6 mL) was added aqueous NaOH (2.0 mL, 2 M) slowly at room 
temperature. The reaction mixture was stirred and heated to reflux for 3 hours. With ice-bath 
cooling, 2 M HCl was added to adjust the pH to about 1 (pH page), and the resulting solution 
was extracted with EtOAc (3 × 50 mL). The organic phase was washed with water (3 × 15 
mL), dried over Na2SO4 and concentrated to obtain the crude diol as a white solid (164.0 mg).  
The crude diol (164.0 mg) was dissolved in acetone (10 mL). Solid K2CO3 (128.8 mg, 0.93 
mmol) was added and the mixture was stirred at room temperature for 10 minutes. Benzyl 
bromide (0.12 ml, 0.93 mmol) was added and the temperature was increased to reflux and 
stirring was continued at this temperature for 5 hours. The resulting solution was filtered and 
the precipitate was washed with CH2Cl2. Then the combined organic phase was dried over 
Na2SO4 and concentrated. The residue was purified by flash chromatography 
(EtOAc:Hexanes = 1:10, v/v) to obtain the title compound as a white solid (171.9 mg, 76%). 
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1H NMR (300 MHz, CDCl3): δ 7.53 (d, J = 8.0 Hz, 1H), 7.48 (m, 2H), 7.40 (m, 3H), 6.88 (d, 
J = 8.0 Hz, 1H), 4.92 (s, 2H), 4.80 (s, 2H), 2.38 (s, 1H), 2.28 (s, 3H); 13C NMR (75.5 MHz, 
CDCl3): δ 156.5, 136.8, 136.6, 135.2, 132.8, 132.4, 128.7, 128.4, 128.1, 97.5, 76.5, 64.6, 
16.3; IR (film): 3357.1, 3272.2, 3035.7, 2952.4, 2928.6, 2881.0, 1572.4, 1454.7, 1367.5, 
1259.0, 1216.2, 1037.6, 975.0, 746.4, 694.1 cm–1; MS (EI): m/z 354.0 (55, M+), 336.0 (17), 
324.0 (4), 278.1 (3), 246.0 (90), 209.1 (4), 119.1 (5), 91.1 (100), 65.1 (7), 51.2 (3); HRMS 
















To a solution of (2-(benzyloxy)-6-iodo-3-methylphenyl)methanol (1.0 g, 2.82 mmol) and 
Et3N (0.5 mL, 3.52 mmol) in anhydrous CH2Cl2 (25 mL) was added MsCl (0.28 mL, 3.52 
mmol) slowly with ice-bath cooling and the reaction was stirred for 3 hours.  
The solution was concentrated and the residue was dissolved in DMSO (10 mL) containing 
NaCN (415.1 mg, 8.47 mmol), and the reaction was stirred at room temperature for 15 hours. 
Water (50 mL) was added to the ice-bath solution, which was extracted with EtOAc (3 × 100 
mL). The organic phase was washed with water (2 × 30 mL) and brine (30 mL), dried over 
Na2SO4 and concentrated. The residue was purified by flash chromatography 
(EtOAc:Hexanes = 1:20, v/v) to obtain the title compound as a white solid (892.9 mg, 87%). 
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Mp: 95–97 °C; 1H NMR (300 MHz, CDCl3): δ 7.55 (d, J = 8.1 Hz, 1H), 7.43 (m, 5H), 6.94 
(d, J = 8.1 Hz, 1H), 4.92 (s, 2H), 3.83 (s, 2H), 2.31 (s, 3H); 13C NMR (75.5 MHz, CDCl3): δ 
156.0, 136.2, 135.4, 133.3, 132.3, 128.8, 128.6, 128.1, 127.9, 117.2, 96.9, 75.5, 24.2, 16.4; 
IR (film): 3064.0, 3032.2, 2925.1, 2878.0, 2247.6, 1569.7 1497.2, 1454.9, 1405.9, 1370.1, 
1261.8, 1214.7, 1201.0, 1125.1, 1004.8, 974.9, 920.3, 808.6, 743.8, 697.4 cm–1; MS (EI): m/z 
363.0 (45, M+), 91.0 (100), 83.9 (8), 65.1 (5); HRMS (EI): calculated for C16H14INO: 










































A mixture of Pd(OAc)2 (61.9 mg, 0.28 mmol) and (2-biphenyl)dicyclohexyl-phosphine 
(386.0 mg, 1.10 mmol) was deoxygenated five times with an argon balloon and a vacuum 
pump. The 2-(2-(benzyloxy)-6-iodo-3-methylphenyl)acetonitrile (2.0 g, 5.51 mmol)  was 
dissolved in dioxane 935 mL). Pinacolborane (2.4 mL, 16.52 mmol) and Et3N (3.1 mL, 22.03 
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mmol) were added and the solution was deoxygenated three times by a freeze-thaw process. 
The deoxygenated solution was then added to the solid mixture of catalyst and ligand and 
stirred at 100 °C for 4 hours under argon atmosphere. The reaction was quenched with 20 mL 
saturated aqueous NH4Cl and extracted with CH2Cl2 (3 × 50 mL). The organic phase was 
dried over Na2SO4 and concentrated. The residue was purified by flash chromatography 
(EtOAc:Hexanes = 1:20, v/v) to obtain the crude as a white solid (1.64 g). 
A mixture of bromoindenone (1.50 g, 5.03 mmol), KF (876.7 mg, 15.09 mmol), Pd2(dba)3 
(230.3 mg, 0.25 mmol) and [(t-Bu)3PH]BF4 (146.0 mg, 0.50 mmol) was deoxygenated five 
times with an argon balloon and a vacuum pump. The crude pinacolboronate (1.64 g) was 
dissolved in a mixture (19:1) of THF and water (60 mL) and the solution was deoxygenated 
three times by the thaw-freeze process. The deoxygenated solution was then added to the 
solid mixture and stirred for 24 hours at room temperature under an argon atmosphere. The 
solution was concentrated to remove THF and the residue was dissolved in CH2Cl2 (200 mL). 
The organic phase washed with water (3 × 20 mL), dried over Na2SO4 and concentrated. The 
residue was purified by flash chromatography (EtOAc:Hexanes = 1:3, v/v) to obtain the 
product as a red-orange solid (1.88 g, 75% for two steps). 1H NMR (300 MHz, CDCl3): δ 
7.49 (m, 2H), 7.39 (m, 3H), 7.29 (dd, J = 8.3, 7.1 Hz, 1H), 7.20 (d, J = 7.2 Hz, 1H), 7.01 (d, J 
= 8.4 Hz, 1H), 6.96 (d, J = 7.8 Hz, 1H), 4.95 (s, 2H), 3.85 (s, 3H), 3.78 (s, 3H), 3.64 (s, br, 

















    K2CO3




To a solution of methyl 2-(3-(benzyloxy)-2-(cyanomethyl)-4-methylphenyl)-7-methoxy-3-
oxo-3H-indene-1-carboxylate (137.9 mg, 0.304 mmol) in 5 mL anhydrous THF was added 
LDA in THF (0.335 mmol in 1 mL) slowly under ice-bath cooling and the solution was 
warmed up to room temperature and continued to stir for 2 hours. The reaction was quenched 
with 10 mL saturated aqueous NH4Cl solution leading to the formation of some red-orange 
precipitate. The suspension was extracted with CH2Cl2 (3 × 50 mL) and then washed with 
H2O (3 ×15 mL). The organic phase was dried over Na2SO4 and concentrated to obtain the 
crude product as a red orange solid (147.5 mg). 
To a solution of the above crude product in acetone (30 mL) was added solid K2CO3 (126.1 
mg, 0.91 mmol) at room temperature and the mixture was stirred for 15 minutes, followed by 
addition of CH3I (0.06 mL, 0.91 mmol). The reaction was heated to reflux and stirred at this 
temperature for 5 hours. The solution was filtered and the precipitate was washed with 
CH2Cl2. The filtrate was dried over Na2SO4 and concentrated. The residue was purified by 
flash chromatography (CH2Cl2: Hexanes = 3:1, v/v) to give the product as an orange solid 
(63.5 mg, 48 % for two steps). Mp: 208–209 °C;1H NMR (300 MHz, CD2Cl2): δ 8.81 (d, J = 
8.7 Hz, 1H), 7.60 (d, J = 6.6 Hz, 2H), 7.36 (m, 6H), 7.16 (dd, J = 8.0, 0.8 Hz, 1H), 5.06 (s, 
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2H), 4.01 (s, 3H), 2.40 (s, 3H); 13C NMR (75.5 MHz, CD2Cl2): δ 193.9, 159.4, 154.8, 150.8, 
138.2, 136.7, 135.7, 133.1, 131.9, 131.7, 130.9, 130.3, 128.5, 128.3, 128.1, 127.4, 127.3, 
120.5, 120.2, 116.9, 116.6, 106.9, 76.4, 63.4, 56.2, 16.6; IR (film): 3041.7, 2958.3, 2875.0, 
2220.1, 1706.6, 1606.1, 1552.5, 1483.6, 1369.8, 1280.2, 1258.0, 1215.9, 1063.3, 948.3, 737.9 
cm–1; MS (EI): m/z 435.2 (21, M+); 406.2 (54), 344.1 (100), 327.1 (28), 301.1 (12), 286.1 (7), 
214.1 (9), 91.1 (65); HRMS (EI): Calc for C28H21NO4: 435.1471, found: 435.1461. 
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Chapter 6 Conclusions and Future Work 
6.1 Conclusions 
This research thesis is mainly focused on developing methodology to set up the 
benzo[a]fluorene skeleton, which provides a potential route to the total synthesis of 
isoprekinamycin and analogues of this natural product so as to study the relationship of the 
structure and bioactivities. 
The synthetic strategy to IPK is based on the retrosynthetic analysis shown in scheme 6-1. 
Basically the strategy assumed that a suitably substituted precursor, which incorporates the 
AB and D rings of the natural product, might be induced to cyclize to provide the full 
benzo[a]fluorene system followed by selective functional group interconversion to provide 



































In summary, the model of IPK 6-5 was synthesized as the sequence shown in Scheme 6-2. 
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The synthesis was initiated from the commercially available dihydrocoumarin 6-1 through 
six steps to generate AB ring synthon, bromoindenone 6-2, in 33% yield. The Suzuki 
coupling of bromoindenone 6-2 and commercial available pinacol boronate 6-3 afforded 
diaryl intermediate 6-4, which was followed by another six steps to achieve the synthesis of 
model compound 6-5. Including the synthesis of bromoindenone 2-63, the longest linear path 












6-4   93%
Suzuki
6 steps









The first total synthesis of IPK was achieved via the sequence as presented in scheme 6-3. 
Suzuki coupling between 6-2 and the D ring building block pinacol boronate 6-7, which was 
obtained from the known benzyl alcohol 6-6 through four steps in 42% yield, gave 6-8 in 
85% yield. Another seven steps generated IPK. Overall, the longest linear path of this 

































This method now provides a reliable method for producing IPK for biological study. The 
fermentation approach was found, in this laboratory, to be problematic since IPK production 
was not observed in some fermentation experiments while the red polyketide-derived 







An analogue of IPK 6-14 was designed, incorporating a side chain at C3 of D ring in order 
to improve solubility and potentially the affinity of the molecule with DNA. The carbamate 
6-13, a precursor of 6-14, was synthesized as shown in scheme 6-4 using the same strategy as 



































R is a solubilizing group or a group 





The benzo[a]fluorene 6-18 was synthesized in 6% overall yield, via an eleven step 
sequence initiated from 3-methyl salicylic acid (6-15) shown in the scheme 6-5. The 
benzo[a]fluorene 6-18 is intended to be the key intermediate for the total synthesis of 






























R is a solubilizing group or a group 





















6.2 Future Work 
For the future work, the methodology for the synthesis of model 6-5 and IPK will be used 
for the synthesis of various analogues to study the mode of action of IPK and kinamycins 
systematically. The goals of this work should be to: 
1. Introduce side chains at D ring to improve the solubility of the analogues of IPK (e.g. 6-
14 and 6-19). 
2. Use handles at D ring to attach group to increase DNA binding ability of the analogues of 
IPK (e.g. 6-14 and 6-19). 
In principle, the above two goals might be achieved via either C3 or C4 substituted 
analogues discussed in this thesis. However, it is suggested that the C3 substituted variations 
will be the most readily achievable via 6-13, since the chemistry of C4-benzyloxy substituted 
intermediate 6-18 was found to be problematic in the present study. 
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Furthermore, benzo[a]fluorene 6-18 should be studied as a precursor for the total synthesis 
of fluostatin A and other fluostatins. As shown below, debenzylation of 6-18, followed by 
reduction to give the aldehyde 6-20, is recommended. This should relieve some of the steric 
effect which made the modification of the cyano group in 6-18 very difficult in the present 
study. Reduction of the cyano group to the aldehyde using completely oxygen-free 
conditions for the DIBAL reduction is also recommended. Decarbonylation might then be 































However, an alternative approach to fluostatins would involve the use of a strategy very 
similar to that used in the total synthesis of IPK (chapter 3). In this approach, different 
protection of the A and D ring oxygenation and a reduction-reoxidation sequence to avoid the 




















































Appendix for Chapter 2 













Appendix 2-4 X-ray Crystallographic Structure of Compound 2-58 
 
Table 1 Crystal Data and Structure Refinement of Compound 2-58 
 
Empirical formula C18 H10 N2 O3 
Formula weight 302.28 
Cell measurement temperature 180(2) K 
Wavelength 0.71073 Å 
Crystal system, space group Orthorhombic, Pna21 
Unit cell dimensions a = 19.6350(16) Å, b = 4.6545(4) Å,  
 c = 14.8606(12) Å 
Volume, Z 1358.13(19) Å3, 4 
Density  1.478 g/cm3 
Absorption coefficient 0.103 mm-1 
F(000) 624 
Crystal size 0.24 mm × 0.11 mm × 0.11 mm 
2θ range for data collection 2.07 to 28.02° 
Limiting indices -24 < h < 25, -6 < k < 6, -19 < l < 19 
Reflections collected / unique 9029 / 1707 [R(int) = 0.0464] 
Completeness to θ = 28.02 100.0 % 
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 1707 / 1 / 210 
Goodness-of-fit on F2 1.044 
Final R indices [I>2σ(I)] R1 = 0.0344, wR2 = 0.0656 
R indices (all data) R1 = 0.0414, wR2 = 0.0673 




Table 2 Atomic Coordinates and Equivalent Isotropic Displacement Parameters 
 
 x/a y/b z/c Ueq 
C(1) -246(1) 805(4) 2184(2) 32(1) 
C(2) -620(1) -1272(4) 1748(2) 38(1) 
C(3) -470(1) -2009(4) 866(2) 39(1) 
C(4) 51(1) -672(4) 410(2) 36(1) 
C(4A) 438(1) 1458(4) 840(2) 30(1) 
C(5) 984(1) 2979(4) 413(1) 33(1) 
C(6) 1386(1) 5326(4) 785(1) 33(1) 
C(6A) 1236(1) 5799(4) 1740(2) 29(1) 
C(6B) 1573(1) 7761(4) 2400(2) 33(1) 
C(7) 2131(1) 9627(5) 2362(2) 41(1) 
C(8) 2317(1) 11128(5) 3144(2) 49(1) 
C(9) 1964(1) 10809(5) 3934(2) 52(1) 
C(10) 1406(1) 8988(5) 3984(2) 44(1) 
C(10A) 1225(1) 7525(4) 3214(2) 34(1) 
C(11) 658(1) 5458(4) 3104(1) 32(1) 
C(11A) 712(1) 4365(4) 2154(1) 28(1) 
C(11B) 289(1) 2214(4) 1741(1) 28(1) 
N(12) 1154(1) 2327(4) -432(1) 41(1) 
N(13) 1330(1) 1849(5) -1130(2) 60(1) 
O(14) 1790(1) 6697(3) 323(1) 48(1) 
O(15) 2470(1) 9880(4) 1567(1) 60(1) 
C(16) 2976(1) 12049(6) 1477(2) 65(1) 
O(17) 232(1) 4848(3) 3667(1) 43(1) 
H(1) -350 1287 2790 39 
H(2) -984 -2204 2053 45 
H(3) -730 -3454 573 46 
H(4) 148 -1189 -194 43 
H(8) 2696 12396 3125 59 
H(9) 2104 11844 4454 62 
H(10) 1157 8760 4528 53 
H(16X) 2781 13917 1639 97 
H(16Y) 3136 12108 852 97 




Table 3 Bond Lengths and Bond Angles 
 
 Length [Å]   Angle [°] 
C1-C2 1.377(3)  C2-C1-C11B 120.5(2) 
C1-C11B 1.403(3) C1-C2-C3 120.3(2) 
C2-C3 1.387(3) C4-C3-C2 120.8(2) 
C3-C4 1.375(3) C3-C4-C4A 119.9(2) 
C4-C4A 1.403(3) C4-C4A-C11B 119.68(19) 
C4A-C11B 1.414(3) C4-C4A-C5 123.5(2) 
C4A-C5 1.434(3) C11B-C4A-C5 116.77(18) 
C5-N12 1.334(3) N12-C5-C4A 119.46(19) 
C5-C6 1.457(3) N12-C5-C6 113.06(19) 
C6-O14 1.227(2) C4A-C5-C6 127.44(18) 
C6-C6A 1.466(3) O14-C6-C5 121.83(19) 
C6A-C11A 1.374(3) O14-C6-C6A 126.4(2) 
C6A-C6B 1.495(3) C5-C6-C6A 111.77(18) 
C6B-C10A 1.392(3) C11A-C6A-C6 120.79(19) 
C6B-C7 1.400(3) C11A-C6A-C6B 109.49(18) 
C7-O15 1.360(3) C6-C6A-C6B 129.72(19) 
C7-C8 1.403(4) C10A-C6B-C7 117.9(2) 
C8-C9 1.372(4) C10A-C6B-C6A 107.80(18) 
C9-C10 1.389(4) C7-C6B-C6A 134.3(2) 
C10-C10A 1.378(3) O15-C7-C6B 118.1(2) 
C10A-C11 1.481(3) O15-C7-C8 123.3(2) 
C11-O17 1.216(2) C6B-C7-C8 118.6(2) 
C11-C11A 1.504(3)  C9-C8-C7 121.6(2) 
C11A-C11B 1.438(3)  C8-C9-C10 120.7(2) 
N12-N13 1.116(3)  C10A-C10-C9 117.4(2) 
O15-C16 1.423(3)  C10-C10A-C6B 123.8(2) 
   C10-C10A-C11 127.3(2) 
   C6B-C10A-C11 108.93(19) 
   O17-C11-C10A 126.4(2) 
   O17-C11-C11A 128.0(2) 
   C10A-C11-C11A 105.68(19) 
   C6A-C11A-C11B 125.40(19) 
   C6A-C11A-C11 108.00(18) 
   C11B-C11A-C11 126.60(19) 
   C1-C11B-C4A 118.88(19) 
   C1-C11B-C11A 123.80(19) 
   C4A-C11B-C11A 117.31(18) 
   N13-N12-C5 176.3(2) 
   C7-O15-C16 119.0(2) 
 225 
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(c) Mixture of Synthetic and Natural IPK
 
 
Comparison of the HPLC retention times of the synthetic and natural isoprekinamycin 
(IPK) with the following experimental setup and conditions: (1) HPLC system: Waters 600 
controller, Waters 996 photodiode array detector, Waters Millennium® software; (2) Column: 
Nova-Pak® C18 60 Å 4 µm, 3.9 × 150 mm; (3) linear gradient (20 minutes): 94% H2O, 5% 
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CH3CN and 0.1% AcOH to 5% H2O, 94% CH3CN and 0.1% AcOH at a flow rate of 1.5 




































0 . 1 0
0 . 2 0
0 . 3 0
0 . 4 0
0 . 5 0
n m
2 5 0 . 0 0 3 0 0 . 0 0 3 5 0 . 0 0 4 0 0 . 0 0 4 5 0 . 0 0 5 0 0 . 0 0 5 5 0 . 0 0 6 0 0 . 0 0
2 1 8 .1 2 4 7 .4
2 8 4 .0
5 6 0 .1
A
U
0 . 0 0
0 . 2 0
0 . 4 0
0 . 6 0
0 . 8 0
n m
2 5 0 . 0 0 3 0 0 . 0 0 3 5 0 . 0 0 4 0 0 . 0 0 4 5 0 . 0 0 5 0 0 . 0 0 5 5 0 . 0 0 6 0 0 . 0 0
2 1 1 . 0
2 4 7 . 4
2 8 4 . 0

























Appendix 3-10 Description of the molecular orbital computational methods 
used 
All molecular orbital calculations were carried out using the Gaussian 0330 software package.  All 
input geometries were constructed using the Gaussview 3.08 graphical interface.31  The electronic 
energies that are quoted were computed using the AM1 semi-empirical molecular orbital method 
within Gaussian 03 with the OPTFREQ options which effects a full geometry optimization and a full 
calculation of the vibrational frequencies.  All of the computed results quoted in Chapter 3 correspond 
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